

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 0 699 760 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:

06.03.1996 Bulletin 1996/10

(21) Application number: 95104961.8

(22) Date of filing: 03.04.1995

(51) Int. Cl.⁶: C12N 15/54, C12N 15/10,
C12N 9/12, C12N 1/21
// (C12N1/21, C12R1:19)

(84) Designated Contracting States:

AT BE CH DE DK ES FR GB IT LI LU NL SE

(30) Priority: 01.04.1994 US 222612

16.09.1994 US 307410

24.02.1995 US 394232

(71) Applicant: GEN-PROBE INCORPORATED

San Diego California 92121-1514 (US)

(72) Inventors:

• Riggs, Michael

San Diego, California 92117 (US)

• Sivaram, Mathoor

Escondido, California 92025 (US)

• Tudor, Starla Dianne

San Diego, California 92117 (US)

(74) Representative: Patentanwälte

Vierling, Jentschura & Partner

Postfach 22 14 43

D-80504 München (DE)

Remarks:


The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(54) Purified DNA polymerase from bacillus stearothermophilus

(57) Composition and methods for the expression of recombinant DNA polymerase enzymes derived from Bacillus stearothermophilus. The present invention also concerns methods for purifying recombinant Bst DNA

polymerase enzymes, compositions containing the purified enzymes in a form suitable for conducting biochemical reactions, and methods for using the purified enzymes.

Figure 13



Description

This application is a Continuation-in-Part of Application Serial No. 08/307,410, filed September 16, 1994, which is a Continuation-in-Part of Application Serial No. 08/222,612, filed April 1, 1994.

Field of the Invention

The invention relates to purified thermostable DNA polymerase enzymes derived from the Gram-positive bacterium *Bacillus stearothermophilus*. These enzymes are useful in biochemical procedures requiring the template-directed synthesis of a nucleic acid strand, such as sequencing and nucleic acid amplification procedures. The invention also relates to methods of making and using these enzymes.

Background of the Invention

DNA polymerase enzymes are naturally-occurring intracellular enzymes, and are used by a cell to replicate a nucleic acid strand using a template molecule to manufacture a complementary nucleic acid strand. Enzymes having DNA polymerase activity catalyze the formation of a bond between the 3' hydroxyl group at the growing end of a nucleic acid primer and the 5' phosphate group of a nucleotide triphosphate. These nucleotide triphosphates are usually selected from deoxyadenosine triphosphate (A), deoxythymidine triphosphate (T), deoxycytidine triphosphate (C) and deoxyguanosine triphosphate (G). However, DNA polymerases may incorporate modified or altered versions of these nucleotides. The order in which the nucleotides are added is dictated by base pairing to a DNA template strand; such base pairing is accomplished through "canonical" hydrogen-bonding (hydrogen-bonding between A and T nucleotides and G and C nucleotides of opposing DNA strands), although non-canonical base pairing, such as G:U base pairing, is known in the art. See e.g., Adams *et al.*, *The Biochemistry of the Nucleic Acids* 14-32 (11th ed. 1992).

The in-vitro use of enzymes having DNA polymerase activity has in recent years become more common in a variety of biochemical applications including cDNA synthesis and DNA sequencing reactions (see Sambrook *et al.*, (2nd ed. Cold Spring Harbor Laboratory Press, 1989) hereby incorporated by reference herein), and amplification of nucleic acids by methods such as the polymerase chain reaction (PCR) (Mullis *et al.*, U.S. Patents No. 4,683,195, 4,683,202, and 4,800,159, hereby incorporated by reference herein) and RNA transcription-mediated amplification methods (e.g., Kacian *et al.*, PCT Publication No. WO91/01384 which enjoys common ownership with the present application and is hereby incorporated by reference herein).

Methods such as PCR make use of cycles of primer extension through the use of a DNA polymerase activity, followed by thermal denaturation of the resulting double-stranded nucleic acid in order to provide a new template for another round of primer annealing and extension. Because the high temperatures necessary for strand denaturation result in the irreversible inactivations of many DNA polymerases, the discovery and use of DNA polymerases able to remain active at temperatures above about 37°C to 42°C (thermostable DNA polymerase enzymes) provides an advantage in cost and labor efficiency. Thermostable DNA polymerases have been discovered in a number of thermophilic organisms including, but not limited to *Thermus aquaticus*, *Thermus thermophilus*, and species of the *Bacillus*, *Thermococcus*, *Sulfolobus*, *Pyrococcus* genera.

DNA polymerases can be purified directly from these thermophilic organisms. However, substantial increases in the yield of DNA polymerase can be obtained by first cloning the gene encoding the enzyme in a multicopy expression vector by recombinant DNA technology methods, inserting the vector into a host cell strain capable of expressing the enzyme, culturing the vector-containing host cells, then extracting the DNA polymerase from a host cell strain which has expressed the enzyme.

The bacterial DNA polymerases that have been characterized to date have certain patterns of similarities and differences which has led some to divide these enzymes into two groups: those whose genes contain introns - intervening non-coding nucleotide sequences - (Class B DNA polymerases), and those whose DNA polymerase genes are roughly similar to that of *E. coli* DNA polymerase I and do not contain introns (Class A DNA polymerases).

By "non-coding" is meant that the nucleotides comprising both nucleic acid strands in such sequences do not contain 3-nucleotide codons that encode and correspond to amino acid residues of the mature protein. Introns are most often found in the genes of eukaryotic higher organisms but have also been found in lower organisms such as archaeobacteria.

Several Class A and Class B thermostable DNA polymerases derived from thermophilic organisms have been cloned and expressed. Among the class A enzymes: Lawyer, *et al.*, *J. Biol. Chem.* 264:6427-6437 (1989) and Gelfund *et al.*, U.S. Patent No. 5,079,352, report the cloning and expression of a full length thermostable DNA polymerase derived from *Thermus aquaticus* (Taq). Lawyer *et al.*, in *PCR Methods and Applications*, 2:275-287 (1993), and Barnes, PCT Publication No. WO92/06188 (1992), disclose the cloning and expression of truncated versions of the same DNA polymerase, while Sullivan, EPO Publication No. 0482714A1 (1992), reports cloning a mutated version of the Taq DNA polymerase. Asakura *et al.*, *J. Ferment. Bioeng.* (Japan), 74:265-269 (1993) have reportedly cloned and expressed a DNA polymerase from *Thermus thermophilus*. Gelfund *et al.*, PCT Publication No. WO92/06202 (1992), have disclosed a purified ther-

mostable DNA polymerase from Thermosipho africanus. A thermostable DNA polymerase from Thermus flavus was reported by Akhmetzjanov and Vakhitov, Nucleic Acids Res., 20:5839 (1992). Uemori et al., J. Biochem., 113:401-410 (1993) and EPO Publication No. 0517418A2 (1992) have reported cloning and expressing a DNA polymerase from the thermophilic bacterium Bacillus caldolenax. Ishino et al., Japanese Patent Application No. HEI 4[1992]-131400 (publication date 11/19/93) report cloning a DNA polymerase from Bacillus stearothermophilus.

Among the Class B enzymes: A recombinant thermostable DNA polymerase from Thermococcus litoralis was reported by Comb et al., EPO Publication No. 0 455 430 A3 (1991), Comb et al., EPO Publication No. 0547920A2 (1993), and Perler et al., Proc. Natl. Acad. Sci. (USA), 89:5577-5581 (1992). A cloned thermostable DNA polymerase from Sulfolobus solofatarius is disclosed in Pisani et al., Nucleic Acids Res., 20:2711-2716 (1992) and in PCT Publication WO93/25691 (1993). The thermostable enzyme of Pyrococcus furiosus is disclosed in Uemori et al., Nucleic Acids Res., 21:259-265 (1993), while a recombinant DNA polymerase was derived from Pyrococcus sp. as disclosed in Comb et al., EPO Publication No. 0547359A1 (1993).

By "thermostable" is meant that the enzyme remains has an optimal temperature of activity at a temperature greater than about 37°C to 42°C. Preferably, the enzymes of the present invention have an optimal temperature for activity of between about 50°C and 75°C; most preferably between 55°C and 70°C, and most preferably between 60°C and 65°C.

Many thermostable DNA polymerases possess activities additional to a DNA polymerase activity; these may include a 5'-3' exonuclease activity and/or a 3'-5' exonuclease activity. The activities of 5'-3' and 3'-5' exonucleases are well known to those of ordinary skill in the art. The 3'-5' exonuclease activity improves the accuracy of the newly-synthesized strand by removing incorrect bases that may have been incorporated; DNA polymerases in which such activity is low or absent, reportedly including Taq DNA polymerase, (see Lawyer et al., J. Biol. Chem., 264:6427-6437), are prone to errors in the incorporation of nucleotide residues into the primer extension strand. In applications such as nucleic acid amplification procedures in which the replication of DNA is often geometric in relation to the number of primer extension cycles, such errors can lead to serious artifactual problems such as sequence heterogeneity of the nucleic acid amplification product (amplicon). Thus, a 3'-5' exonuclease activity is a desired characteristic of a thermostable DNA polymerase used for such purposes.

By contrast, the 5'-3' exonuclease activity often present in DNA polymerase enzymes is often undesired in a particular application since it may digest nucleic acids, including primers, that have an unprotected 5' end. Thus, a thermostable DNA polymerase with an attenuated 5'-3' exonuclease activity, or in which such activity is absent, is also a desired characteristic of an enzyme for biochemical applications. Various DNA polymerase enzymes have been described where a modification has been introduced in a DNA polymerase which accomplishes this object. For example, the Klenow fragment of E. coli DNA polymerase I can be produced as a proteolytic fragment of the holoenzyme in which the domain of the protein controlling the 5'-3' exonuclease activity has been removed. The Klenow fragment still retains the polymerase activity and the 3'-5' exonuclease activity. Barnes, supra, and Gelfund et al., U.S. Patent No. 5,079,352 have produced 5'-3' exonuclease-deficient recombinant Taq DNA polymerases. Ishino et al., EPO Publication No. 0517418A2, have produced a 5'-3' exonuclease-deficient DNA polymerase derived from Bacillus caldolenax.

Preparation of antisera or monoclonal antibodies to particular DNA polymerase enzymes has been described and is well known in the art. For example, Hu et al., J. Virol., 60:267-274 (1986) report specific immunoprecipitation of cloned reverse transcriptase and fusion proteins from Moloney Murine Leukemia Virus expressed in E. coli by recovering PAGE-separated MMLV reverse transcriptase from the gel, immunizing rabbits with the purified protein, and recovering the antisera. Livingston et al., Virology, 50:388-395 (1972) disclose affinity chromatography of Avian Type C Viral transcriptase using antibodies able to differentiate between viral and host cell DNA polymerases. Spadari and Weissbach, J. Biol. Chem., 249:5809-5815 (1974) report that HeLa-derived DNA polymerase is not inhibited by antisera prepared against reverse transcriptases obtained from either the Mason-Pfizer monkey virus, the Wooley monkey virus, or the Rauscher murine leukemia virus. These publications are hereby incorporated herein by reference.

Summary of the Invention

The present invention provides recombinant and/or purified thermostable DNA polymerase enzymes from Bacillus stearothermophilus (Bst). One or more of the enzymes of the present invention may be produced and purified from a culture of Bacillus stearothermophilus or the genes encoding these enzymes may be cloned into a suitable expression vector, expressed in a heterologous host and purified. Among the DNA polymerase enzymes disclosed herein are mutated or truncated forms of the native enzyme which contain deletions in the 5'-3' exonuclease domain of the enzyme and/or its corresponding gene.

These enzymes may be used in nucleic acid amplification methods and other biochemical protocols that require a DNA polymerase activity. Furthermore, because the enzymes provided herein are thermostable, they are suitable for use in biochemical applications using higher temperatures than many other DNA polymerase enzymes, such as the Klenow fragment from E. coli DNA polymerase I. As permitted by the particular biochemical application, the enzymes provided herein may be used in an unpurified form. Alternatively, these enzymes may be purified prior to use.

Accordingly, the present invention also provides methods for the purification and use of Bst DNA polymerase enzymes. A preferred method of purification of the Bst DNA polymerases comprises two anion-exchange steps and phosphocellulose chromatography. Preferred chromatography conditions are described herein. However, it will be appreciated that variation of these conditions or their order would be apparent to one of skill in the art in light of the present disclosure.

Additionally, the present invention provides compositions comprising DNA fragments containing the genes encoding the enzymes of the present invention, vectors containing these genes, and methods of producing these recombinant enzymes.

The invention also encompasses a stable enzyme formulation comprising one or more of the DNA polymerase enzymes of the present invention in a buffer containing stabilizing agents.

Both the full length Bst polymerase enzyme and the variants thereof described and claimed herein may be cloned as a single uninterrupted gene on a multicopy vector in an *E. coli* host strain without being lethal to the host cell or under the control of a strong repressor. Moreover, the Bst polymerases may be expressed constitutively within the *E. coli* host cell; inducible expression of these enzymes, while possible, is not necessary to obtain a high yield of active enzyme.

Brief Description of the Drawings

Figure 1 shows the nucleotide sequences of the oligonucleotides used as primers and probes in the present invention.

Figure 2 is a graphical representation of the Bst polymerase gene, the location of nucleotide sequences therein complementary to the probes and PCR primers used in generating Bst amplicons, and the location with respect to the Bst gene of the amplicons so generated.

Figure 3 is a illustration of plasmid pGEM Bst 885.

Figure 4 is a illustration of plasmid pGEM Bst 1143.

Figure 5 is a schematic diagram of the results of Southern blot experiments with various labeled probes.

Figure 6 is a illustration of plasmid pGEM Bst 2.1 Sst.

Figure 7 is a illustration of plasmid pGEM Bst 5' end.

Figure 8 is a representation of the strategy for the construction of plasmid pUC Bst 1.

Figure 9 is a representation of the strategy for the construction of plasmid pUC Bst 2.

Figure 10 is a representation of the strategy for the construction of plasmid pUC Bst 3.

Figure 11 is a representation of the strategy for the construction of plasmids pUC Bst 2 AB, pUC Bst 2 CD, and pUC Bst 2 EF.

Figure 12 shows the N-terminal amino acid residues of various "Klenow-like" Bst polymerase enzymes.

Figure 13 is a schematic diagram of the relation of the Bst polymerase DNA inserts of pUC Bst 1, 2, 3, 4, 5 and 6, the 5' and 3' Bst genomic fragments, and the 1143 amplicon and the 885 amplicon to the Bst DNA polymerase gene and its three domains.

Figure 14 is an SDS-PAGE gel photograph of a cell lysate, a crude cell lysate containing purified Bst 1, a purified subtilisin fragment of Bst 1, partly purified Bst 3, and a purified preparation of a natural cleavage product of Bst 3.

Description of the Preferred Embodiments

The present invention relates to purified DNA polymerase enzymes derived from *Bacillus stearothermophilus*, DNA fragments encoding said enzymes for expression in a heterologous host cell, and methods of their production, purification and use. These enzymes are useful in biochemical applications, such as nucleic acid sequencing and amplification, including transcription based amplification systems. Preferably, the enzymes of the present invention are optimally active at temperatures above about 37°C to 42°C, and are thus suitable for biochemical applications that require a relatively high temperature of reaction. Most preferably, the enzymes of the present invention are optimally active at a temperature of about 60°C to 65°C.

The enzymes of the present invention have an amino acid sequence that bears some resemblance to DNA polymerase enzymes of the Class A designation, of which the non-thermostable *E. coli* DNA polymerase I is a member. A comparison of the amino acid sequences of the Class A DNA polymerases reveals regions of relative sequence homology separated by a number of reasonably well-defined "variable" regions. By variable regions is meant that a comparison of the amino acid sequences in these regions reveals that about 10% or more of the contiguous amino acid residues within a given region of the compared DNA polymerase sequences are different. For this purpose, a region is defined as 20 or more contiguous amino acid residues.

Likewise, a comparison of the nucleotide sequences of the genes encoding the Class A DNA polymerases reveal regions in which the nucleotide sequences are highly conserved between species, and other, variable regions. Because of the degeneracy of the genetic code, the amount of nucleotide sequence variability may be greater than the amount of amino acid variability between the corresponding proteins, expressed as a percentage. Alternatively, because each

amino acid is encoded by three nucleotide residues and a change in one of them may result in a codon corresponding to a different amino acid, the amount of nucleotide sequence variability in the genes encoding these enzymes may be less than that of the corresponding amino acid sequence on a percentage basis.

Expression of recombinant proteins in RNase-deficient cells and the use of tetracycline-resistance as a selectable marker gene have been described in the co-pending application by Kacian, *et al.* entitled Highly Purified Recombinant Reverse Transcriptase, which enjoys common ownership with and was filed the same day as this application. This application is hereby incorporated by reference herein.

Definitions

As used herein the following terms have the indicated meanings unless expressly indicated otherwise.

By "selectable marker gene" is meant a DNA fragment encoding a gene which, when carried and expressed by a host cell, is capable of conferring a growth advantage to that host cell as compared to cells not containing the selectable marker gene when both are grown in a culture media of a given composition. For example, the gene encoding β -lactamase will confer resistance to ampicillin on host cells containing this gene, whereas cells not containing the gene will be sensitive to ampicillin; thus only cells expressing the gene for β -lactamase will grow in media containing ampicillin. Similarly, cells unable to synthesize an essential amino acid will not grow in media not containing that amino acid, whereas cells containing a gene allowing the cell to make the essential amino acid will grow in the same media.

A selectable marker gene may be covalently linked, for example in a plasmid or expression vector, to one or more other gene or genetic element as a means of identifying cells containing both the selectable gene and the "silent" gene(s) and/or genetic element(s).

By a "purified" nucleic acid or protein is meant a nucleic acid or protein subjected to at least one step which removes cellular components such as carbohydrates, lipids, unwanted nucleic acids, or unwanted proteins from the indicated nucleic acid or protein.

By "upstream" is meant to the 5' side of a given locus on a nucleic acid strand, or in the case of a double stranded nucleic acid molecule, to the 5' side of a particular locus with respect to the direction of gene transcription in that region of the nucleic acid molecule.

By "downstream" is meant to the 3' side of a given locus on a nucleic acid strand, or in the case of a double stranded nucleic acid molecule, to the 3' side of a particular locus with respect to the direction of gene transcription in that region of the nucleic acid molecule.

By " T_m " is meant the temperature at which 50% of a population of a double-stranded nucleic acid molecules, or nucleic acid molecules having a double-stranded region, become single-stranded or thermally denatured.

By "recombinant" is meant that a nucleic acid molecule or protein is at least partially the result of *in vitro* biochemical techniques. A "recombinant DNA molecule" is thus a non-naturally occurring molecule. Such recombinant molecules include, but are not limited to molecules which comprise restriction endonuclease fragments, *in vitro* nucleic acid ligation products, *in vitro* exonuclease fragments, and expression vectors comprising heterologous genetic elements such as one or more of the following: promoters, repressor genes, selectable marker genes, temperature-sensitive DNA replication elements, structural genes, and the like.

"Recombinant" proteins or enzymes are those not found in nature. These include purified protein preparations and proteins produced from recombinant DNA molecules. The latter proteins are usually expressed in a heterologous host cell, i.e., one not native to the protein or enzyme in question. However, the gene encoding a recombinant protein may reside on an expression vector contained within a host cell of the same species as the organism from which the protein in question was derived.

By "truncated" is meant a smaller version of the gene or protein in question; with respect to the primary nucleotide or amino acid sequence, a truncated form of a reference nucleic acid or protein is one that lacks one or more nucleotides or amino acids as compared to the reference molecule.

By "substantial sequence homology" is meant that a first nucleic acid or protein molecule has a recognizably non-random similarity to a second reference nucleic acid or protein over at least about 89% of its nucleotide or amino acid sequence respectively.

By a nucleic acid or protein "domain" is meant at least one definite region of contiguous nucleotide or amino acid residues.

By "origin of replication" is meant a specific region of DNA at which primer production and initiation of DNA polymerase activity begins. In this specification, the term is used to mean a nucleic acid element present on a DNA expression vector that allows the expression vector to increase in copy number within a given host cell.

By "promoter" is meant a genetic element comprising a specific region of DNA at which an RNA polymerase enzyme can bind and begin transcription of a DNA template, thus providing the first step of translating the genetic information contained in the sequence of a nucleic acid into the production of a protein of an amino acid sequence corresponding to that nucleic acid sequence.

By "expression", "gene expression" or "protein expression" is meant the production of protein from information contained within a gene by a host organism.

By "transformation" is meant a biochemical method of inducing a host cell to internalize a nucleic acid molecule. Such nucleic acid molecules are usually genetic elements comprising at least an origin of replication, a selectable marker gene, and a promoter for expression of the selectable marker gene within the host cell.

By "heterologous" is meant not of the same species. Thus, an enzyme expressed in a heterologous host cell is produced in a host cell of a different species than the one from which the enzyme was originally derived.

By "gene" is meant a nucleic acid region having a nucleotide sequence that encodes an expressible protein or polypeptide. A gene may comprise one or more "coding sequences" containing codons that correspond to amino acid residues of the expressed protein; the gene may also comprise, but need not comprise, one or more "non-coding" nucleotide sequence regions that do not contain codons corresponding to amino acid residues of the expressed protein.

Materials and Methods

Sources of Bacterial Strains, Plasmids and Enzymes

The *Bacillus stearothermophilus* (Bst) ATCC type strain number 12980 was obtained from the American Type Culture Collection, Rockville, MD. Three strains of the bacterium *Escherichia coli* were used as host cells for cloning and expression of the Bst DNA polymerase enzymes of the present invention: *E. coli* strains XL1-Blue MRF' and JM109 were obtained from Stratagene Cloning Systems (San Diego, CA), and *E. coli* strain 1200 (CGSC strain # 4449) was obtained from the *E. coli* Genetic Stock Center (Yale University, New Haven, CT).

Plasmid vector pUC 18 was obtained from Life Technologies Inc. (Gaithersburg, MD), and vector pGem 3Z was obtained from Promega Corp. (Madison, WI). All restriction endonucleases and nucleic acid modifying enzymes, such as T4 DNA ligases, the Klenow fragment from *E. coli* DNA polymerase I, thermostable DNA polymerase, and polynucleotide kinase were obtained from commercial suppliers and were used in accordance with the manufacturer's instructions unless stated otherwise.

Bacterial cultures

Bacillus stearothermophilus and *E. coli* cultures were grown in 1% (w/v) tryptone, 0.5% (w/v) yeast extract and 0.5% (w/v) sodium chloride (LB broth) or on Petri plates of the same solution containing 1.3% (w/v) agar (LB agar). When required and as indicated in the following disclosure, ampicillin was used at a concentration of 100 µg/ml, tetracycline at a concentration of 12 µg/ml, isopropylthio-β-galactoside (IPTG) at a concentration of 0.5 mM, and 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal) at 50 µg/ml. *B. stearothermophilus* cultures were incubated at 55°C and *E. coli* cultures were incubated at 37°C, both with shaking to aerate.

DNA preparations

Plasmid DNA preparations were done by one of two methods as indicated in the following disclosure. The first is a standard boiling method for plasmid minipreparations as described in Sambrook *et al.*, *supra* at page 1.29, previously incorporated by reference herein. The second method utilized the Qiagen Plasmid Kit available from Qiagen Inc. (Chatsworth, CA) which was used for preparing purified DNA. This method makes use of a proprietary anion exchange resin and a series of proprietary elution buffers to prepare plasmid DNA without the need for CsCl gradients. The method is described in the *Qiagen Plasmid Handbook for Plasmid Midi Kit and Plasmid Maxi Kit* ©1992 Qiagen GmbH, Qiagen, Inc. For preparations of *B. stearothermophilus* genomic DNA, overnight cultures of cells were centrifuged and the pellet was resuspended in 1/50 the original volume of 10 mM Tris-HCl, 100 mM NaCl and 5 mM ethylenediamine tetraacetic acid (EDTA) (pH 7.0). Lysozyme was added to a final concentration of 2 mg/ml, and the suspension was incubated at 37°C for 20 minutes. Nine volumes of a solution containing 10 mM Tris-Cl (pH 8.0), 250 mM NaCl, 1.2% (v/v) Triton X-100, 100 µg/ml RNase A, 12 mM EDTA and 0.5 M guanidine-HCl were added to the cell suspension and the mixture was incubated on ice for 20 minutes. The mixture was made 2 mg/ml in proteinase K and incubated at 50°C for 2 hours with gentle shaking. The solution was then centrifuged at 15-20,000 X g for 10 minutes and the supernatant decanted off. Bst genomic DNA was then prepared using a variation of the Qiagen method described above for the recovery of plasmid DNA; other methods of preparing genomic DNA from cleared cell lysates are well known to those of ordinary skill in the art.

Probe labeling

Single-stranded DNA oligomer probes were labeled by one of two methods as indicated in the following disclosure. The first method was by utilizing T4 polynucleotide kinase to label the 5' end of an oligonucleotide with radioactive ³²P.

as exemplified in Sambrook *et al.*, *supra*, at page 10.60, previously incorporated by reference. Other methods of labeling probes with radioactive atoms are well known to those of ordinary skill in the art. This protocol was used to label oligonucleotides 16, 24 and 25. The second labeling method utilized was the LIGHTSMITH™ chemiluminescent system (high stringency) obtained from Promega Corp., which was used to label oligonucleotides 15, 21 and 20. This method makes use of non-radioactive labels and is thus generally more convenient than using ³²P or other radionuclides for detection. However, oligonucleotides 15, 20 and 21 may easily be labelled with radioactive atoms as described above with no loss in detection ability.

Gel electrophoresis and gel isolation of DNA fragments

Unless indicated otherwise, agarose gels were 1% (w/v) agarose (Life Technologies Inc.). The agarose gels were run in 1 X TAE buffer (40 mM Tris base (pH 8.0), 20 mM sodium acetate, 2 mM EDTA) containing 2 µg/ml ethidium bromide. To gel purify DNA fragments, agarose gel slices containing the desired fragments were excised and frozen on dry ice. The gel slices were then thawed, crushed and extracted with TAE-saturated phenol. Following a brief centrifugation, the aqueous phases were collected and extracted with a solution of 50% (v/v) TE-(10 mM Tris (pH 8.0) and 1 mM EDTA) saturated phenol, 49% (v/v) chloroform and 1% (v/v) isoamyl alcohol. This was followed by extraction of the aqueous phase with a solution of 24:1 (v/v) chloroform:isoamyl alcohol. To ethanol precipitate the nucleic acids, the aqueous phases were then collected, given 1/10 volume of 3 M sodium acetate and 2 1/2 volumes of ethanol, and centrifuged. The pellets were dissolved in an appropriate volume of TAE buffer.

Southern blot, hybridization, wash and detection methods

DNA fragments were separated on 1% (w/v) agarose gels and transferred by capillary action in 20 X SSC (3 M sodium chloride, 0.3 M sodium citrate) to Nytran (+) nylon membranes (Schleicher & Schuell, Inc., Keene, NH) by the method of Southern as described in Sambrook *et al.*, *supra*, at page 9.38, previously incorporated by reference herein. The membranes were air dried and baked at 80°C in a vacuum oven for 2 hours prior to hybridization.

Membranes to be hybridized with the ³²P labeled probes were first pre-hybridized at 37°C for approximately 2 hours in 6 X SSPE (20 X SSPE = 3.0 M NaCl, 0.2 M NaH₂PO₄ (pH 7.4), 0.02 M EDTA) (Life Technologies Inc.), 5 X Denhardt's solution (0.1% (w/v) of each of the following: bovine serum albumin, ficoll and polyvinylpyrrolidone), 1% (w/v) SDS (sodium dodecyl sulfate), 100 µg/ml sonicated denatured salmon sperm DNA and formamide (25% (v/v) for oligomer 16 and 20% (v/v) for oligomers 24 and 25). The membranes were then incubated overnight at 37°C in a hybridization solution made as above except with 1 X (rather than 5 X) Denhardt's solution and with the addition of 1 X 10⁶ counts per minute (CPM)/ml of the labeled probe. The membranes were then sequentially washed at room temperature in aqueous solutions of 5 X SSC and 0.1% SDS, 1 X SSC and 0.5% SDS, and 0.2 X SSC and 0.5% SDS. Membranes incubated with labeled oligonucleotides 24 and 25 were additionally washed with a solution of 0.1 X SSC and 0.1% (w/v) SDS. Following the wash steps, the membranes were dried and allowed to expose X-ray film using intensifier screens at -80°C for 3 hours.

Membranes to be hybridized with oligomers 15, 21 and 20 were processed according to the manufacturer's "high stringency" protocol (Promega, Inc.). As stated above, the use of chemiluminescent probes was for convenience only; had the probes been ³²P labelled, the Southern hybridization procedure could have been performed as described above. The hybridization and wash temperatures used were 56°C for oligomer 15, 48°C for oligomer 21 and 51°C for oligomer 20.

Sequencing reactions

Plasmid DNA preparations of clones pGem Bst 2.1 Sst and pGem Bst 5' end were used as the templates for sequencing the Bst DNA polymerase gene using the dideoxy chain-termination method. *See e.g.*, Sanger *et al.*, *Proc. Nat. Acad. Sci.* (USA) 74:5463-5467 (1977) hereby incorporated by reference herein. Four µg of DNA were used with 1 pmol of primer in each reaction. Sequencing was done using a Sequenase™ kit (version 2.0) obtained from United States Biochemical Co. according to the manufacturer's protocol. In regions of the nucleic acid strand which were difficult to sequence a variety of techniques known to those of skill in the art were used to minimize inter- and intramolecular reannealing in the sequencing reactions and the polyacrylamide gel. The most successful technique for resolving hard to read regions of the nucleotide sequences was the inclusion of 40% (v/v) formamide in the sequencing gel. Variations of the dideoxy sequencing method are well known to those of ordinary skill in the art, as are other nucleic acid sequencing methods such as the method of Maxam and Gilbert, *Methods in Enzymology* 65:497-559 (1980) hereby incorporated by reference herein.

Bst DNA polymerase activity assays

Bst DNA polymerase activity was determined by a cDNA synthesis reaction using a synthetic single-stranded template and primer complementary to a portion of the template. Detection of the cDNA strand was accomplished by hybridizing the polymerase product with an acridinium ester-labeled probe designed to be complementary to the cDNA strand. The labeled double-stranded hybrid was detected using the hybridization protection assay (HPA) as described in Arnold et al., *Clin. Chem.* 35:1588-1594 (1989) and Arnold et al., U.S. Patent No. 5,283,174, the latter of which enjoys common ownership with the present application and both of which are hereby incorporated by reference herein. The sample suspected of containing *Bst* DNA polymerase was incubated in a reaction mixture containing 50 mM Tris (pH 7.5), 25 mM KCl, 4 mM MgCl₂, 2 mM spermidine, 0.2 mM each dNTP at 60°C for 8 minutes with 20 fmol of an 86 base pair synthetic DNA template derived from bacteriophage T7 gene 10 plus 30 pmol of a 23 base primer complementary to the 3' end of the template strand. The reaction mixture was incubated at 95°C for 3 minutes to denature the DNA strands, then incubated at 60°C for 10 minutes with 1.5 pmol of the acridinium ester labeled detection probe. Unhybridized probe was hydrolysed at 60°C for 7 minutes with an alkaline borate buffer and the remaining chemiluminescence, contributed by the hybridized labeled probe, was measured in a LEADER-1™ luminometer, (Gen-Probe Incorporated, San Diego, CA), after injection of a dilute solution of H₂O₂ and a solution of sodium hydroxide.

Primer and probe design

Several DNA polymerase genes have been cloned and sequenced, and alignment of these sequences reveals numerous areas in which the nucleotide sequences of the DNA polymerase genes are somewhat conserved between species. See e.g., Delarue, *Protein Engineering* 3:461-4670 (1990). The published *Bca* sequence (see Uemori et al., *J. Biochem.* 113:401-410 (1993)) was used as a basis for designing primers and probes to some of these conserved regions using the *Bca* nucleotide sequence as a starting point; the *Bca* DNA polymerase nucleotide sequence contained in this publication is hereby incorporated by reference herein. The nucleotide sequences of the primers and probes used in the course of the present invention are shown in Figure 1. Mismatches between the *Bca* DNA polymerase sequence and these primers and probes are present in some cases. These primers and probes were purposely designed with mismatches for one of two reasons. First, a mismatch was sometimes designed in order to create a codon, based on an analysis of codon usage in various *B. stearothermophilus* genes encoding proteins of known sequence, thought to be preferred by *B. stearothermophilus* over the codon present in the *Bca* DNA polymerase gene. The second reason that a mismatch between the *Bca* DNA polymerase nucleotide sequence and the primers described herein was designed was to better match an interspecies consensus of the nucleotides present in that relative position, as deduced from alignments of other DNA polymerases. Occasionally, a T was used in the *Bst* primers and probes in place of a C in the *Bca* DNA polymerase sequence since a G/T mismatch is relatively stable and therefore the oligonucleotides would be better able to hybridize to different targets.

Purification of Bst Polymerase Enzymes

Bacterial host cells containing genes encoding *Bst* polymerase enzymes were grown in liquid culture for sixteen hours with shaking, as described above. The preferred host cell strain was *E. coli* strain 1200. After sixteen hours at 37°C, the cell cultures were centrifuged at 9000 x g for 10 minutes, and the cell pellets were washed once with 20 mM Tris HCl (pH 7.5) containing 0.1 mM EDTA. Fifty grams of cell pellets were suspended in ten volumes of lysis buffer (25 mM Tris HCl, 10 mM EDTA, 5 mM DTT, 1%(v/v) Triton X-100, 10 mM NaCl, 10%(v/v) glycerol and 1 mM phenylmethylsulfonyl fluoride (PMSF)). The cell suspension was then passed twice through a Gaulin cell homogenizer at 8000 psi to lyse the cells. The cell lysate was then centrifuged at 12,000 x g for 15 minutes and the supernatant collected and stored at -70°C.

Chromatography was performed at 25°C. Two hundred fifty ml of the cell lysate was applied to a 190 x 26 mm column of Poros-HQ anion exchange resin (PerSeptive Biosystems, Cambridge, MA). The column was washed with 160 ml of a solution containing 20 mM Tris-HCl (pH 8.0) and 0.1 mM EDTA (Buffer A). The bound proteins were eluted with a 500 ml linear gradient from 0 to 0.5 M NaCl in Buffer A at a flow rate of 5 ml/minute. DNA polymerase activity eluted at an ionic strength corresponding to a salt concentration of between 0.1 and 0.2 M NaCl. Ten ml fractions were collected. In some cases, active fractions were pooled and passed through a second Poros-HQ column under similar conditions.

The pooled anion exchange fractions, in a volume of 40 ml, were diluted with 3 volumes of buffer A and applied to a 190 x 26 mm phosphocellulose P-11 column equilibrated in Buffer A containing 50 mM NaCl. The column was washed with 200 ml of the same buffer. The bound proteins were eluted in a linear gradient of 0.1 M to 0.7 M NaCl in Buffer A at a flow rate of 3 ml/minute. The DNA polymerase activity eluted from this column at an ionic strength corresponding to a salt concentration of about 0.25-0.30 M NaCl. Fractions of 10 ml were collected.

The pooled active fractions from the phosphocellulose step were dialyzed twice against 1 liter of Buffer A at 25°C and applied to an 250 x 10 mm SynChropak AX-300 anion exchange HPLC column pre-equilibrated in Buffer A (Rainin

Corp., Emeryville, CA) at a flow rate of 2.4 ml/minute. Samples were in Buffer A. Bound proteins were eluted with a fifty ml linear gradient from 100 mM to 700 mM NaCl in Buffer A at 2.4 ml/minute. Bst DNA polymerase activity eluted at an ionic strength corresponding to a salt concentration of between about 0.2 and 0.4 M NaCl.

In some cases, the purified full-length Bst polymerase was further treated with a protease to generate an active truncated form of the enzyme. In such cases, purified Bst polymerase (0.33 mg/ml) was treated with subtilisin in Buffer A at a 1:200 (w/w) ratio of protease to Bst polymerase at 25°C. The reaction mixture was incubated at 25°C for 40 minutes, and the reaction was terminated with the addition of PMSF to a final concentration of 1 mM. The active proteolytic fragment of Bst DNA polymerase was purified using a 60 x 10 mm column of hydroxyapatite (HA) (Bio Gel-HT, BioRad Laboratories, Richmond, CA) according to the method of Jacobsen *et al.*, *Eur. J. Biochem.* 45:623 (1974) the disclosure of which is hereby incorporated by reference herein. The HA column was equilibrated in 20 mM sodium phosphate (pH 7.0), and Bst polymerase was eluted with a linear gradient from 20 to 350 mM sodium phosphate (pH 7.0) at a flow rate of 1 ml/minute. The active protein eluted at an ionic strength corresponding to about 0.3 M sodium phosphate. The active fractions were pooled.

Figure 14 is a photograph of an SDS-PAGE gel containing a crude bacterial lysate, purified Bst 1, purified Bst 3, a purified preparation of the naturally-occurring breakdown product of Bst 3, and Bst 4 (described further below).

The purification scheme described above resulted in the preparation of highly purified Bst polymerase enzymes as determined by SDS-PAGE followed by staining with Coomassie Brilliant Blue. However, variations based on this scheme or alteration of the order of the steps outlined above will be readily apparent to one of ordinary skill in the art in light of the present specification.

Examples

The examples which follow are intended to illustrate various embodiments of the present invention in order to allow one of ordinary skill in the art to make and use the methods and compositions of the present invention. However, it will be appreciated that variations in the nucleotide sequences of the nucleic acids described herein or in the amino acid sequences of the proteins described herein, or both, may exist due to variation between different strains of *Bacillus stearothermophilus*, or due to spontaneous mutations arising as the result of genetic drift. Furthermore, the nucleotide and/or amino acid sequences disclosed herein may easily be modified by genetic and biochemical techniques to produce derivative proteins having DNA polymerase activities. The resulting protein will have substantially the same amino acid sequence as the Bst polymerase enzymes disclosed herein, and may exhibit a higher or lower level of DNA polymerase activity. The activity of any such derivative may be detected or measured as described above.

Thus, the scope of the present invention is not to be limited solely to the embodiments which follow, said scope to be determined solely by the claims which follow this disclosure.

Example 1: Identification of the Genomic Bst DNA Polymerase Gene

Amplicons 885 and 764

The location of PCR amplicons and primers used to generate these amplicons are shown in Figure 2 relative to the Bst DNA polymerase gene. The polymerase chain reaction (PCR) is a proprietary method of conducting nucleic acid amplification, and is patented under the following U.S. patents: Mullis *et al.*, U.S. Patents No. 4,683,195, 4,683,202, and 4,800,159, assigned to Hoffman-La Roche, Inc., Nutley, NJ. Amplicon 885 was produced by PCR amplification of Bst genomic DNA. Amplicon 764 was generated using amplicon 885 as a substrate using a second set of primers to nucleotide sequences within amplicon 885.

Oligonucleotides 16 and 25, shown in Figure 1 (SEQ ID NOS: 1 and 3, respectively) were used as primers in a PCR reaction using genomic Bst DNA as the template. The PCR reaction mixtures contained 50 pmol of each primer, 0.5 µg template DNA and 5 units of *Thermus thermophilus* DNA polymerase in 100 µl of 10 mM Tris-HCl (pH 8.3), 50 mM potassium chloride, 1.5 mM magnesium chloride, and 0.2 mM each of dATP, dCTP, dGTP and dTTP. The reaction mixtures were overlaid with 100 µl of silicone oil and incubated in a thermocycler apparatus at 95°C for 1.5 minutes followed by thirty cycles of 95°C 0.5 min, 50°C 2.5 min and 72°C 1.5 min. A second set of reactions was done as above except dimethylsulfoxide (DMSO) was added to a final concentration of 13.3% (v/v) to reduce the T_m of the primers by approximately 8°C. The effective annealing temperature of the resulting reaction was 58°C (see Chester and Marshak, *Anal. Biochem.* 209:284-290 (1993)). Separate reactions were run with no Bst template DNA added as negative controls.

Oligomers 17 and 24, also shown in Figure 1 (SEQ ID NO: 5 and 7, respectively) were used as primers in secondary PCR reactions. Aliquots of 2 µl containing the amplicons from each of the primary reaction mixtures described above were used as templates. All reaction conditions were the same as in the primary reactions; amplicons generated at the 50°C annealing temperature in the primary amplifications were used at 50°C in the secondary reactions, and amplicons generated using 13.3% DMSO in the primary amplifications were similarly incubated with 13.3% DMSO in the secondary reactions.

Aliquots of 16 µl from each reaction mixture were subjected to electrophoresis on a 1.5% agarose gel and the gels were stained with ethidium bromide. Expected amplicon sizes were calculated based on the published Bca sequence. In each gel lane corresponding to a reaction mixture containing template DNA, a single band appeared having approximately the expected size: a band of approximately 885 base pairs in the reaction mixture using oligomers 16 and 25 as PCR primers, and a band of approximately 764 base pairs in the reaction mixture using oligomers 17 and 24 as PCR primers. No amplicons were observed in the negative controls lacking template DNA. The gel was Southern blotted and probed with labelled oligonucleotide 20, shown in Figure 1 (SEQ ID NO: 11) as described above. The primer extension products of both the primary and secondary PCR reactions were detected by labelled oligonucleotide 20. No hybridization was observed in the negative control reactions.

Amplicon 1143

Amplicon 1143 (also shown in Figure 2) was produced by PCR amplification of Bst genomic DNA using the same conditions as in the primary amplifications above. The primers used in this reaction were oligonucleotides 20 and 21, shown in Figure 1 (SEQ ID NOS: 11 and 9, respectively). An aliquot of this reaction mixture was subjected to electrophoresis on a 1% agarose gel and stained with ethidium bromide. A single amplicon of approximately the expected size of 1143 base pairs was observed, and no amplicon was observed in the negative controls. The gel was subjected to the Southern transfer method and the membrane probed with labelled oligonucleotide 16 (Figure 1) as described above. The primer extension product hybridized with labelled oligonucleotide 16 (SEQ ID NO:1). No hybridization was observed with the negative control reactions.

Cloning of amplicons 885 and 1143

Amplicons 885 and 1143 were gel isolated as described above. The purified amplicons were incubated with T4 DNA polymerase (Stratagene Cloning Systems) to assure that the ends were blunt. The amplicons were incubated at 11°C for 20 minutes with 5 units of T4 DNA polymerase in a 50 µl reaction containing 10 mM Tris-HCl (pH 7.9), 10 mM magnesium chloride, 50 mM sodium chloride, 1 mM dithiothreitol, 100 µg/ml acetylated bovine serum albumin (BSA) (New England Biolabs) and 0.1 mM each of dATP, dCTP, dGTP and dTTP. Following the reaction, the amplicons were diluted with TE buffer (10 mM Tris-HCl, 1 mM EDTA (pH 8.0)) and extracted with solutions of phenol/chloroform/isoamyl alcohol and chloroform/isoamyl alcohol as described above. The primer extension products were co-precipitated in ethanol with 0.15 µg plasmid pGem3Z which had been digested with Sma I and again extracted using the same two solutions as above. The precipitated nucleic acids were resuspended and incubated overnight at room temperature in a 10 µl total volume containing 50 mM Tris-HCl (pH 7.6), 10 mM magnesium chloride, 1 mM ATP, 1 mM dithiothreitol, 5% polyethylene glycol-8000, and 10 units T4 DNA ligase. Eight units of Sma I were also added to this reaction to prevent religation of the vector.

The resulting circularized amplicon-containing plasmids were used to transform XL1-Blue MRF⁺ cells. The transformed cells were plated on LB agar plates containing ampicillin, IPTG and X-gal. White colonies, indicating the presence of DNA inserts, were selected and grown in LB broth with ampicillin. Plasmid minipreparations were made according to the standard boiling procedure (see e.g., Sambrook, *supra*, previously incorporated by reference) and the isolates were analyzed using restriction endonuclease digestions of the clones.

Detection of the 885 amplicon insert was accomplished by digesting each plasmid miniprep with Eco RI plus Hind III. The digests were subjected to electrophoresis on a 1% agarose gel and Southern blotted as described above. The Southern blots were hybridized with labelled oligonucleotide 20. The probe detected faint low molecular weight bands. Since the sequence of oligonucleotide 20 was expected to be near the end of the amplicon (see Figures 2 and 3), it appeared likely that its corresponding sequence within the amplicon was located between the vector restriction site and an Eco RI or Hind III restriction site within the amplicon; oligonucleotide 16 (one of the primers) contained a known Eco RI site but would not generate such a small restriction fragment. Two isolates were tested further by performing both separate and combined Eco RI and Hind III digestions, as well as Sst I and Hind III digestions, followed by Southern blotting and hybridization with labelled oligonucleotide 20. The structure of the amplicon 885-containing clone was deduced from these experiments, and is shown in Figure 3. This clone was named pGem Bst 885.

Detection of the 1143 amplicon insert was performed as above by digesting each plasmid miniprep with Eco RI and Hind III followed by agarose gel electrophoresis. Inserts of the predicted size were observed in several isolates as determined by ethidium bromide staining. After Southern blot hybridization analysis, the inserts were found to hybridize strongly with labelled oligonucleotide 16. One clone was selected as representative and the deduced restriction map is shown in Figure 4. This clone was named pGem Bst 1143.

Partial sequencing of the amplicon clones

Sequencing reactions were performed as described above using both pGem Bst 885 and pGem Bst 1143 DNA samples. The primers used in both sets of reactions were the SP6 and T7 promoter primers available from Promega Corp. (SEQ ID NOS: 15 and 16, respectively). These primers were specific for the SP6 and T7 promoter regions in the pGem vector, and were useful for sequencing the Bst amplicon inserts in both directions. The resulting amplicon sequences were aligned with the known *Bca* polymerase gene sequence and were found to be approximately 88% homologous in the overlapping regions. In addition, the sequences present in the overlap region of the two amplicons were the same, indicating that they had arisen from the same gene. The evidence therefore indicated that the amplicons represented true fragments of the Bst DNA polymerase gene.

The sequences obtained from the 885 and 1143 amplicon clones provided two pieces of information that would allow the isolation of gene fragments obtained from genomic Bst DNA. First, the sequence of the Bst polymerase gene in the regions corresponding to oligonucleotides 16, 17, 20 and 24 indicated that these oligonucleotides would be suitable for use as probes of genomic Bst DNA in Southern blots. Second, two restriction endonuclease sites within the Bst DNA polymerase gene were identified: an Sst I restriction site at *Bca* coordinate 1516 and a Hind III restriction site at *Bca* coordinate 1687. These sites provide a strategy for isolating fragments of the Bst polymerase gene from the genomic DNA.

Example 2: Identification and Cloning of Bst DNA Polymerase*Cloning the 3' End of the Gene*

Aliquots of genomic Bst DNA were digested with Sst I and subjected to electrophoresis on 1% agarose gels, and Southern blotted as described above. The transfer membranes were then probed separately with six different labelled oligonucleotides and autoradiographed as described above. As shown in Figure 5, labelled oligonucleotides 16, 20, 24 and 25 hybridized to an Sst I fragment approximately 2.1 kb in length. These oligonucleotides were designed based upon *Bca* DNA polymerase sequences near the 3' end of the gene. Two other oligonucleotides, 15 and 21, based upon *Bca* sequences toward the 5' end of the gene, did not hybridize to this Sst I fragment. These results indicated that the Sst I restriction site could be used to isolate a genomic DNA fragment containing the 3' end of the gene.

Twenty five µg of purified Bst genomic DNA was digested with Sst I and subjected to electrophoresis on a 1% agarose gel. Gel slices were excised in a region of the gel corresponding to approximately 2.1 kb. The DNA was purified from the gel slices as described above; approximately 0.45 µg were recovered.

Vector pGem 3Z was digested with Sst I and sequentially extracted with solutions of phenol/chloroform/isoamyl alcohol and chloroform/isoamyl alcohol as described above. The gel purified 2.1 kb Sst I fragment was ethanol precipitated together with 0.23 µg of the Sst I-digested pGem 3Z vector. The precipitated DNA was redissolved and ligated at 16°C in a 15 µl reaction overnight as described above. The ligation mixture was used to transform XL1-Blue MRF' cells and the transformed cells were plated onto LB agar plates containing ampicillin, IPTG and X-gal. White colonies, indicating insert DNA, were selected and grown overnight in 200 µl LB broth cultures containing ampicillin in microtiter dishes. One hundred µl aliquots of each culture were filtered onto a Schleicher & Schuell Nytran (+) membrane using a Bio Rad Bio-Dot microfiltration apparatus and washed with 200 µl of 10 X SSC. The membrane was air dried for 5 minutes and then successively placed onto filter papers soaked with: 10% SDS for 3 minutes, 0.5 M sodium hydroxide for 5 minutes, 1M Tris-HCl (pH 8.0) for 5 minutes and 0.7 M Tris-HCl (pH 8.0) containing 1.5 M sodium chloride for 5 minutes. The filter was air dried, baked in a vacuum oven at 80°C for 2 hours and then hybridized with labelled oligonucleotide 20, as described above.

A clone was identified which hybridized to oligonucleotide 20. This clone was cultured overnight at 37°C in LB broth containing ampicillin. Plasmid minipreparations were made as described above, and plasmid DNA was digested with Sst I and Hind III, both separately and together. The restriction digests were subjected to electrophoresis on a 1% agarose gel and stained with ethidium bromide. Two Sst I bands were observed at locations corresponding to approximately 2.1 kb and 2.7 kb, and virtually the same pattern was observed on gels loaded with plasmid DNA digested with Sst I plus Hind III. Plasmid DNA digested with Hind III alone gave rise to a large band upon electrophoresis of approximately 4.5 kb, and a very small band of approximately 0.1-0.2 kb. The gel was Southern blotted and allowed to hybridize with labelled oligonucleotide 25 as described above. The probe hybridized to the 2.1 kb Sst I bands in lanes corresponding to both the Sst I and Sst I plus Hind III restriction digestion reactions and to the 4.5 kb band in lanes corresponding to the Hind III digestion.

To verify that the clone contained the expected 5' end of the 2.1 kb Sst I fragment, it was also probed with labelled oligonucleotide 16, which was expected to be complementary to a region of the Bst DNA polymerase gene very near the Sst I site. In this case, DNA dot blots were used to identify clones containing the desired nucleotide sequence, rather than a Southern hybridization procedure. One µg aliquots of plasmids pGem 3Z, pGem Bst 1143 and the plasmid thought to contain the 2.1 kb Sst I fragment were denatured in 110 µl 0.3 M sodium hydroxide at 65°C for one hour. One hundred

and ten μ l of 2M ammonium acetate was added and the samples were filtered onto a Schleicher & Schuell Nytran (+) membrane using a Bio Rad Bio-Dot microfiltration apparatus as described above. The membrane was washed with 1 M ammonium acetate and baked in a vacuum oven at 80°C for 45 minutes. The membrane was then allowed to hybridize with oligonucleotide 16 as described above. Both the plasmid thought to contain the 2.1 kb Sst I genomic fragment clone and the pGem Bst 1143 amplicon clone hybridized strongly with the labelled probe, indicating that the 5' end of the fragment was present in both plasmids. Preliminary sequencing reactions were done as described above, using the SP6 promoter primer (SEQ ID NO: 15). The resulting nucleotide sequence matched the sequence deduced from the amplicon clones pGem Bst 885 and pGem Bst 1143 and also confirmed the presence of the Hind III site in the genomic clone.

Additional restriction endonuclease digestions of this plasmid with restriction endonuclease Sal I yielded two bands of approximately 3.1 and 1.8 kb which indicated that a Sal I site was present in the 3' non-coding region downstream from the 3' end of the polymerase gene. This clone was named pGem Bst 2.1 Sst and is shown in Figure 6.

Cloning the 5' End of the Gene

Because the 3' end clone pGem Bst 2.1 Sst contained a Hind III restriction site near the 5' end, the Hind III site was used to isolate a genomic Bst DNA fragment overlapping the 2.1 kb Sst I gene fragment of pGem Bst 2.1 Sst. In order to accomplish this, Bst genomic DNA was digested with Hind III plus a panel of second enzymes to identify a fragment of at least 1.7 kb, calculated to be large enough to contain the missing 5' portion of the DNA polymerase gene.

Bst genomic DNA was digested with Hind III alone and with Hind III plus the following second enzymes: Bam HI, Eco RI, Kpn I, Sph I, Xba I and Xmn I. Three microgram aliquots of each reaction mixture were subjected to electrophoresis in duplicate 1% agarose gels. Each gel was then analyzed by Southern blot using labelled oligonucleotide 20 or 21 as a probe, as described above. Upon analysis, each of the duplicate membranes displayed identical hybridization patterns. In lanes corresponding to each restriction digest, except the Hind III plus Sph I and Hind III plus Xmn I samples, a single band of approximately 4 kb was seen, indicating that the closest Hind III site upstream from the previously determined Hind III site in the 3' fragment clone was 4 kb distant, and that there were no restriction sites for the second enzymes between these Hind III sites. The lanes corresponding to the Hind III plus Xmn I digests displayed a single band of approximately 1.4 kb, which would not be long enough to contain the entire 5' end of the gene, as predicted from the Bca nucleotide sequence. The lanes corresponding to the Hind III plus Sph I digests displayed a single band of approximately 2.8-3 kb.

This 3 kb fragment was purified and cloned as follows. Bst genomic DNA was digested with Hind III plus Sph I at 37°C. Vector pGem 3Z was also digested with the same enzymes. Both digests were subjected to electrophoresis on a 1% agarose gel and stained with ethidium bromide. The resulting vector fragment and the 3 kb Hind III/Sph I Bst genomic fragment were excised from the gel, and the DNA was gel purified as described above. Approximately 125 ng of the vector DNA were ethanol precipitated together with the 3 kb Hind III/Sph I fragment. The precipitated DNA was redissolved and allowed to ligate overnight at 16°C in a reaction mixture containing one unit of T4 DNA ligase in a total volume of 15 μ l. The ligation reaction mixture was used to transform XL1-Blue MRF⁺ cells and the transformed cells were plated onto LB agar plates containing ampicillin, IPTG and X-gal. White colonies, indicating DNA inserts, were selected and grown overnight in 200 μ l LB broth cultures containing ampicillin in microtiter dishes. One hundred μ l aliquots of each culture were filtered onto duplicate hybridization membranes as described above, air dried, baked in a vacuum oven at 80°C for 2 hours. The duplicate membranes were separately allowed to hybridize with labelled oligonucleotides 20 and 21. Samples obtained from three cultures showed some hybridization with each probe. These cultures were cultured overnight in LB broth containing ampicillin and plasmid minipreparations were made as described above. The resulting plasmid DNA from each sample was digested with Xmn I alone and with Hind III plus Sph I, subjected to electrophoresis on a 1% agarose gel and stained with ethidium bromide. Samples from two of the clones appeared to yield DNA bands of the expected size. (The Hind III plus Sph I reaction was expected to yield fragments of approximately 3 kb and 2.7 kb. These bands could not be resolved on the gel. The Xmn I reaction was expected to yield DNA fragments of approximately 3.4 kb and 2.4 kb). One of these clones was selected for further analysis. The plasmid DNA from this clone was digested with Hind III and subjected to electrophoresis, as described above. A single band of approximately 5.6 kb was present as predicted for the linear plasmid. The same plasmid DNA was also digested with Xmn I, Hind III plus Xmn I and Hind III plus Sph I, subjected to electrophoresis on triplicate 1% agarose gels, stained with ethidium bromide and transferred to hybridization membranes by the method of Southern, as described above. The triplicate membranes were then separately allowed to hybridize with labelled oligonucleotides 15, 21 and 20. A summary of the results obtained

are indicated below.

	Observed ethidium stained bands (kb)	Detected with labelled oligo 15	Detected with labelled oligo 20	Detected with labelled oligo 21
Digested with Xmn I	3.2		3.2	3.2
	1.1	1.1		
	0.9			
	0.23			
Digested with Hind III + Xmn I	1.8			
	1.4		1.4	1.4
	1.1	1.1		
	0.9			
Digested with Hind III + Sph I	0.23			
	2.7 (doublet)	2.7	2.7	2.7

These results indicated that this clone contained the 5' end of the Bst DNA polymerase gene. Preliminary sequencing reactions were done as described above, using the SP6 promoter primer of nucleotide sequence SEQ ID NO: 15. This promoter-primer primes a sequencing reaction beginning from outside the Bst DNA polymerase coding region and extending towards the 5' end of the gene. The results of the sequencing reaction showed that the nucleotide sequence of the DNA polymerase gene nearest the vector cloning site matched the sequence that had been previously obtained from the 5' end of the 3' gene fragment of pGem Bst 2.1 Sst. These data thereby indicated that the new 5' gene fragment clone overlapped the cloned 3' gene fragment insert. Additional restriction mapping of the new insert also revealed the presence of two Sal I sites: one approximately 0.2 kb upstream from the 5' end of the gene in the 5' flanking region, and one approximately 0.5 kb downstream from the 5' end of the gene, in the coding region. This new plasmid was named pGem Bst 5' end, and is shown in Figure 7.

Example 3: Construction of a Plasmid Containing the Full Length Bst DNA Polymerase Gene

A plasmid containing a full length copy of the Bst DNA polymerase gene was constructed by combining segments of the 5' and 3' gene fragment clones pGem Bst 5' end and pGem Bst 2.1 Sst. The strategy used is outlined in Figure 8.

First, a precursor plasmid was constructed which contained the portion of the 3' end of the gene shown as fragment A in Figure 8. Purified plasmid pGem Bst 2.1 Sst DNA was digested with Hind III plus Sal I and subjected to electrophoresis on a 1% agarose gel. A gel slice containing a DNA band of approximately 1.6 kb (fragment A) was excised and the DNA was gel purified, as described above. Plasmid vector pUC 18 was digested with the same two enzymes, and purified at the same time. Approximately 0.25 µg fragment A and 0.15 µg pUC 18 fragment were ethanol precipitated together. The nucleic acids were redissolved and ligated overnight at 16°C in a reaction mixture containing 10 units T4 DNA ligase in a volume of 15 µl, as described above. The ligation mixture was used to transform XL1-Blue MRF' cells and the transformed cells were plated on LB agar plates containing ampicillin, IPTG and X-gal. White colonies, indicating a DNA insert, were selected and grown in LB broth with ampicillin. Plasmid minipreparations were made, as described above, and the resulting plasmid DNA was digested with Hind III plus Sal I, subjected to electrophoresis on a 1% agarose gel and stained with ethidium bromide. A sample was identified which gave rise to DNA bands of the expected sizes of 1.6 and 2.7 kb. This plasmid clone was named pUC Bst 3' end.

pGem Bst 5' end was used for isolating the portion of the 5' end of the gene shown as an Aat II/Hind III fragment (fragment B) in Figure 8 as follows. Sequencing and restriction mapping of this clone had revealed the Sal I and Aat II restriction sites indicated. Purified pGem Bst 5' end DNA was digested with Hind III plus Sph I plus Ssp I and the precursor 2.86 kb Hind III/Sph I fragment was gel purified, as described above. The precursor fragment was subsequently digested with Aat II and the 2.3 kb fragment B was gel purified, as described above. (This fragment was prepared in two stages, with the initial Sph I and Ssp I digestions in order to eliminate unwanted plasmid fragments that would have co-migrated with the desired fragment during electrophoresis.)

Plasmid pUC Bst 3' end DNA was digested with Hind III plus Aat II and the large fragment was gel purified as described above. Approximately 0.6 µg of the digested pUC Bst 3' end DNA was ethanol precipitated together with

approximately 0.5 µg fragment B and allowed to ligate overnight at 16°C in a reaction mixture containing 10 units of T4 DNA ligase. The ligation mixture was used to transform XL1-Blue MRF' cells and the transformed cells were plated on LB agar plates containing ampicillin. Colonies were selected, grown in LB broth containing ampicillin and plasmid minipreparations were made, as described above. The plasmid DNA was digested with Sal I digestions and subjected to agarose gel electrophoresis, as described above. Three bands having the expected sizes of approximately 2.7, 2.6 and 0.7 kb were observed in the majority of the plasmid preparations so screened, indicating successful construction of the full length DNA polymerase gene, including 5' and 3' genomic flanking sequences. One of these clones was selected as a representative clone. This plasmid was named pUC Bst I and is shown in Figure 8. The Bst DNA polymerase gene and its 5' and 3' flanking sequences are shown in SEQ ID NO: 19.

Example 4: Construction of a Bst DNA Polymerase Clone Lacking the 5'-3' Exonuclease Domain

A plasmid clone was constructed which contained only the 3'-5' exonuclease and polymerase domains of the Bst DNA polymerase gene as follows. Generally, the plasmid was constructed by first inserting the lac I^q repressor gene from plasmid pMAL™-P2 (New England Biolabs) into a modified pUC 18 plasmid so that the final clone would be inducible with IPTG in a variety of host cells. Previous publications had indicated that expression of full length DNA polymerase I is lethal to *E. coli* host cells. See, e.g., Joyce, et al., *Proc. Natl. Acad. Sci. USA* 80:1830-1834 (1983). The DNA polymerase gene fragment to be cloned was assembled from three components: a 3' gene fragment containing the Hind III to Sal I region from pGem Bst 2.1 Sst, a middle gene fragment containing the region from a Sty I site to the Hind III site in pGem Bst 5' end, and a fragment made using synthetic oligonucleotides to complete the 5' end of the coding region for Bst DNA polymerase, and to provide a cloning site. The cloning strategy is shown in Figure 9.

Step 1: One µg plasmid pMAL™-p2 was digested with restriction endonucleases Msc I plus Ssp I, subjected to electrophoresis in an agarose gel, and the resulting band of approximately 1.39 kb containing the lac I^q repressor gene was gel purified, as described above. This fragment was then ligated to 20 pmol of Sph I linkers (New England Biolabs) overnight at room temperature in a reaction mixture containing 20 units of T4 DNA ligase, as described above. The T4 ligase was heat-inactivated at 75°C for 5 minutes and the ligation mixture was ethanol precipitated. The DNA fragment was then redissolved and digested with Sph I, then subjected to electrophoresis and gel purified, as described above. The resulting DNA fragment is shown as fragment "a" in Figure 9. Plasmid vector pUC 18N had been constructed previously by making a two base substitution in pUC 18 which resulted in the creation of a new Nco I cloning site. As indicated below, the A nucleotide 11 bases upstream from the Eco RI site was substituted with a G, and the T residue 15 bases upstream from the Eco RI site was substituted with a C. Nucleotide sequences comprising a restriction endonuclease site are indicated by underlining.

```

pUC 18      5' - . . . . . CTATGACCATGATTACGAATTC . . . . . - 3'
pUC 18N     5' - . . . . . CCATGGCCATGATTACGAATTC . . . . . - 3'
                        Nco I           Eco RI

```

Plasmid pUC 18N was digested with Sph I, subjected to electrophoresis in an agarose gel and gel purified, as described above. The linearized plasmid was then co-ethanol precipitated with the lac I^q fragment described above, and the two DNA fragments were ligated overnight at 16°C in a reaction mixture containing 2 units of T4 DNA ligase, as previously described. The ligation mixture was used to transform XL1-Blue MRF' cells and the transformed cells were plated on LB plates containing ampicillin, IPTG and X-gal. White colonies, indicating the presence of DNA inserts, were selected and grown in LB broth containing ampicillin and plasmid minipreparations were made as previously described. The plasmid DNA preps were each digested with Eco RI plus Eco RV and with Hind III plus Eco RV, and subjected to electrophoresis in an agarose gel. A plasmid clone was selected which displayed DNA bands of the expected size (Eco RI / Eco RV: 3.15 kb + 0.96 kb, Hind III/Eco RV: 3.59 kb + 0.52 kb) and was designated pUC 18N I^q.

Step 2: The synthetic fragment required to complete the 5' end of the cloned gene was constructed using two partially complementary single-stranded synthetic oligonucleotides (SEQ ID NOS: 17 and 18). These oligonucleotides were designed based on the sequence of the Bst DNA polymerase gene obtained by sequencing pGem Bst 5' end DNA. The oligonucleotides were structured so that their complementary regions would cause the oligonucleotides to overlap each other by 28 bases at their 3' ends upon hybridization. The annealed single-stranded oligonucleotides were extended with the Klenow fragment from *E. coli* DNA polymerase I, which caused the formation of a double-stranded DNA molecule. The resulting duplex DNA molecule contained an Nco I restriction endonuclease site near the 5' end, a Sty I restriction endonuclease site near the 3' end, and the Bst DNA polymerase gene sequence corresponding to gene coordinates 868-1012. This fragment contains the 5' end of the 3'-5' exonuclease domain of the Bst DNA polymerase gene with a

new Nco I cloning site added at the 5' end of this domain, and the native Sty I cloning site at the 3' end of the fragment. This DNA fragment is represented as fragment "b" in Figure 9.

To accomplish step 2, 15 pmol each of oligonucleotides having SED ID NOS: 17 and 18 were mixed in a total volume of 96 μ l of a solution containing 50 mM potassium chloride, 2 mM magnesium chloride and 20 mM Tris-HCl (pH 8.0). The solution was incubated at 76°C for 10 minutes and then allowed to slowly cool to room temperature over a few hours in order to anneal the oligonucleotides. The mixture was brought to 100 μ l total volume with the addition of 10 units of the Klenow fragment of *E. coli* DNA polymerase I and 0.2 mM each of dATP, dCTP, dGTP and dTTP. The resulting reaction mixture was incubated at room temperature for 6 minutes, 37°C for 45 minutes and 42°C for 10 minutes. The solution was then sequentially extracted with solutions of phenol/chloroform/isoamyl alcohol and chloroform/isoamyl alcohol as previously described, then ethanol precipitated. The double-stranded fragment was redissolved and digested in a reaction mixture containing 25 U of Nco I, and the resulting 0.15 kb fragment was gel purified, as described above.

Step 3: Plasmid pUC18N I^q, constructed in Step 1, was digested with Nco I, combined with fragment "b" from Step 2, and the plasmid and DNA fragment were ligated overnight at 16°C. The ligase was heat inactivated at 65°C for 10 minutes and the ligation products were ethanol precipitated. The plasmid was digested with Sty I plus Sal I and gel purified, as described above.

Step 4: Bst DNA polymerase gene fragments were isolated and reassembled as follows. Plasmid pGem Bst 5' end was digested with Sty I plus Hind III, subjected to electrophoresis, and the resulting 0.68 kb DNA fragment (termed fragment "c") was gel purified. Plasmid pGem Bst 2.1 Sst was digested with Hind III plus Sal I. This digestion mixture was also subjected to electrophoresis, and the 1.57 kb DNA fragment (termed fragment "d") was gel purified, as previously described. Purified fragments "c" and "d" were combined and co-ethanol precipitated. The pelleted DNA was redissolved and allowed to ligate overnight in a 30 μ l reaction mixture containing 4 U of T4 ligase at 16°C. The ligase was heat inactivated at 65°C for 10 minutes and ligated fragments "c" and "d" were ethanol precipitated, then digested with Sal I. Following agarose gel electrophoresis, the resulting 2.25 kb ligation fragment "cd" was gel purified, as described above.

Step 5: The gel purified fragment "cd" was ligated with the plasmid produced in Step 3 in a 17 μ l reaction mixture containing 2 U of T4 ligase at 16°C overnight. The ligation reaction mixture was used to transform XL1-Blue MRF' cells and the transformants were plated on LB agar plates containing ampicillin. Colonies were selected, grown in LB broth containing ampicillin and plasmid minipreparations of the selected colonies were made. The DNA preparations were analyzed using restriction endonuclease digestions with Nco I plus Hind III and with Sph I plus Sty I. The restriction digests were subjected to agarose gel electrophoresis, and ethidium bromide staining. A clone was identified which gave rise to restriction fragments of the expected size (Nco I + Sty I: 2 bands at 2.62 kb, 0.83 kb, 0.37 kb and Sph I + Sty I: 2.77 kb, 1.41 kb, 1.05 kb, 0.88 kb, 0.33 kb). This clone was named pUC Bst 2 and is shown in Figure 9; the Bst 2 gene insert, without its 5' and 3' untranslated regions (but with the untranslated termination codon) has a nucleotide sequence of SEQ ID NO: 22.

Example 5: Construction of Modified Versions of pUC Bst 2

In order to evaluate the effect of the lac I^q repressor gene on the expression of the Bst DNA polymerase gene, modified versions of pUC Bst 2 were constructed in which the lac I^q repressor gene was either deleted or reversed in orientation. To create these clones, pUC Bst 2 DNA was digested with Sph I restriction endonuclease to liberate the lac I^q insert. The reaction mixture was sequentially extracted with solutions of phenol/chloroform/isoamyl alcohol and chloroform/isoamyl alcohol as previously described, and then ethanol precipitated. The sample was then redissolved and religated in a 20 μ l reaction mixture containing 1 U of T4 DNA ligase overnight at 16°C. The ligation reaction mixture was used to transform *E. coli* 1200 cells, and the transformed cells were plated on LB agar plates containing ampicillin. Colonies were selected and grown in LB broth containing ampicillin. Plasmid minipreparations were made as described above. The samples were then digested with Eco RV plus Hind III, subjected to electrophoresis on a 1% agarose gel and then stained with ethidium bromide. Plasmids pUC Bst 2 "AB", "CD" and "EF" were identified based on the expected band sizes indicated in the table below and in Figure 11.

	pUC Bst 2 AB	pUC Bst 2 CD	pUC Bst 2 EF
Expected Eco RV and Hind III Restriction Fragments (base pairs)	3445	3445	3445
	2477	2094	1573
	518	901	

Example 6 : Construction of a Bst DNA Polymerase Clone with a Deletion in the 5'-3' Exonuclease Domain

A plasmid containing an in-frame deletion in the 5'-3' exonuclease domain of the Bst DNA polymerase gene was constructed in order to inactivate or diminish the 5'-3' exonuclease activity of the expressed gene product without modifying the domains of the gene affecting the 3'-5' exonuclease and DNA polymerase activities.

The experimental strategy is outlined in Figure 10, and utilized two restriction fragments from pUC Bst 1. The first fragment was prepared by digesting pUC Bst 1 DNA with Pvu II. The restriction digest was subjected to agarose gel electrophoresis. A fragment of 3,321 base pairs was identified and gel purified, as described. The purified fragment was then partially digested with Hinc II. Conditions suitable for partial digestion of this fragment were previously determined; conditions for conducting partial restriction digests of a substrate DNA are easily determined and well known to those of ordinary skill in the art. Upon agarose gel electrophoresis, a 3,126 base pair fragment was identified and gel purified.

To prepare the second restriction fragment, pUC Bst 1 was first digested to completion with Aat II in order to eliminate a DNA fragment predicted to co-migrate with the desired DNA fragment during agarose gel electrophoresis. The DNA was then partially digested with Pvu II under conditions previously determined by small scale pilot digestions. Following gel electrophoresis, the desired fragment of having a size of 2754 base pairs was excised from the gel and gel purified.

The two gel purified fragments so isolated were combined, ethanol precipitated, and the pellets were redissolved and allowed to ligate overnight in a 10 µl reaction mixture containing 1.5 U of T4 DNA ligase at room temperature. The ligation reaction mixture was used to transform XL1-Blue MRF⁺ cells and the transformed cells were plated on LB agar plates containing ampicillin. Colonies were isolated and grown in LB broth containing ampicillin. Plasmid miniprepations were made, as previously described. The samples containing plasmid DNA were then digested with Pvu II, Sal I, Hind III plus Aat II and Sal I plus Sty I and subjected to electrophoresis on 1% agarose gels. A plasmid clone was identified which produced restriction fragments of molecular weight predicted from the map shown in Figure 10; this clone was named pUC Bst 3; the DNA sequence of the Bst 3 cleavage product, without its 5' and 3' untranslated regions (and with the untranslated termination codon) is given in SEQ ID NO: 24.

Plasmid pUC Bst 3 is 195 base pairs shorter than the full length DNA polymerase clone pUC Bst 1 due to the removal of nucleotides from within the 5'-3' exonuclease domain of the DNA polymerase gene. This deletion results in the absence of 65 amino acid residues from the 5'-3' exonuclease domain of the expressed modified enzyme (residues 178-242). Among these 65 amino acids are two glycine residues which were thought to correspond to amino acids of *E. coli* DNA polymerase I necessary for 5'-3' exonuclease activity (see Joyce, et al., *J. Mol. Biol.* 186:283-293 (1985)).

Example 7: Insertion of the Tetracycline Resistance Gene into all Bst DNA Polymerase Clones

All of the Bst DNA polymerase containing plasmids described above contained a selectable marker gene conferring ampicillin resistance on the transformed host cells. This gene encodes β-lactamase. Cultures of host cells transformed with plasmids containing this gene and grown in media containing ampicillin are often found to have a relatively high rate of reversion, with resulting loss of cloned genes. In an attempt to stabilize the plasmids within host cells during culture, an additional selectable marker gene, conferring tetracycline resistance (tet^r), was added to each plasmid. A fragment containing this gene was isolated from pBR322 by digesting the plasmid with Eco RI plus Ava I, subjecting the digestion mixture to electrophoresis, and gel purifying the 1427 bp tet^r fragment, as described above. The purified fragment was end-filled using the Klenow fragment of *E. coli* DNA polymerase I, and the resulting blunt-ended tet^r fragment was ligated with Aat II oligonucleotide linkers (New England Biolabs); ligation of a gel purified DNA fragment with synthetic linkers was previously described above, and is well known to those of skill in the art. (See Sambrook, *supra*, previously incorporated by reference herein). The ligation mixture was ethanol precipitated and the DNA ligase was heat inactivated. The linker-containing fragment was then digested with Aat II, subjected to agarose gel electrophoresis and gel purified. Plasmid vector pUC 18 was digested with Aat II and following agarose gel electrophoresis, the linearized large fragment was gel purified. The Aat II digested vector and tet^r fragment containing Aat II linkers were sequentially extracted in solutions of phenol/chloroform/isoamyl alcohol and chloroform/isoamyl alcohol, as described above. The extracted DNA fragments were combined, ethanol precipitated together and allowed to ligate in a reaction mixture containing T4 ligase. *E. coli* JM109 cells were transformed with this ligation mixture and plated on LB agar plates containing tetracycline. Colonies were isolated, cultured in LB broth containing tetracycline and plasmid minipreps were made, as described above. The plasmid preparations were digested with Eco RV and with Ssp I plus Hind III and subjected to electrophoresis on agarose gels. A clone was identified which gave rise to DNA fragments of the sizes expected for a plasmid containing the tet^r gene in one of two possible orientations. The expected fragment sizes were: Eco RV: 4121, Ssp I + Hind III: 2102, 1868 and 150. This plasmid was named pUC Tet (+). Purified pUC Tet (+) DNA was isolated from a cell culture of this clone. This DNA was digested with Aat II, the digestion mixture subjected to agarose gel electrophoresis, and the 1435 bp tet^r fragment was gel purified, as previously described. This fragment was then used as a source of the tet^r gene for insertion into each of the Bst DNA polymerase clones at their unique Aat II vector site.

To accomplish this, a preparation of plasmid DNA from each Bst DNA polymerase clone was digested with Aat II, subjected to agarose gel electrophoresis, and the linearized plasmid gel purified. The purified plasmid fragment was

sequentially extracted with solutions of phenol/chloroform/isoamyl alcohol and chloroform/isoamyl alcohol. The purified Aat II linearized plasmid DNA was combined with the 1435 bp *tet^r* fragment, and ethanol precipitated. The DNA pellet was dissolved, and the DNA fragments were allowed to ligate in a reaction mixture containing T4 DNA ligase, as described above. The ligation mixtures were used to transform *E. coli* 1200 cells, and the transformants were plated on LB agar containing tetracycline. Individual colonies were cultured in LB broth containing tetracycline, and plasmid minipreps of these cultures were made. In order to determine the orientation of the *tet^r* gene in each plasmid, the plasmid DNA from each preparation was digested with either Hind III or with Eco RV in combination with another restriction endonuclease having a convenient recognition site within the cloned Bst DNA polymerase gene. Following gel electrophoresis and ethidium bromide staining, clones were selected which contained the *tet^r* insert in each orientation relative to that of the Bst DNA polymerase gene. Plus (+) orientation was designated as the same orientation, relative to transcription, as the Bst polymerase gene and minus (-) orientation was designated as that opposite to the Bst DNA polymerase gene. Stock cultures of each of these clones were made, and the clones named as indicated below.

Bst DNA Polymerase Clones without <i>tet^r</i>	<i>tet^r</i> Gene in (+) Orientation	<i>tet^r</i> Gene in (-) Orientation
pUC Bst 1	pUC Bst 1 T (+)	pUC Bst 1 T (-)
pUC Bst 2	pUC Bst 2 T	
pUC Bst 2 AB	pUC Bst 2 A	pUC Bst 2 B
pUC Bst 2 CD	pUC Bst 2 C	pUC Bst 2 D
pUC Bst 2 EF	pUC Bst 2 E (same as pUC Bst 2 T)	pUC Bst 2 F
pUC Bst 3	pUC Bst 3 T (+)	pUC Bst 3 T (-)
pUC Bst 4	pUC Bst 4 T (+)	pUC Bst 4 T (-)

Example 8: Preliminary Evaluation of Enzyme Expression in Bst DNA Polymerase Clones

As a preliminary determination of the expression of active Bst DNA polymerase from the clones constructed as described herein, they were grown overnight in cultures of LB broth containing either ampicillin or tetracycline. Cultures of pUC Bst 2 containing the *lac I^q* gene in each orientation were also given 1 mM IPTG to induce expression of the enzyme. The amino acid sequences of Bst 1, Bst 2, and the cleavage product of Bst 3 are shown as SEQ ID NOS: 20, 23, and 25, respectively. Aliquots of 0.5 ml of each culture were analysed by SDS gel and by enzyme activity assays as follows.

Each aliquot for enzyme activity assays was centrifuged for 2 minutes in a microcentrifuge, and the cell pellets were washed one time with wash buffer (50 mM sodium chloride, 5 mM EDTA, 0.25 M sucrose, 50 mM Tris-HCl (pH 8.0)). The pellets were frozen at -80°C and each resuspended in 200 µl of lysis buffer (10 mM sodium chloride, 1 mM EDTA, 1% glycerol, 25 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride (PMSF), 500 µg/ml lysozyme, 10 mM Tris-HCl (pH 8.0)). After 20 minutes on ice, 100 µl of 0.75% (v/v) Triton X-100 was added to each sample, and the sample was frozen on dry ice and thawed three times. The resulting cell lysate was diluted 5,000 fold in enzyme dilution buffer (100 mM sodium chloride, 0.1 mM EDTA, 0.01% NP-40 (a nonionic detergent comprising a polyglycol ether derivative; Sigma Chemical Co., St. Louis, MO), 10% glycerol, 20 mM Tris-HCl (pH 7.5)) and 10 µl aliquots were assayed for DNA polymerase activity at 60°C, as described above. The results of two experiments are shown in the tables below. The assay results are expressed in RLU (relative light units).

The first experiment made use of two *E. coli* host cell strains, strain XL1-Blue MRF⁺ and the *E. coli* 1200 strain. *E. coli* XL1-Blue MRF⁺ contains an episomal copy of *tet^r*. Strain XL1-Blue MRF⁺ was transformed with plasmids pUC Bst 1, pUC Bst 2 and pUC Bst 3, all lacking the *tet^r* gene. The enzyme activities of lysates from cultures of these clones were compared with those of lysates from *E. coli* 1200 host cells containing versions of the same plasmids but with the *tet^r*

gene in each orientation.

DNA Polymerase Activity at 60°C (RLU)			
	Host Cell Strain		
	XL1-Blue MRF ^r	<i>E. coli</i> 1200	
	No tet ^r Gene	tet ^r (+) Orientation	tet ^r (-) Orientation
pUC Bst 1	38,834	75,644	70,968
pUC Bst 2	4,868	9,382	Not Done
pUC Bst 3	27,737	63,675	45,992
pUC 18 (Negative Control)	4,324		
pUC tet ^r (+) (Negative Control)		4,730	

In a second experiment, the versions of pUC Bst 2 (A,B,C,D,E and F), constructed as described above, were compared with pUC Bst 1 T(+) and pUC Bst 3 T(+) to examine the effect of the lac I^q repressor gene on Bst DNA polymerase expression. All clones used for this experiment were in the *E. coli* 1200 host cell line, and all clones which contained the lac I^q gene (pUC Bst 2 A, B, C and D) were grown in the presence of 1 mM IPTG to induce expression of the Bst DNA polymerase gene, under the control of the lac promoter in these plasmids.

DNA Polymerase Activity at 60°C (RLU)	
pUC Bst 1 T (+)	67,747
pUC Bst 2 A	2,993
pUC Bst 2 B	2,644
pUC Bst 2 C	2,729
pUC Bst 2 D	3,664
pUC Bst 2 E	3,895
pUC Bst 2 F	7,876
pUC Bst 3 T (+)	49,275
pUC tetr (+) (Negative Control)	1,094

Aliquots of cell lysates generated in both experiments were run on SDS polyacrylamide gels, and stained with Coomassie Brilliant Blue as described in Sambrook, *supra*, previously incorporated by reference herein. These gels revealed prominent new bands in all cell lysates made from host cells containing pUC Bst 1 and pUC Bst 3 as compared to the negative controls. By contrast, no new bands were visible in gel lanes corresponding to lysates made from host cells containing any of the pUC Bst 2 series of plasmids. The newly appearing bands from cells containing the pUC Bst 1 series of plasmids ran at approximately the same position as a 97 kDa molecular weight marker, while the new bands from host cells containing the pUC Bst 3 series of plasmids was several kDa smaller. These protein bands migrate at approximately the predicted size of the Bst DNA polymerase enzymes encoded by the particular plasmid construct.

The data obtained from these two experiments indicate several things. The Bst DNA polymerase gene is able to be expressed in *E. coli* host cells without the use of a heterologous promoter such as the lac promoter. Clones of the pUC Bst 1 series and pUC Bst 3 series contain approximately 600 base pairs of Bst genomic DNA flanking the 5' end of the polymerase gene. Although not wishing to be bound by theory, Applicant believes that expression of the DNA polymerase gene product is driven by at least one native promoter or promoter-like sequence in this region. Although these clones contain a lac promoter in the cloning vector, it is downstream from the polymerase gene and directs transcription in the opposite orientation than the Bst polymerase gene. Thus, this promoter would not be expected to function in expressing the polymerase gene.

Surprisingly, the recombinant Bst DNA polymerase gene of the present invention may be constitutively expressed in *E. coli* host cells without the use of an inducible or repressible promoter, such as the lac promoter under the control of the lac^l gene. By contrast, attempts to express full length DNA polymerase genes derived from other organisms using *E. coli* as a host cell have often been unsuccessful. For example, Uemori, *et al.*, *J. Biochem.* 113:401-410 (1983) and Joyce, *et al.*, *J. Biol. Chem.* 257:1958-1964 (1982) report that clones containing full length DNA polymerase genes are unstable, and the DNA polymerase gene can only be propagated as a Klenow-type fragment where the 5'-3' exonuclease activity is greatly diminished or absent. Although not wishing to be limited by theory, Applicants believe that the clones of the present invention may have improved stability by virtue of the tet^r gene and by the relatively low activity level of Bst DNA polymerase at 37°C as compared to the optimal temperature of 60°C (Kaboev, *et al.*, *J. Bacteriol.* 145:21-26 (1981).

The experiments demonstrate that the tet^r clones in the *E. coli* 1200 host cell line expressed higher levels of enzyme activity than their non-tet^r counterparts in the *E. coli* XL1-Blue MRF⁺ host cell line. While not wishing to be bound by theory, the present Applicant believes that this is due to a lower frequency of reversion when the tet^r gene is used as a selectable marker.

Clones containing the tet^r gene in the (+) orientation (the same orientation as the cloned polymerase gene) also gave rise to higher levels of DNA polymerase activity than clones having the tet^r gene in the (-) orientation.

Example 9: Comparison of pUC Bst 1 T (+) derived Bst DNA polymerase with a commercial preparation of Bst DNA polymerase.

The full length Bst DNA polymerase was purified from a culture of *E. coli* 1200 cells containing plasmid pUC Bst 1 T (+) as described previously, and an aliquot was digested with subtilisin. The resulting large "Klenow-type" fragment, of approximately 66,000 Daltons, contained the DNA polymerase and 3' to 5' exonuclease domains; and was purified as detailed above. A commercial preparation of a Bst DNA polymerase subtilisin fragment, obtained from Bio-Rad Laboratories was purchased and used for comparison. The latter enzyme is reportedly directly purified from a strain of *B. stearothermophilus* prior to subtilisin cleavage; this strain is a different strain than the one used as the starting material for the compositions of the present invention. This enzyme is described in Ye and Hong, *Scientia Sinica* 30:503-506 (1987), and its use in DNA sequencing reactions is reported in Lu *et al.*, *BioTechniques* 11:465-466 (1991), McClary *et al.*, *DNA Sequence* 1: 173-180 (1991), and Mead *et al.*, *BioTechniques* 11:76-87 (1991).

An assay of these two enzymes was performed using a nucleic acid having the same nucleotide sequence as a portion of the HIV genome as a template for DNA synthesis in nucleic acid amplification reactions performed as described in Ryder *et al.*, U.S. Patent Application No. 08/097262, hereby incorporated by reference herein, and which enjoys common ownership with the present application. This method makes use of both DNA and RNA synthesis to amplify a nucleic acid sequence. Nucleic acid amplification was performed using 5 copies of the single-stranded HIV template and the same number of units of each DNA polymerase enzyme. The results of the comparison experiments are shown below and are expressed in relative light units (RLU).

	<u>No added Bst</u>	<u>Bio-Rad Bst Sub-</u> <u>tillisin Fragment</u>	<u>Gen-Probe Bst 1</u> <u>Subtillisin Fragment</u>	<u>Gen-Probe Bst</u> <u>1 Full Length</u>
No Template	1,008	1,123	1,007	1,186
Template	897	499,250	431,779	398,745
	938	478,090	412,632	414,696
	966	511,314	421,338	317,848
	993	499,573	392,560	441,114
	959	464,196	399,665	326,355
(Geometric Mean)	950	490,188	411,349	376,510

The results indicate that both the full length and the subtilisin fragments of the recombinant enzymes of the present invention are able to promote the amplification of HIV DNA.

Example 10: Nucleic Acid Amplification in the Presence of a Cell Lysate from Normal White Blood Cells.

Another set of amplification reactions was performed as above, except the reactions were performed in the presence of normal human white blood cell lysate purified from 0.5 ml of whole blood, as described in Ryder, *supra*. In this experiment, 10 copies of the HIV template DNA were used rather than 5 as in the previous experiment. The results were as indicated in the table below.

	<u>No added Bst</u>	<u>Bio-Rad Subtilisin Fragment</u>	<u>Gen-Probe Bst 1 Subtilisin Fragment</u>	<u>Gen-Probe Bst 1 Full Length</u>
No Template	1,099	1,144	1,129	1,245
Template	1,123	1,002,133	1,088,906	1,009,661
	1,095	1,041,312	1,035,826	1,007,071
	1,058	1,030,350	1,000,339	1,020,751
(Geometric Mean)	1,091	1,024,464	1,014,911	1,012,476

These data indicate that both the full-length Bst DNA polymerase and the subtilisin-generated large fragment recombinant enzymes of the present invention supported amplification reactions in the presence of a cell lysate.

Example 11: Sensitivity Assay of Recombinant Bst DNA Polymerase Enzymes

Another set of nucleic acid amplification experiments was performed as in Example 9, except that the number of template molecules was lowered to either 2.5 or 0.5 copies per reaction, and both the pol and gag regions of the HIV genome were used as target sequences for primer binding and amplification. Detection of the resulting amplicons was performed as described in Ryder *et al.*, *supra*, previously incorporated by reference. In place of the subtilisin large fragment of pUC Bst 1 T, a Bst DNA polymerase fragment of similar size, from *E. coli* 1200/ pUC Bst 3 T (+) was used. This fragment is spontaneously produced by an endogenous protease activity during the purification of the pUC Bst 3 T enzyme.

<u>2.5 Copies Template per Reaction</u>			<u>0.5 Copies Template per Reaction</u>		
Commercial Subtilisin Fragment	pUC Bst 3 T Fragment	Full Length Enzyme	Commercial Subtilisin Fragment	pUC Bst 3 T Fragment	Full Length Enzyme
75,351	1,414,081	1,514,059	685,121	4,937	1,778
880,648	1,137,354	2,101,167	973	5,909	2,248
125,304	1,515,839	1,565,670	481,529	52,426	1,355,728
384,228	2,173,285	1,585,148	906	647,230	1,465
430,392	356,737	1,879,384	290,032	18,428	1,796
3,019	968,199	942,562	780,481	20,518	1,666
492,167	1,351,785	944,147	1,122	878,148	1,632
433,327	2,468,726	423,967	1,100	352,646	1,215
729,439	1,374,685	684,638	2,241	1,251,116	4,698
232,912	2,414,018	642,848	8,149	4,384	21,432
207,839 (mean)	1,351,069 (mean)	1,094,169 (mean)	16,484 (mean)	60,301 (mean)	4,651 (mean)

These data indicate that, especially at the lower template levels, both the full length and "Klenow" forms of the preferred enzymes of the present invention support nucleic acid amplification reactions.

Example 12: N-terminal Sequencing of Selected DNA Polymerase Enzymes

In order to better understand the structure/function relationships between the different truncated Bst DNA polymerase enzymes, samples of the active subtilisin fragment ("Klenow" fragment) of Bst 1, a naturally-occurring breakdown product of the *E. coli*-expressed cloned Bst 3 DNA polymerase, and a biologically active subtilisin fragment from a preparation of an uncloned Bst DNA polymerase (obtained from Bio-Rad Laboratories, Inc.) were purified as described above, and subjected to N-terminal amino acid sequencing. Methods for amino acid sequence determination are well-known to those of skill in the art; such methods are described in Hewick *et al.*, *J. Biol. Chem.* 256:7990-7997 (1981), the disclosure of which is hereby incorporated by reference herein. Automated methods of N-terminal amino acid sequence determination are also well known in the art; the amino acid sequencing described herein was performed using an Applied Biosystems-470A Gas-Phase sequencer with an in-line HPLC (Applied Biosystems, Foster City, CA) according to the manufacturer's instructions.

The polypeptides described above were subjected to amino acid sequence determination and the resulting sequences aligned and compared in the region corresponding to amino acid residue 285 of the full length Bst DNA polymerase (as encoded by the pUC Bst 1 clone). The resulting alignment is shown in Figure 12; the amino acid sequences of Bst 1, Bst 2 and Bst 4 (see Example 13) are those predicted by the nucleic acid sequences. In the cases of Bst 2 and Bst 4, the translational start codon ATG (which encodes methionine) was the first codon of the coding region. Thus, these enzymes may have a Met residue at the N-terminus before the indicated residue. Alternatively, this residue may be removed by *E. coli* in the expressed protein. As can be seen, the subtilisin fragment of the full length Bst polymerase of the present invention is a polypeptide fragment beginning with a threonine residue corresponding to amino acid position 289 of the full length DNA polymerase. This peptide has DNA polymerase activity.

The Bst 2 protein, encoded by pUC Bst 2 in which a restriction fragment corresponding to the 5'-3' exonuclease domain of the full length protein had been engineered out of the Bst DNA polymerase gene, begins with aspartic acid. This amino acid occupies a position corresponding to amino acid 290 of the full length DNA polymerase, and is the second residue of the subtilisin fragment of Bst 1. This enzyme, as expressed in *E. coli*, is active in DNA polymerase assays, but at a lower level of activity than Bst 1 or its subtilisin fragment.

The protein expressed by cells including pUC Bst 3 is found in two forms. In the first of these forms, the uncleaved protein contains a deletion in the 5'-3' exonuclease domain of the full length Bst 1 protein. However, both proteins have the same N-terminus, and the region corresponding to amino acid residue 285 of the Bst 1 protein is similar in both proteins. The second form of the Bst 3 enzyme appears to be a cleavage product of the Bst 3 protein by an *E. coli* protease. This fragment begins with a valine as the first amino acid residue; this residue corresponds to amino acid 287 of the full length Bst polymerase clone of the present invention. The third residue of this proteolytic fragment is the threonine residue that begins the Bst 1 subtilisin fragment's amino acid sequence; the fourth residue is the aspartic acid residue which begins the amino acid sequence of the Bst 2 protein.

Surprisingly, the sequence information derived from the commercial Bst DNA polymerase preparation ("Klenow" fragment) revealed that the N-terminal residue of this subtilisin fragment began with an alanine residue at a position corresponding to amino acid 290 of the full length Bst 1 protein sequence. As disclosed above, the Bst 2 protein begins with an aspartic acid residue at this position. All the other enzymes of the present invention that were sequenced in this region also showed an aspartic acid residue at this position. Moreover, the sequence of the N-terminal first 21 amino acids of this fragment revealed that 7 residues (or 33%) of the amino acids were different between the commercial, uncloned Bst DNA polymerase preparation and the enzymes of the present invention in this region. See Figure 12.

Additionally, a comparison of the amino acid sequences of the proteins of the present invention with the published Bca DNA polymerase sequence shows that 12 out of 25 residues, or almost 50% of the amino acids, are different between the published Bca DNA polymerase sequence, previously incorporated by reference, and the Bst DNA polymerase of the present invention in this region (see Figure 12). Overall, 105 out of 876 (almost 12%) of the amino acids of the Bst DNA polymerase amino acid sequence are not found in the corresponding position of the published Bca DNA polymerase sequence.

Example 13: Construction of a Bst DNA Polymerase (Bst 4) Having the Same N-Terminus as the Active Proteolytic Fragment of Bst 3

A plasmid clone was constructed similarly to the method used in the construction of plasmid pUC Bst 2 in order to encode a protein beginning with a valine residue and having the amino acid sequence of the naturally-occurring degradation product of Bst 3, as described in Example 12 above. The coding region of the DNA gene insert had a nucleotide sequence of SEQ ID NO: 26. The plasmid was used to transform strain 1200. A lysate from a culture of this transformant was electrophoresed by SDS-PAGE, and a protein band of the expected mobility was observed as shown in Figure 14. This protein was termed Bst 4. The N-terminal amino acids predicted for the clone are indicated in Figure 12, and the entire deduced amino acid sequence of Bst 4 is shown as SEQ ID NO: 27.

Figure 13 shows a schematic diagram of the Bst DNA polymerase gene inserts and their relation to the genomic Bst gene and its 3 domains.

Example 14: Construction of Bst DNA Polymerase Point Mutants Lacking 5'-3' Exonuclease Activity.

Two different additional plasmid clones were constructed, each of which encoded Bst DNA polymerase enzymes having a single amino acid substitution in the 5'-3' exonuclease domain. Because a single substitution in this domain was unlikely to significantly affect the polymerase activity or expression of the enzyme, it was thought that such a substitution presented a strategy for constructing mutant enzymes with DNA polymerase activity but being defective in the 5'-3' exonuclease activity.

The first strategy was to cause the change of the tyrosine at position 73 of the wild-type Bst 1 enzyme (SEQ ID NO: 20) to a phenylalanine residue. This substitution was chosen because the hydroxyl group of the tyrosine residue would no longer be available for reaction at or near the active site of the 5'-3' exonuclease domain, but the overall conformation of the enzyme should be otherwise little affected, since the space-filling phenyl ring is common to both tyrosine and phenylalanine. The Phe₇₃ mutant is termed Bst 5.

The other mutant enzyme, termed Bst 6, results from the substitution of an alanine residue for the tyrosine at position 73 of the Bst 1 amino acid sequence. Since this residue not only replaces a polar group with a non-polar group, but replaces a sterically large amino acid side group with a much smaller side group, this substitution would be expected to change the conformation of the polymerase enzyme to a greater degree than was seen in Bst 5.

A diagrammatic representation of the pUC Bst 5 and pUC Bst 6 DNA inserts in relation to the other Bst inserts and to the three domains of the Bst DNA polymerase gene is shown in Figure 13.

Construction of Bst 5

Plasmid pUC Bst 1 was partially digested with Acc I and Xmn I restriction enzymes and electrophoresed on an agarose gel. An Acc I/Xmn I DNA band corresponding to the full length plasmid minus a 153 bp region from an Acc I site at Bst 1 (SEQ ID NO: 21) coordinate 103 to an Xmn I site at Bst 1 coordinate 256 was excised from the gel and gel purified using standard methods.

Synthetic oligonucleotides of SEQ ID NOs: 28 and 29 were synthesized using a method similar to that described in Example 4 above. Fifteen picomoles of each oligonucleotide were combined in duplicate reactions and incubated at 72°C for 5 minutes in a solution of 20 mM Tris-HCl (pH 8.0), 2 mM MgCl₂ and 50 mM KCl. The solutions were then cooled slowly to 40°C to anneal the oligonucleotides, which had complementary nucleotide sequences at their 3' ends. The solutions were then given 0.2 mM each dNTP and 10 units of the Klenow fragment of *E. coli* DNA polymerase I to create a blunt-ended double-stranded DNA fragment which contained the native Bst DNA polymerase nucleotide sequence with the desired changes at the codon corresponding to amino acid 72 of the Bst DNA polymerase enzyme, as well as an Acc I site near the 5' end of the coding strand and an Xmn I site near the 3' end of the coding strand. A single degenerate mutation was also introduced by the synthetic oligonucleotides into the nucleotide sequence in order to create a new diagnostically useful restriction site; this mutation did not result in additional amino acid substitutions in the Bst enzyme. The reaction mixtures were incubated at 37°C for 50 minutes. The duplicate reactions were pooled and extracted, first with phenol/chloroform, then with chloroform, and finally the double-stranded oligonucleotide fragment was precipitated with ethanol. The resulting fragment was redissolved and phosphorylated using 30 units T4 polynucleotide kinase and 0.5 mM ATP at 37°C for one hour.

Plasmid pGem-3Z (1.22 µg) was digested with 10 units of Sma I at room temperature for 65 minutes, then extracted with phenol/chloroform and chloroform alone. Approximately 11 picomoles of the phosphorylated synthetic double-stranded fragments were combined with 0.24 µg of the Sma I-digested plasmid pGem-3Z and the nucleic acids co-ethanol precipitated. The pellet was reconstituted and ligated using 15 units of T4 DNA ligase at room temperature overnight. The resulting ligation mixture was used to transform *E. coli* strain 1200, and the transformants plated onto LB agar plus ampicillin. Following incubation overnight at 37°C, ampicillin-resistant colonies were picked, grown in LB plus ampicillin, and the plasmids purified and screened using restriction endonuclease digestion (Xmn I). Clones were identified which had the expected synthetic DNA fragment insert; plasmid preparations were made of these clones and the plasmids were digested with Acc I and Xmn I. The restriction digests were then electrophoresed and the 153 bp fragment was gel isolated and ligated with the pUC Bst 1 fragment previously gel isolated as described above.

The ligation mixture was used to transform XL1-Blue MRF' cells, and the transformants were plated onto LB agar containing ampicillin. Ampicillin-resistant colonies were chosen, grown in LB plus ampicillin, and the plasmids purified and screened using restriction endonuclease digestion. The plasmids containing the expected Bst 5 insert were digested with Aat II and ligated with the 1435 bp tetracycline resistance gene fragment, as described in Example 7 above. The ligation mixture was used to transform *E. coli* strain 1200, and the transformants were plated onto LB agar containing tetracycline. Tetracycline resistant colonies were grown in LB plus tetracycline and the plasmids purified and screened using restriction endonuclease digestion. Clones containing the tetracycline resistance gene in both orientations were

identified and named pUC Bst 5 T [+] and pUC Bst 5 T [-]. An SDS-PAGE analysis of the protein expressed by these transformants showed protein bands migrating at the position expected for Bst DNA polymerase. Lysates of these transformants displayed DNA polymerase activity. The plasmid DNA from these transformants was also sequenced in the region of the mutations and confirmed to have the expected DNA sequence within the Bst polymerase gene. The sequencing reactions were as described above.

Construction of Bst 6

Bst 6 was constructed exactly as was Bst 5, except the synthetic oligonucleotide pair used for this construction were oligonucleotides of SEQ ID NOS: 28 AND 30.

The tetracycline-resistant clones of Bst 6 having the tetracycline resistance gene in both orientations were named pUC Bst 6 T [+] and pUC Bst 6 T [-]. These also expressed a protein migrating on SDS-PAGE gels at the position correlating with Bst DNA polymerase and lysates from cultures of these transformants expressed a DNA polymerase activity. Sequencing of the plasmid DNA revealed the expected nucleotide sequence within the Bst 6 gene.

DNA Polymerase Activity Assays for Bst 5 and Bst 6

Cultures of each of the four Bst 5 and Bst 6 clones were grown overnight in LB plus tetracycline and analyzed for the expression of DNA polymerase activity as described in Example 8. Results of the assay are shown below.

DNA Polymerase Activity at 60°C (In RLU)	
pUC Bst 1 T [+]	58,837
pUC Bst 5 T [+]	58,729
pUC Bst 5 T [-]	53,118
pUC Bst 6 T [+]	63,206
pUC Bst 6 T [-]	66,582
pUC Tet [+] (negative control)	704

Analysis of lysates from the Bst 5 and 6 clones by SDS-PAGE showed approximately equal amounts of a prominent band at around 97 KDa; this band was absent from a lysate from *E. coli* 1200/pUC Tet [+].

5'-3' Exonuclease Activity Assays of the Bst 5 and Bst 6 Clones

The Bst 5 and Bst 6 enzymes were purified in substantially the same manner as described above. The purified Bst 1, Bst 5 and Bst 6 enzymes, and the purified subtilisin DNA polymerase fragment from Bst 1 were assayed for 5'-3' exonuclease activity. Vent® DNA polymerase from New England Biolabs, which is known to be deficient in 5'-3' exonuclease activity, was used as a negative control. rTth DNA polymerase, obtained from Perkin Elmer, is known to contain a 5'-3' exonuclease activity; this was used as a positive control.

The assay was performed as follows. Plasmid pGem 3Z DNA was linearized using Hind III restriction endonuclease, then treated with alkaline phosphatase to dephosphorylate the 5' ends. The DNA was then labeled at the 5' ends with ³²P using T4 polynucleotide kinase, as described above. Approximately 0.015 pmoles (130,000 cpm) of this labeled substrate was used in each assay reaction.

For each assay of Bst 1, Bst 5, and Bst 6 enzymes, different amounts of each enzyme were added to the substrate nucleic acid in a reaction mixture containing 0.5 mM of each dNTP, 1.5 mM MgCl₂, 90 mM KCl and 10 mM Tris-HCl (pH 8.3); the total volume of each reaction was 50 µl. The reaction mixtures were incubated at 60°C for 3 hours, then chilled on ice. Ten microliters of 10 mg/ml BSA was then added to each tube as a carrier, then each reaction tube was given 20 µl of cold 50% trichloroacetic acid. The tubes were incubated for 20 minutes on ice, then centrifuged for 5 minutes in a microcentrifuge. The supernatants and pellets were separated and each was counted in a scintillation counter for the presence of radioactivity. The percentage of total cpm released in the supernatant was used as a measure of 5'-3' exonuclease activity.

The Vent® and rTth enzymes were assayed in a similar manner with the following changes, made according to the manufacturer's instructions. For the Vent® enzyme, the enzyme was added to the substrate in a reaction mixture con-

aining 0.5 mM each dNTP, 10 mM KCl, 10 mM (NH₄)₂SO₄, 20 mM Tris-HCl (pH 8.8), 2 mM MgSO₄, and 0.1% (v/v) Triton® X-100 in a total volume of 50 µl. The reaction mixtures were incubated at 70°C.

For the rTth enzyme, the enzyme was added to the same reaction mixture as for the Bst enzymes with the further addition of 0.6 mM MnCl₂, 100 mM KCl, 0.75 mM EGTA, 0.05% (v/v) Tween® 20, and 5% (v/v) glycerol in a total volume of 50 µl. The reaction mixtures were incubated at 70°C.

Because the manufacturers' units of enzyme activity are not the same as Gen-Probe's units of enzyme activity, the concentrations of enzyme added to the Vent® and rTth reactions was based on the amount of enzyme determined to be active in DNA polymerase assays.

The following table presents data which are the averages of duplicate assays.

5'-3' Exonuclease Assay		
	Gen-Probe Units or Manufacturer's Units	% cpm in supernatant
Bst 1	96,000	95
	19,100	69
	2,000	26
	200	12
Bst 5	136,100	16
	68,000	15
	27,200	15
	2,700	13
Bst 6	136,100	17
	68,000	18
	27,200	18
	2,700	14
Bst 1 subtilisin fragment	78,500	17
	no enzyme	13
rTth (+) control	25 (Mfr's units)	42
	no enzyme	13
Vent® (-) control	5 (Mfr's units)	16
	no enzyme	14

These data shown that the Bst 5 and Bst 6 enzymes do not contain detectable 5'-3' exonuclease activities, even at high enzyme concentrations. The data also confirm that the purified subtilisin polymerase fragment of Bst 1 also contains no detectable 5'-3' exonuclease activity.

Example 15: Ability of Bst 5 and Bst 6 to support Nucleic Acid Amplification

The purified Bst enzymes were tested for their ability to support nucleic acid amplification. Nucleic acid amplification was performed substantially as described in Example 9, except the commercial source of the non-recombinant Bst DNA polymerase subtilisin fragment was Molecular Biological Resources (Milwaukee WI). An equal number of units of each

enzyme was used for each assay.

Copies of HIV Template	Commercial Subtilisin Fragment of Native Enzyme	Bst-1	Subtilisin Fragment of Bst-1	Bst-5	Bst-6
5	2,538,405	2,190,958	2,680,877	2,560,438	2,600,262
	2,503,380	2,520,161	2,645,578	2,571,370	2,651,576
	2,654,329	2,651,948	2,703,753	2,433,015	2,630,750
	2,714,339	2,486,977	2,581,356	2,495,086	2,658,697
	2,572,544	2,521,970	2,622,247	2,492,034	2,686,534
	2,700,737	2,624,428	2,601,453	2,401,619	2,655,092
	2,719,892	2,574,901	2,638,163	2,639,461	2,667,916
	2,712,654	2,572,914	2,638,399	2,294,487	2,672,463
	2,603,278	2,633,240	2,535,452	2,675,323	2,663,664
0	7,016	5,114	6,698	6,845	6,449

Example 16: Use of purified Bst 1 subtilisin fragment and Bst 5 and 6 enzymes in sequencing reactions

Bst 1, Bst 5 and Bst 6 enzymes and the subtilisin fragment from the Bst 1 clone were purified as described above and tested for their ability to support sequencing reactions. Sequencing reactions were done using the Bio-Rad (Hercules, CA) Bst sequencing reagents according to the manufacturers protocol and were compared with reactions done using the Bio-Rad Bst DNA polymerase, which is the subtilisin fragment of the non-recombinant (native) enzyme. The primer and template used were the T7 promoter-primer and pGem 3Z plasmid obtained from Promega Corp.

Both the Bst 1 and native enzyme subtilisin fragments, as well as both of the Bst 5 and 6 enzymes, produced clear sequencing ladders, whereas the use of the Bst 1 holoenzyme resulted in no signal at all. Because the full length Bst 1 enzyme has a 5'-3' exonuclease activity, the rate of degradation of newly synthesized stands is in equilibrium with the rate of synthesis of these strands, and sequencing is not effective. Thus, the results indicate the single amino acid substitutions of the Bst 5 and 6 enzymes have eliminated the undesired 5'-3' exonuclease activity to the extent that the Bst 5 and Bst 6 enzymes are comparable to the subtilisin fragment of Bst DNA polymerase in these sequencing reactions, with the added advantage of obviating the need for subtilisin digestion and repurification.

The foregoing examples exemplify various embodiments of the present invention and are not intended to limit the invention, the scope of the invention and its equivalents being determined solely by the claims which follow.

SEQUENCE LISTING

5

10

(2) INFORMATION FOR SEQ ID NO: 1:

15

(i) SEQUENCE CHARACTERISTICS:

20

- (A) LENGTH: 38 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

25

30

35

40

45

50

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

5 GAGCAGCGCA TTTATGAGCT CGCCGGCCAA GAATTCAA 38

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

15 TTGAATTCTT GGCCGGCGAG CTCATAAATG CGCTGCTC 38

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

25 CATCGCCTTT TTAATAATGT CAGCGGCGCT CCCTTGAATC GG 42

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 42 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

35 CCGATTCAAG GGAGCGCCGC TGACATTATT AAAAAGGCCA TG 42

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

45 AATTCACCGA AACAGCTCGG CGTCAATTTA TTTGAAAA 38

(2) INFORMATION FOR SEQ ID NO:6:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 38 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

5 TTTTCAAATA AATTGACGCC GAGCTGTTTC GGTGAATT 38

(2) INFORMATION FOR SEQ ID NO:7:

(i) SEQUENCE CHARACTERISTICS:

10 (A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

15 TTGAAGTTGC GGCTCGTAAT ATCCGGCAAA TAGCGGCGCC G 41

(2) INFORMATION FOR SEQ ID NO:8:

(i) SEQUENCE CHARACTERISTICS:

20 (A) LENGTH: 41 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

25 CGGCGCCGCT ATTTGCCGGA TATTACGAGC CGCAACTTCA A 41

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

30 (A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

35 TTGATGGGTG ATAAGTCGGA TAACATTCCT GGGGT 35

(2) INFORMATION FOR SEQ ID NO:10:

(i) SEQUENCE CHARACTERISTICS:

40 (A) LENGTH: 35 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

45 ACCCCAGGAA TGTTATCCGA CTTATCACCC ATCAA 35

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

50 (A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

55

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

5 TTCCAGCACA TCCGCTGATG TGGAGTAGCC GGTTTT

36

(2) INFORMATION FOR SEQ ID NO:12:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 36 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

15 AAAACCGGCT ACTCCACATC AGCGGATGTG CTGGAA

36

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

25 TTAATCGACG GCAGCAGCGT GCGGTACCGC GCCTTTTTCG CCTTG

45

(2) INFORMATION FOR SEQ ID NO:14:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 45 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

35 CAAGGCGAAA AAGGCGCGGT ACGCCACGCT GCTGCCGTCG ATTAA

45

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

- 40 (A) LENGTH: 19 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

45 GATTTAGGTG ACACTATAG

19

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- 50 (A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

5 TAATACGACT CACTATAGGG 20

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:

- 10 (A) LENGTH: 94 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

15 AGCATGCCAT GGATGAAGGC GAAAAGCCGC TCGCCGGGAT GGATTTTGCG ATCGCCGACA 60
 GCGTCACGGA CGAAATGCTC GCCGACAAAG CGGC 94

(2) INFORMATION FOR SEQ ID NO:18:

(i) SEQUENCE CHARACTERISTICS:

- 20 (A) LENGTH: 96 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

25 CAGACACCAA GGCGATCCCG ACAATCGGGG CATGGTGATA GTTGTGCGCC ACCACCTCCA 60
 CGACGAGGGC CGCTTTGTCTG GCGAGCATTT CGTCCG 96

(2) INFORMATION FOR SEQ ID NO:19:

(i) SEQUENCE CHARACTERISTICS:

- 30 (A) LENGTH: 2761 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:

- 35 (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 103...2730
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

40 TTTACGATTC ATTTCCCGAA GCCGGAGCGG TAGCCGGCTT CTTTTATGG CCGCCCGCCG 60

GCGTGGTACA ATAGAACAAG GAACGTCCGA GGAGGGATGA TG TTG AAA AAC AAG 114
 Leu Lys Asn Lys
 1

45 CTC GTC TTA ATT GAC GGC AAC AGC GTG GCG TAC CGC GCC TTT TTC GCG 162
 Leu Val Leu Ile Asp Gly Asn Ser Val Ala Tyr Arg Ala Phe Phe Ala
 5 10 15 20

50 TTG CCG CTT TTG CAT AAC GAT AAA GGG ATT CAT ACG AAC GCA GTC TAC 210
 Leu Pro Leu Leu His Asn Asp Lys Gly Ile His Thr Asn Ala Val Tyr
 25 30 35

5	GGG TTT ACG ATG ATG TTA AAC AAA ATT TTG GCG GAA GAG CAG CCG ACC Gly Phe Thr Met Met Leu Asn Lys Ile Leu Ala Glu Glu Gln Pro Thr	258
	40 45 50	
	CAC ATT CTC GTG GCG TTT GAC GCC GGG AAA ACG ACG TTC CGC CAT GAA His Ile Leu Val Ala Phe Asp Ala Gly Lys Thr Thr Phe Arg His Glu	306
	55 60 65	
10	ACG TTC CAA GAC TAT AAA GGC GGG CGG CAG CAG ACG CCG CCG GAA CTG Thr Phe Gln Asp Tyr Lys Gly Gly Arg Gln Gln Thr Pro Pro Glu Leu	354
	70 75 80	
15	TCG GAA CAG TTT CCG CTG CTG CGC GAA TTG CTC AAG GCG TAC CGC ATC Ser Glu Gln Phe Pro Leu Leu Arg Glu Leu Leu Lys Ala Tyr Arg Ile	402
	85 90 95 100	
	CCC GCC TAT GAG CTC GAC CAT TAC GAA GCG GAC GAT ATT ATC GGA ACG Pro Ala Tyr Glu Leu Asp His Tyr Glu Ala Asp Asp Ile Ile Gly Thr	450
	105 110 115	
20	ATG GCG GCG CGG GCT GAG CGA GAA GGG TTT GCA GTG AAA GTC ATT TCC Met Ala Ala Arg Ala Glu Arg Glu Gly Phe Ala Val Lys Val Ile Ser	498
	120 125 130	
25	GGC GAC CGC GAT TTA ACC CAG CTT GCT TCC CCG CAA GTG ACG GTG GAG Gly Asp Arg Asp Leu Thr Gln Leu Ala Ser Pro Gln Val Thr Val Glu	546
	135 140 145	
	ATT ACG AAA AAA GGG ATT ACC GAC ATC GAG TCG TAC ACG CCG GAG ACG Ile Thr Lys Lys Gly Ile Thr Asp Ile Glu Ser Tyr Thr Pro Glu Thr	594
	150 155 160	
30	GTC GTG GAA AAA TAC GGC CTC ACC CCG GAG CAA ATT GTC GAC TTG AAA Val Val Glu Lys Tyr Gly Leu Thr Pro Glu Gln Ile Val Asp Leu Lys	642
	165 170 175 180	
35	GGA TTG ATG GGC GAC AAA TCC GAC AAC ATC CCT GGC GTG CCC GGC ATC Gly Leu Met Gly Asp Lys Ser Asp Asn Ile Pro Gly Val Pro Gly Ile	690
	185 190 195	
	GGG GAA AAA ACA GCC GTC AAG CTG CTC AAG CAA TTC GGC ACG GTC GAA Gly Glu Lys Thr Ala Val Lys Leu Leu Lys Gln Phe Gly Thr Val Glu	738
	200 205 210	
40	AAC GTA CTG GCA TCG ATC GAT GAG ATC AAA GGG GAG AAG CTG AAA GAA Asn Val Leu Ala Ser Ile Asp Glu Ile Lys Gly Glu Lys Leu Lys Glu	786
	215 220 225	
45	AAT TTG CGC CAA TAC CGG GAT TTG GCG CTT TTA AGC AAA CAG CTG GCC Asn Leu Arg Gln Tyr Arg Asp Leu Ala Leu Leu Ser Lys Gln Leu Ala	834
	230 235 240	
	GCT ATT TGC CGC GAC GCC CCG GTT GAG CTG ACG CTC GAT GAC ATT GTC Ala Ile Cys Arg Asp Ala Pro Val Glu Leu Thr Leu Asp Asp Ile Val	882
	245 250 255 260	
50	TAC AAA GGA GAA GAC CGG GAA AAA GTG GTC GCC TTG TTT CAG GAG CTC Tyr Lys Gly Glu Asp Arg Glu Lys Val Val Ala Leu Phe Gln Glu Leu	930
	265 270 275	

55

5	GGA TTC CAG TCG TTT CTC GAC AAG ATG GCC GTC CAA ACG GAT GAA GGC Gly Phe Gln Ser Phe Leu Asp Lys Met Ala Val Gln Thr Asp Glu Gly	978
	280 285 290	
	GAA AAG CCG CTC GCC GGG ATG GAT TTT GCG ATC GCC GAC AGC GTC ACG Glu Lys Pro Leu Ala Gly Met Asp Phe Ala Ile Ala Asp Ser Val Thr	1026
	295 300 305	
10	GAC GAA ATG CTC GCC GAC AAA GCG GCC CTC GTC GTG GAG GTG GTG GGC Asp Glu Met Leu Ala Asp Lys Ala Ala Leu Val Val Glu Val Val Gly	1074
	310 315 320	
15	GAC AAC TAT CAC CAT GCC CCG ATT GTC GGG ATC GCC TTG GCC AAC GAA Asp Asn Tyr His His Ala Pro Ile Val Gly Ile Ala Leu Ala Asn Glu	1122
	325 330 335 340	
	CGC GGG CCG TTT TTC CTG CGC CCG GAG ACG GCG CTC GCC GAT CCG AAA Arg Gly Arg Phe Phe Leu Arg Pro Glu Thr Ala Leu Ala Asp Pro Lys	1170
	345 350 355	
20	TTT CTC GCT TGG CTT GGC GAT GAG ACG AAG AAA AAA ACG ATG TTT GAT Phe Leu Ala Trp Leu Gly Asp Glu Thr Lys Lys Lys Thr Met Phe Asp	1218
	360 365 370	
25	TCA AAG CCG GCG GCC GTC GCG CTA AAA TGG AAA GGA ATC GAA CTG CGC Ser Lys Arg Ala Ala Val Ala Leu Lys Trp Lys Gly Ile Glu Leu Arg	1266
	375 380 385	
	GGC GTC GTG TTC GAT CTG TTG CTG GCC GCT TAC TTG CTC GAT CCG GCG Gly Val Val Phe Asp Leu Leu Leu Ala Ala Tyr Leu Leu Asp Pro Ala	1314
	390 395 400	
30	CAG GCG GCG GGC GAC GTT GCC GCG GTG GCG AAA ATG CAT CAG TAC GAG Gln Ala Ala Gly Asp Val Ala Ala Val Ala Lys Met His Gln Tyr Glu	1362
	405 410 415 420	
35	GCG GTG CGA TCG GAT GAG GCG GTC TAT GGA AAA GGA GCG AAG CGG ACG Ala Val Arg Ser Asp Glu Ala Val Tyr Gly Lys Gly Ala Lys Arg Thr	1410
	425 430 435	
	GTT CCT GAT GAA CCG ACG CTT GCC GAG CAT CTC GCC CGC AAG GCG GCG Val Pro Asp Glu Pro Thr Leu Ala Glu His Leu Ala Arg Lys Ala Ala	1458
	440 445 450	
40	GCC ATT TGG GCG CTT GAA GAG CCG TTG ATG GAC GAA CTG CGC CGC AAC Ala Ile Trp Ala Leu Glu Glu Pro Leu Met Asp Glu Leu Arg Arg Asn	1506
	455 460 465	
45	GAA CAA GAT CCG CTG CTG ACC GAG CTC GAA CAG CCG CTG GCT GGC ATT Glu Gln Asp Arg Leu Leu Thr Glu Leu Glu Gln Pro Leu Ala Gly Ile	1554
	470 475 480	
	TTG GCC AAT ATG GAA TTT ACT GGA GTG AAA GTG GAC ACG AAG CGG CTT Leu Ala Asn Met Glu Phe Thr Gly Val Lys Val Asp Thr Lys Arg Leu	1602
	485 490 495 500	
50	GAA CAG ATG GGG GCG GAG CTC ACC GAG CAG CTG CAG GCG GTC GAG CGG Glu Gln Met Gly Ala Glu Leu Thr Glu Gln Leu Gln Ala Val Glu Arg	1650
	505 510 515	

55

5	CGC ATT TAC GAA CTC GCC GGC CAA GAG TTC AAC ATT AAC TCG CCG AAA Arg Ile Tyr Glu Leu Ala Gly Gln Glu Phe Asn Ile Asn Ser Pro Lys 520 525 530	1698
	CAG CTC GGG ACG GTT TTA TTT GAC AAG CTG CAG CTC CCG GTG TTG AAA Gln Leu Gly Thr Val Leu Phe Asp Lys Leu Gln Leu Pro Val Leu Lys 535 540 545	1746
10	AAG ACA AAA ACC GGC TAT TCG ACT TCA GCC GAT GTG CTT GAG AAG CTT Lys Thr Lys Thr Gly Tyr Ser Thr Ser Ala Asp Val Leu Glu Lys Leu 550 555 560	1794
15	GCA CCG CAC CAT GAA ATC GTC GAA CAT ATT TTG CAT TAC CGC CAA CTC Ala Pro His His Glu Ile Val Glu His Ile Leu His Tyr Arg Gln Leu 565 570 575 580	1842
	GGC AAG CTG CAG TCA ACG TAT ATT GAA GGG CTG CTG AAA GTG GTG CAC Gly Lys Leu Gln Ser Thr Tyr Ile Glu Gly Leu Leu Lys Val Val His 585 590 595	1890
20	CCC GTG ACG GGC AAA GTG CAC ACG ATG TTC AAT CAG GCG TTG ACG CAA Pro Val Thr Gly Lys Val His Thr Met Phe Asn Gln Ala Leu Thr Gln 600 605 610	1938
25	ACC GGG CGC CTC AGC TCC GTC GAA CCG AAT TTG CAA AAC ATT CCG ATT Thr Gly Arg Leu Ser Ser Val Glu Pro Asn Leu Gln Asn Ile Pro Ile 615 620 625	1986
	CGG CTT GAG GAA GGG CGG AAA ATC CGC CAG GCG TTC GTG CCG TCG GAG Arg Leu Glu Glu Gly Arg Lys Ile Arg Gln Ala Phe Val Pro Ser Glu 630 635 640	2034
30	CCG GAC TGG CTC ATC TTT GCG GCC GAC TAT TCG CAA ATC GAG CTG CGC Pro Asp Trp Leu Ile Phe Ala Ala Asp Tyr Ser Gln Ile Glu Leu Arg 645 650 655 660	2082
35	GTC CTC GCC CAT ATC GCG GAA GAT GAC AAT TTG ATT GAA GCG TTC CGG Val Leu Ala His Ile Ala Glu Asp Asp Asn Leu Ile Glu Ala Phe Arg 665 670 675	2130
	CGC GGG TTG GAC ATC CAT ACG AAA ACA GCC ATG GAC ATT TTC CAT GTG Arg Gly Leu Asp Ile His Thr Lys Thr Ala Met Asp Ile Phe His Val 680 685 690	2178
40	AGC GAA GAA GAC GTG ACA GCC AAC ATG CGC CGC CAA GCG AAG GCC GTC Ser Glu Glu Asp Val Thr Ala Asn Met Arg Arg Gln Ala Lys Ala Val 695 700 705	2226
45	AAT TTT GGC ATC GTG TAC GGC ATT AGT GAT TAC GGT CTG GCG CAA AAC Asn Phe Gly Ile Val Tyr Gly Ile Ser Asp Tyr Gly Leu Ala Gln Asn 710 715 720	2274
	TTG AAC ATT ACG CGC AAA GAA GCG GCT GAA TTT ATT GAG CGA TAT TTT Leu Asn Ile Thr Arg Lys Glu Ala Ala Glu Phe Ile Glu Arg Tyr Phe 725 730 735 740	2322
50	GCC AGT TTT CCA GGT GTA AAG CAA TAT ATG GAC AAC ATT GTG CAA GAA Ala Ser Phe Pro Gly Val Lys Gln Tyr Met Asp Asn Ile Val Gln Glu 745 750 755	2370

55

5 GCG AAA CAA AAA GGG TAT GTG ACG ACG CTG CTG CAT CGG CGC CGC TAT 2418
 Ala Lys Gln Lys Gly Tyr Val Thr Thr Leu Leu His Arg Arg Arg Tyr
 760 765 770
 TTG CCC GAT ATT ACA AGC CGC AAC TTC AAC GTC CGC AGC TTC GCC GAG 2466
 Leu Pro Asp Ile Thr Ser Arg Asn Phe Asn Val Arg Ser Phe Ala Glu
 775 780 785
 10 CGG ACG GCG ATG AAC ACA CCG ATC CAA GGG AGT GCC GCT GAT ATT ATT 2514
 Arg Thr Ala Met Asn Thr Pro Ile Gln Gly Ser Ala Ala Asp Ile Ile
 790 795 800
 AAA AAA GCG ATG ATC GAT CTA AGC GTG AGG CTG CGC GAA GAA CGG CTG 2562
 Lys Lys Ala Met Ile Asp Leu Ser Val Arg Leu Arg Glu Glu Arg Leu
 805 810 815 820
 CAG GCG CGC CTG TTG CTG CAA GTG CAT GAC GAA CTC ATT TTG GAG GCG 2610
 Gln Ala Arg Leu Leu Leu Gln Val His Asp Glu Leu Ile Leu Glu Ala
 825 830 835
 20 CCG AAA GAG GAA ATC GAG CGG CTG TGC CGC CTC GTT CCA GAG GTG ATG 2658
 Pro Lys Glu Glu Ile Glu Arg Leu Cys Arg Leu Val Pro Glu Val Met
 840 845 850
 GAG CAA GCC GTC GCA CTC CGC GTG CCG CTG AAA GTC GAT TAC CAT TAC 2706
 Glu Gln Ala Val Ala Leu Arg Val Pro Leu Lys Val Asp Tyr His Tyr
 855 860 865
 25 GGT CCG ACG TGG TAC GAC GCC AAA TAAAGCGGC CTGCCCGCCA GCTGCTCGGTT 2761
 Gly Pro Thr Trp Tyr Asp Ala Lys
 870 875

(2) INFORMATION FOR SEQ ID NO:20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 876 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

40 Leu Lys Asn Lys Leu Val Leu Ile Asp Gly Asn Ser Val Ala Tyr Arg
 1 5 10 15
 Ala Phe Phe Ala Leu Pro Leu Leu His Asn Asp Lys Gly Ile His Thr
 20 25 30
 Asn Ala Val Tyr Gly Phe Thr Met Met Leu Asn Lys Ile Leu Ala Glu
 35 40 45
 45 Glu Gln Pro Thr His Ile Leu Val Ala Phe Asp Ala Gly Lys Thr Thr
 50 55 60
 Phe Arg His Glu Thr Phe Gln Asp Tyr Lys Gly Gly Arg Gln Gln Thr
 65 70 75 80
 Pro Pro Glu Leu Ser Glu Gln Phe Pro Leu Leu Arg Glu Leu Leu Lys
 85 90 95
 50 Ala Tyr Arg Ile Pro Ala Tyr Glu Leu Asp His Tyr Glu Ala Asp Asp
 100 105 110
 Ile Ile Gly Thr Met Ala Ala Arg Ala Glu Arg Glu Gly Phe Ala Val

		115				120				125			
5	Lys	Val	Ile	Ser	Gly	Asp	Arg	Asp	Leu	Thr	Gln	Leu	Ala
		130				135						140	
	Val	Thr	Val	Glu	Ile	Thr	Lys	Lys	Gly	Ile	Thr	Asp	Ile
	145					150					155		160
	Thr	Pro	Glu	Thr	Val	Val	Glu	Lys	Tyr	Gly	Leu	Thr	Pro
					165					170			175
10	Val	Asp	Leu	Lys	Gly	Leu	Met	Gly	Asp	Lys	Ser	Asp	Asn
			180						185				190
	Val	Pro	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Val	Lys	Leu	Leu
		195						200				205	
	Gly	Thr	Val	Glu	Asn	Val	Leu	Ala	Ser	Ile	Asp	Glu	Ile
		210				215					220		
15	Lys	Leu	Lys	Glu	Asn	Leu	Arg	Gln	Tyr	Arg	Asp	Leu	Ala
	225					230					235		240
	Lys	Gln	Leu	Ala	Ala	Ile	Cys	Arg	Asp	Ala	Pro	Val	Glu
					245					250			255
	Asp	Asp	Ile	Val	Tyr	Lys	Gly	Glu	Asp	Arg	Glu	Lys	Val
			260						265				270
20	Phe	Gln	Glu	Leu	Gly	Phe	Gln	Ser	Phe	Leu	Asp	Lys	Met
		275						280					285
	Thr	Asp	Glu	Gly	Glu	Lys	Pro	Leu	Ala	Gly	Met	Asp	Phe
		290				295						300	
	Asp	Ser	Val	Thr	Asp	Glu	Met	Leu	Ala	Asp	Lys	Ala	Ala
	305					310					315		320
25	Glu	Val	Val	Gly	Asp	Asn	Tyr	His	His	Ala	Pro	Ile	Val
					325					330			335
	Leu	Ala	Asn	Glu	Arg	Gly	Arg	Phe	Phe	Leu	Arg	Pro	Glu
			340					345					350
	Ala	Asp	Pro	Lys	Phe	Leu	Ala	Trp	Leu	Gly	Asp	Glu	Thr
		355						360				365	
30	Thr	Met	Phe	Asp	Ser	Lys	Arg	Ala	Ala	Val	Ala	Leu	Lys
		370				375						380	
	Ile	Glu	Leu	Arg	Gly	Val	Val	Phe	Asp	Leu	Leu	Leu	Ala
	385					390				395			400
	Leu	Asp	Pro	Ala	Gln	Ala	Ala	Gly	Asp	Val	Ala	Ala	Val
					405				410				415
35	His	Gln	Tyr	Glu	Ala	Val	Arg	Ser	Asp	Glu	Ala	Val	Tyr
					420				425				430
	Ala	Lys	Arg	Thr	Val	Pro	Asp	Glu	Pro	Thr	Leu	Ala	Glu
		435						440				445	
	Arg	Lys	Ala	Ala	Ala	Ile	Trp	Ala	Leu	Glu	Glu	Pro	Leu
		450				455					460		465
40	Leu	Arg	Arg	Asn	Glu	Gln	Asp	Arg	Leu	Leu	Thr	Glu	Leu
		465				470					475		480
	Leu	Ala	Gly	Ile	Leu	Ala	Asn	Met	Glu	Phe	Thr	Gly	Val
					485				490				495
	Thr	Lys	Arg	Leu	Glu	Gln	Met	Gly	Ala	Glu	Leu	Thr	Glu
					500				505				510
45	Ala	Val	Glu	Arg	Arg	Ile	Tyr	Glu	Leu	Ala	Gly	Gln	Glu
		515						520				525	
	Asn	Ser	Pro	Lys	Gln	Leu	Gly	Thr	Val	Leu	Phe	Asp	Lys
		530					535				540		545
50	Pro	Val	Leu	Lys	Lys	Thr	Lys	Thr	Gly	Tyr	Ser	Thr	Ser
		545				550					555		560
	Leu	Glu	Lys	Leu	Ala	Pro	His	His	Glu	Ile	Val	Glu	His
					565				570				575
	Tyr	Arg	Gln	Leu	Gly	Lys	Leu	Gln	Ser	Thr	Tyr	Ile	Glu
				580				585				590	

55

Lys Val Val His Pro Val Thr Gly Lys Val His Thr Met Phe Asn Gln
 595 600 605
 5 Ala Leu Thr Gln Thr Gly Arg Leu Ser Ser Val Glu Pro Asn Leu Gln
 610 615 620
 Asn Ile Pro Ile Arg Leu Glu Glu Gly Arg Lys Ile Arg Gln Ala Phe
 625 630 635 640
 Val Pro Ser Glu Pro Asp Trp Leu Ile Phe Ala Ala Asp Tyr Ser Gln
 645 650 655
 10 Ile Glu Leu Arg Val Leu Ala His Ile Ala Glu Asp Asp Asn Leu Ile
 660 665 670
 Glu Ala Phe Arg Arg Gly Leu Asp Ile His Thr Lys Thr Ala Met Asp
 675 680 685
 Ile Phe His Val Ser Glu Glu Asp Val Thr Ala Asn Met Arg Arg Gln
 690 695 700
 15 Ala Lys Ala Val Asn Phe Gly Ile Val Tyr Gly Ile Ser Asp Tyr Gly
 705 710 715 720
 Leu Ala Gln Asn Leu Asn Ile Thr Arg Lys Glu Ala Ala Glu Phe Ile
 725 730 735
 Glu Arg Tyr Phe Ala Ser Phe Pro Gly Val Lys Gln Tyr Met Asp Asn
 740 745 750
 20 Ile Val Gln Glu Ala Lys Gln Lys Gly Tyr Val Thr Thr Leu Leu His
 755 760 765
 Arg Arg Arg Tyr Leu Pro Asp Ile Thr Ser Arg Asn Phe Asn Val Arg
 770 775 780
 Ser Phe Ala Glu Arg Thr Ala Met Asn Thr Pro Ile Gln Gly Ser Ala
 785 790 795 800
 25 Ala Asp Ile Ile Lys Lys Ala Met Ile Asp Leu Ser Val Arg Leu Arg
 805 810 815
 Glu Glu Arg Leu Gln Ala Arg Leu Leu Gln Val His Asp Glu Leu
 820 825 830
 Ile Leu Glu Ala Pro Lys Glu Glu Ile Glu Arg Leu Cys Arg Leu Val
 835 840 845
 30 Pro Glu Val Met Glu Gln Ala Val Ala Leu Arg Val Pro Leu Lys Val
 850 855 860
 Asp Tyr His Tyr Gly Pro Thr Trp Tyr Asp Ala Lys
 865 870 875

(2) INFORMATION FOR SEQ ID NO:21:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2631 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 1...2628
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

TTG AAA AAC AAG CTC GTC TTA ATT GAC GGC AAC AGC GTG GCG TAC CGC
 Leu Lys Asn Lys Leu Val Leu Ile Asp Gly Asn Ser Val Ala Tyr Arg
 1 5 10 15
 GCC TTT TTC GCG TTG CCG CTT TTG CAT AAC GAT AAA GGG ATT CAT ACG
 96

	Ala	Phe	Phe	Ala	Leu	Pro	Leu	Leu	His	Asn	Asp	Lys	Gly	Ile	His	Thr	
				20					25					30			
5	AAC	GCA	GTC	TAC	GGG	TTT	ACG	ATG	ATG	TTA	AAC	AAA	ATT	TTG	GCG	GAA	144
	Asn	Ala	Val	Tyr	Gly	Phe	Thr	Met	Leu	Asn	Lys	Ile	Leu	Ala	Glu		
			35					40				45					
	GAG	CAG	CCG	ACC	CAC	ATT	CTC	GTG	GCG	TTT	GAC	GCC	GGG	AAA	ACG	ACG	192
10	Glu	Gln	Pro	Thr	His	Ile	Leu	Val	Ala	Phe	Asp	Ala	Gly	Lys	Thr	Thr	
		50					55				60						
	TTC	CGC	CAT	GAA	ACG	TTC	CAA	GAC	TAT	AAA	GGC	GGG	CGG	CAG	CAG	ACG	240
	Phe	Arg	His	Glu	Thr	Phe	Gln	Asp	Tyr	Lys	Gly	Gly	Arg	Gln	Gln	Thr	
	65					70				75					80		
15	CCG	CCG	GAA	CTG	TCG	GAA	CAG	TTT	CCG	CTG	CTG	CGC	GAA	TTG	CTC	AAG	288
	Pro	Pro	Glu	Leu	Ser	Glu	Gln	Phe	Pro	Leu	Leu	Arg	Glu	Leu	Leu	Lys	
					85				90						95		
	GCG	TAC	CGC	ATC	CCC	GCC	TAT	GAG	CTC	GAC	CAT	TAC	GAA	GCG	GAC	GAT	336
20	Ala	Tyr	Arg	Ile	Pro	Ala	Tyr	Glu	Leu	Asp	His	Tyr	Glu	Ala	Asp	Asp	
				100					105					110			
	ATT	ATC	GGA	ACG	ATG	GCG	GCG	CGG	GCT	GAG	CGA	GAA	GGG	TTT	GCA	GTG	384
	Ile	Ile	Gly	Thr	Met	Ala	Ala	Arg	Ala	Glu	Arg	Glu	Gly	Phe	Ala	Val	
			115					120					125				
25	AAA	GTC	ATT	TCC	GGC	GAC	CGC	GAT	TTA	ACC	CAG	CTT	GCT	TCC	CCG	CAA	432
	Lys	Val	Ile	Ser	Gly	Asp	Arg	Asp	Leu	Thr	Gln	Leu	Ala	Ser	Pro	Gln	
		130					135				140						
	GTG	ACG	GTG	GAG	ATT	ACG	AAA	AAA	GGG	ATT	ACC	GAC	ATC	GAG	TCG	TAC	480
30	Val	Thr	Val	Glu	Ile	Thr	Lys	Lys	Gly	Ile	Thr	Asp	Ile	Glu	Ser	Tyr	
	145					150					155					160	
	ACG	CCG	GAG	ACG	GTC	GTG	GAA	AAA	TAC	GGC	CTC	ACC	CCG	GAG	CAA	ATT	528
	Thr	Pro	Glu	Thr	Val	Val	Glu	Lys	Tyr	Gly	Leu	Thr	Pro	Glu	Gln	Ile	
					165					170					175		
35	GTC	GAC	TTG	AAA	GGA	TTG	ATG	GGC	GAC	AAA	TCC	GAC	AAC	ATC	CCT	GGC	576
	Val	Asp	Leu	Lys	Gly	Leu	Met	Gly	Asp	Lys	Ser	Asp	Asn	Ile	Pro	Gly	
				180					185					190			
	GTG	CCC	GGC	ATC	GGG	GAA	AAA	ACA	GCC	GTC	AAG	CTG	CTC	AAG	CAA	TTC	624
40	Val	Pro	Gly	Ile	Gly	Glu	Lys	Thr	Ala	Val	Lys	Leu	Leu	Lys	Gln	Phe	
			195					200					205				
	GGC	ACG	GTC	GAA	AAC	GTA	CTG	GCA	TCG	ATC	GAT	GAG	ATC	AAA	GGG	GAG	672
	Gly	Thr	Val	Glu	Asn	Val	Leu	Ala	Ser	Ile	Asp	Glu	Ile	Lys	Gly	Glu	
		210					215					220					
45	AAG	CTG	AAA	GAA	AAT	TTG	CGC	CAA	TAC	CGG	GAT	TTG	GCG	CTT	TTA	AGC	720
	Lys	Leu	Lys	Glu	Asn	Leu	Arg	Gln	Tyr	Arg	Asp	Leu	Ala	Leu	Leu	Ser	
	225					230				235						240	
	AAA	CAG	CTG	GCC	GCT	ATT	TGC	CGC	GAC	GCC	CCG	GTT	GAG	CTG	ACG	CTC	768
50	Lys	Gln	Leu	Ala	Ala	Ile	Cys	Arg	Asp	Ala	Pro	Val	Glu	Leu	Thr	Leu	
					245					250					255		

55

5	GAT GAC ATT GTC TAC AAA GGA GAA GAC CGG GAA AAA GTG GTC GCC TTG Asp Asp Ile Val Tyr Lys Gly Glu Asp Arg Glu Lys Val Val Ala Leu 260 265 270	816
	TTT CAG GAG CTC GGA TTC CAG TCG TTT CTC GAC AAG ATG GCC GTC CAA Phe Gln Glu Leu Gly Phe Gln Ser Phe Leu Asp Lys Met Ala Val Gln 275 280 285	864
10	ACG GAT GAA GGC GAA AAG CCG CTC GCC GGG ATG GAT TTT GCG ATC GCC Thr Asp Glu Gly Glu Lys Pro Leu Ala Gly Met Asp Phe Ala Ile Ala 290 295 300	912
15	GAC AGC GTC ACG GAC GAA ATG CTC GCC GAC AAA GCG GCC CTC GTC GTG Asp Ser Val Thr Asp Glu Met Leu Ala Asp Lys Ala Ala Leu Val Val 305 310 315 320	960
	GAG GTG GTG GGC GAC AAC TAT CAC CAT GCC CCG ATT GTC GGG ATC GCC Glu Val Val Gly Asp Asn Tyr His His Ala Pro Ile Val Gly Ile Ala 325 330 335	1008
20	TTG GCC AAC GAA CGC GGG CCG TTT TTC CTG CGC CCG GAG ACG GCG CTC Leu Ala Asn Glu Arg Gly Arg Phe Phe Leu Arg Pro Glu Thr Ala Leu 340 345 350	1056
25	GCC GAT CCG AAA TTT CTC GCT TGG CTT GGC GAT GAG ACG AAG AAA AAA Ala Asp Pro Lys Phe Leu Ala Trp Leu Gly Asp Glu Thr Lys Lys Lys 355 360 365	1104
	ACG ATG TTT GAT TCA AAG CCG GCG GCC GTC GCG CTA AAA TGG AAA GGA Thr Met Phe Asp Ser Lys Arg Ala Ala Val Ala Leu Lys Trp Lys Gly 370 375 380	1152
30	ATC GAA CTG CGC GGC GTC GTG TTC GAT CTG TTG CTG GCC GCT TAC TTG Ile Glu Leu Arg Gly Val Val Phe Asp Leu Leu Leu Ala Ala Tyr Leu 385 390 395 400	1200
35	CTC GAT CCG GCG CAG GCG GCG GGC GAC GTT GCC GCG GTG GCG AAA ATG Leu Asp Pro Ala Gln Ala Ala Gly Asp Val Ala Ala Val Ala Lys Met 405 410 415	1248
	CAT CAG TAC GAG GCG GTG CGA TCG GAT GAG GCG GTC TAT GGA AAA GGA His Gln Tyr Glu Ala Val Arg Ser Asp Glu Ala Val Tyr Gly Lys Gly 420 425 430	1296
40	GCG AAG CGG ACG GTT CCT GAT GAA CCG ACG CTT GCC GAG CAT CTC GCC Ala Lys Arg Thr Val Pro Asp Glu Pro Thr Leu Ala Glu His Leu Ala 435 440 445	1344
45	CGC AAG GCG GCG GCC ATT TGG GCG CTT GAA GAG CCG TTG ATG GAC GAA Arg Lys Ala Ala Ala Ile Trp Ala Leu Glu Glu Pro Leu Met Asp Glu 450 455 460	1392
	CTG CGC CGC AAC GAA CAA GAT CCG CTG CTG ACC GAG CTC GAA CAG CCG Leu Arg Arg Asn Glu Gln Asp Arg Leu Leu Thr Glu Leu Glu Gln Pro 465 470 475 480	1440
50	CTG GCT GGC ATT TTG GCC AAT ATG GAA TTT ACT GGA GTG AAA GTG GAC Leu Ala Gly Ile Leu Ala Asn Met Glu Phe Thr Gly Val Lys Val Asp 485 490 495	1488

55

5	ACG AAG CGG CTT GAA CAG ATG GGG GCG GAG CTC ACC GAG CAG CTG CAG Thr Lys Arg Leu Glu Gln Met Gly Ala Glu Leu Thr Glu Gln Leu Gln 500 505 510	1536
	GCG GTC GAG CGG CGC ATT TAC GAA CTC GCC GGC CAA GAG TTC AAC ATT Ala Val Glu Arg Arg Ile Tyr Glu Leu Ala Gly Gln Glu Phe Asn Ile 515 520 525	1584
10	AAC TCG CCG AAA CAG CTC GGG ACG GTT TTA TTT GAC AAG CTG CAG CTC Asn Ser Pro Lys Gln Leu Gly Thr Val Leu Phe Asp Lys Leu Gln Leu 530 535 540	1632
15	CCG GTG TTG AAA AAG ACA AAA ACC GGC TAT TCG ACT TCA GCC GAT GTG Pro Val Leu Lys Lys Thr Lys Thr Gly Tyr Ser Thr Ser Ala Asp Val 545 550 555 560	1680
	CTT GAG AAG CTT GCA CCG CAC CAT GAA ATC GTC GAA CAT ATT TTG CAT Leu Glu Lys Leu Ala Pro His His Glu Ile Val Glu His Ile Leu His 565 570 575	1728
20	TAC CGC CAA CTC GGC AAG CTG CAG TCA ACG TAT ATT GAA GGG CTG CTG Tyr Arg Gln Leu Gly Lys Leu Gln Ser Thr Tyr Ile Glu Gly Leu Leu 580 585 590	1776
25	AAA GTG GTG CAC CCC GTG ACG GGC AAA GTG CAC ACG ATG TTC AAT CAG Lys Val Val His Pro Val Thr Gly Lys Val His Thr Met Phe Asn Gln 595 600 605	1824
	GCG TTG ACG CAA ACC GGG CGC CTC AGC TCC GTC GAA CCG AAT TTG CAA Ala Leu Thr Gln Thr Gly Arg Leu Ser Ser Val Glu Pro Asn Leu Gln 610 615 620	1872
30	AAC ATT CCG ATT CGG CTT GAG GAA GGG CGG AAA ATC CGC CAG GCG TTC Asn Ile Pro Ile Arg Leu Glu Glu Gly Arg Lys Ile Arg Gln Ala Phe 625 630 635 640	1920
35	GTG CCG TCG GAG CCG GAC TGG CTC ATC TTT GCG GCC GAC TAT TCG CAA Val Pro Ser Glu Pro Asp Trp Leu Ile Phe Ala Ala Asp Tyr Ser Gln 645 650 655	1968
	ATC GAG CTG CGC GTC CTC GCC CAT ATC GCG GAA GAT GAC AAT TTG ATT Ile Glu Leu Arg Val Leu Ala His Ile Ala Glu Asp Asp Asn Leu Ile 660 665 670	2016
40	GAA GCG TTC CGG CGC GGG TTG GAC ATC CAT ACG AAA ACA GCC ATG GAC Glu Ala Phe Arg Arg Gly Leu Asp Ile His Thr Lys Thr Ala Met Asp 675 680 685	2064
45	ATT TTC CAT GTG AGC GAA GAA GAC GTG ACA GCC AAC ATG CGC CGC CAA Ile Phe His Val Ser Glu Glu Asp Val Thr Ala Asn Met Arg Arg Gln 690 695 700	2112
	GCG AAG GCC GTC AAT TTT GGC ATC GTG TAC GGC ATT AGT GAT TAC GGT Ala Lys Ala Val Asn Phe Gly Ile Val Tyr Gly Ile Ser Asp Tyr Gly 705 710 715 720	2160
50	CTG GCG CAA AAC TTG AAC ATT ACG CGC AAA GAA GCG GCT GAA TTT ATT Leu Ala Gln Asn Leu Asn Ile Thr Arg Lys Glu Ala Ala Glu Phe Ile 725 730 735	2208

55

5	GAG CGA TAT TTT GCC AGT TTT CCA GGT GTA AAG CAA TAT ATG GAC AAC	2256
	Glu Arg Tyr Phe Ala Ser Phe Pro Gly Val Lys Gln Tyr Met Asp Asn	
	740 745 750	
	ATT GTG CAA GAA GCG AAA CAA AAA GGG TAT GTG ACG ACG CTG CTG CAT	2304
	Ile Val Gln Glu Ala Lys Gln Lys Gly Tyr Val Thr Thr Leu Leu His	
	755 760 765	
10	CGG CGC CGC TAT TTG CCC GAT ATT ACA AGC CGC AAC TTC AAC GTC CGC	2352
	Arg Arg Arg Tyr Leu Pro Asp Ile Thr Ser Arg Asn Phe Asn Val Arg	
	770 775 780	
15	AGC TTC GCC GAG CGG ACG GCG ATG AAC ACA CCG ATC CAA GGG AGT GCC	2400
	Ser Phe Ala Glu Arg Thr Ala Met Asn Thr Pro Ile Gln Gly Ser Ala	
	785 790 795 800	
	GCT GAT ATT ATT AAA AAA GCG ATG ATC GAT CTA AGC GTG AGG CTG CGC	2448
	Ala Asp Ile Ile Lys Lys Ala Met Ile Asp Leu Ser Val Arg Leu Arg	
	805 810 815	
20	GAA GAA CGG CTG CAG GCG CGC CTG TTG CTG CAA GTG CAT GAC GAA CTC	2496
	Glu Glu Arg Leu Gln Ala Arg Leu Leu Leu Gln Val His Asp Glu Leu	
	820 825 830	
25	ATT TTG GAG GCG CCG AAA GAG GAA ATC GAG CGG CTG TGC CGC CTC GTT	2544
	Ile Leu Glu Ala Pro Lys Glu Glu Ile Glu Arg Leu Cys Arg Leu Val	
	835 840 845	
	CCA GAG GTG ATG GAG CAA GCC GTC GCA CTC CGC GTG CCG CTG AAA GTC	2592
	Pro Glu Val Met Glu Gln Ala Val Ala Leu Arg Val Pro Leu Lys Val	
	850 855 860	
30	GAT TAC CAT TAC GGT CCG ACG TGG TAC GAC GCC AAA TAA	2631
	Asp Tyr His Tyr Gly Pro Thr Trp Tyr Asp Ala Lys	
	865 870 875	

(2) INFORMATION FOR SEQ ID NO:22:

- 35 (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1764 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- 40 (ix) FEATURE:
- (A) NAME/KEY: Coding Sequence
 - (B) LOCATION: 1...1761
 - (D) OTHER INFORMATION:
- 45 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

GAT GAA GGC GAA AAG CCG CTC GCC GGG ATG GAT TTT GCG ATC GCC GAC	48
Asp Glu Gly Glu Lys Pro Leu Ala Gly Met Asp Phe Ala Ile Ala Asp	
1 5 10 15	

AGC GTC ACG GAC GAA ATG CTC GCC GAC AAA GCG GCC CTC GTC GTG GAG	96
Ser Val Thr Asp Glu Met Leu Ala Asp Lys Ala Ala Leu Val Val Glu	

	20							25					30					
5	GTG	GTG	GGC	GAC	AAC	TAT	CAC	CAT	GCC	CCG	ATT	GTC	GGG	ATC	GCC	TTG	144	
	Val	Val	Gly	Asp	Asn	Tyr	His	His	Ala	Pro	Ile	Val	Gly	Ile	Ala	Leu		
			35					40					45					
	GCC	AAC	GAA	CGC	GGG	CGG	TTT	TTC	CTG	CGC	CCG	GAG	ACG	GCG	CTC	GCC	192	
10	Ala	Asn	Glu	Arg	Gly	Arg	Phe	Phe	Leu	Arg	Pro	Glu	Thr	Ala	Leu	Ala		
		50					55				60							
	GAT	CCG	AAA	TTT	CTC	GCT	TGG	CTT	GGC	GAT	GAG	ACG	AAG	AAA	AAA	ACG	240	
	Asp	Pro	Lys	Phe	Leu	Ala	Trp	Leu	Gly	Asp	Glu	Thr	Lys	Lys	Lys	Thr		
	65				70				75							80		
15	ATG	TTT	GAT	TCA	AAG	CGG	GCG	GCC	GTC	GCG	CTA	AAA	TGG	AAA	GGA	ATC	288	
	Met	Phe	Asp	Ser	Lys	Arg	Ala	Ala	Val	Ala	Leu	Lys	Trp	Lys	Gly	Ile		
					85				90						95			
	GAA	CTG	CGC	GGC	GTC	GTG	TTC	GAT	CTG	TTG	CTG	GCC	GCT	TAC	TTG	CTC	336	
20	Glu	Leu	Arg	Gly	Val	Val	Phe	Asp	Leu	Leu	Leu	Ala	Ala	Tyr	Leu	Leu		
				100					105					110				
	GAT	CCG	GCG	CAG	GCG	GCG	GGC	GAC	GTT	GCC	GCG	GTG	GCG	AAA	ATG	CAT	384	
	Asp	Pro	Ala	Gln	Ala	Ala	Gly	Asp	Val	Ala	Ala	Val	Ala	Lys	Met	His		
			115					120					125					
25	CAG	TAC	GAG	GCG	GTG	CGA	TCG	GAT	GAG	GCG	GTC	TAT	GGA	AAA	GGA	GCG	432	
	Gln	Tyr	Glu	Ala	Val	Arg	Ser	Asp	Glu	Ala	Val	Tyr	Gly	Lys	Gly	Ala		
		130					135					140						
	AAG	CGG	ACG	GTT	CCT	GAT	GAA	CCG	ACG	CTT	GCC	GAG	CAT	CTC	GCC	CGC	480	
30	Lys	Arg	Thr	Val	Pro	Asp	Glu	Pro	Thr	Leu	Ala	Glu	His	Leu	Ala	Arg		
	145					150				155						160		
	AAG	GCG	GCG	GCC	ATT	TGG	GCG	CTT	GAA	GAG	CCG	TTG	ATG	GAC	GAA	CTG	528	
	Lys	Ala	Ala	Ala	Ile	Trp	Ala	Leu	Glu	Glu	Pro	Leu	Met	Asp	Glu	Leu		
					165				170						175			
35	CGC	CGC	AAC	GAA	CAA	GAT	CGG	CTG	CTG	ACC	GAG	CTC	GAA	CAG	CCG	CTG	576	
	Arg	Arg	Asn	Glu	Gln	Asp	Arg	Leu	Leu	Thr	Glu	Leu	Glu	Gln	Pro	Leu		
				180				185						190				
	GCT	GGC	ATT	TTG	GCC	AAT	ATG	GAA	TTT	ACT	GGA	GTG	AAA	GTG	GAC	ACG	624	
40	Ala	Gly	Ile	Leu	Ala	Asn	Met	Glu	Phe	Thr	Gly	Val	Lys	Val	Asp	Thr		
			195					200					205					
	AAG	CGG	CTT	GAA	CAG	ATG	GGG	GCG	GAG	CTC	ACC	GAG	CAG	CTG	CAG	GCG	672	
	Lys	Arg	Leu	Glu	Gln	Met	Gly	Ala	Glu	Leu	Thr	Glu	Gln	Leu	Gln	Ala		
		210					215					220						
45	GTC	GAG	CGG	CGC	ATT	TAC	GAA	CTC	GCC	GGC	CAA	GAG	TTC	AAC	ATT	AAC	720	
	Val	Glu	Arg	Arg	Ile	Tyr	Glu	Leu	Ala	Gly	Gln	Glu	Phe	Asn	Ile	Asn		
	225				230					235					240			
	TCG	CCG	AAA	CAG	CTC	GGG	ACG	GTT	TTA	TTT	GAC	AAG	CTG	CAG	CTC	CCG	768	
50	Ser	Pro	Lys	Gln	Leu	Gly	Thr	Val	Leu	Phe	Asp	Lys	Leu	Gln	Leu	Pro		
				245					250						255			
	GTG	TTG	AAA	AAG	ACA	AAA	ACC	GGC	TAT	TCG	ACT	TCA	GCC	GAT	GTG	CTT	816	

55

5	Val	Leu	Lys	Lys	Thr	Lys	Thr	Gly	Tyr	Ser	Thr	Ser	Ala	Asp	Val	Leu	
			260						265					270			
	GAG	AAG	CTT	GCA	CCG	CAC	CAT	GAA	ATC	GTC	GAA	CAT	ATT	TTG	CAT	TAC	864
	Glu	Lys	Leu	Ala	Pro	His	His	Glu	Ile	Val	Glu	His	Ile	Leu	His	Tyr	
			275					280					285				
10	CGC	CAA	CTC	GGC	AAG	CTG	CAG	TCA	ACG	TAT	ATT	GAA	GGG	CTG	CTG	AAA	912
	Arg	Gln	Leu	Gly	Lys	Leu	Gln	Ser	Thr	Tyr	Ile	GAA	Gly	Leu	Leu	Lys	
			290				295					300					
	GTG	GTG	CAC	CCC	GTG	ACG	GGC	AAA	GTG	CAC	ACG	ATG	TTC	AAT	CAG	GCG	960
	Val	Val	His	Pro	Val		Gly	Lys	Val	His		Met	Phe	Asn	Gln	Ala	
15						310					315					320	
	TTG	ACG	CAA	ACC	GGG	CGC	CTC	AGC	TCC	GTC	GAA	CCG	AAT	TTG	CAA	AAC	1008
	Leu	Thr	Gln	Thr	Gly	Arg	Leu	Ser	Ser	Val	Glu	Pro	Asn	Leu	Gln	Asn	
					325					330					335		
20	ATT	CCG	ATT	CGG	CTT	GAG	GAA	GGG	CGG	AAA	ATC	CGC	CAG	GCG	TTC	GTG	1056
	Ile	Pro	Ile	Arg	Leu	Glu	Glu	Gly	Arg	Lys	Ile	Arg	Gln	Ala	Phe	Val	
				340					345					350			
	CCG	TCG	GAG	CCG	GAC	TGG	CTC	ATC	TTT	GCG	GCC	GAC	TAT	TCG	CAA	ATC	1104
	Pro	Ser	Glu	Pro	Asp	Trp	Leu	Ile	Phe	Ala	Ala	Asp	Tyr	Ser	Gln	Ile	
25				355				360					365				
	GAG	CTG	CGC	GTC	CTC	GCC	CAT	ATC	GCG	GAA	GAT	GAC	AAT	TTG	ATT	GAA	1152
	Glu	Leu	Arg	Val	Leu	Ala	His	Ile	Ala	Glu	Asp	Asp	Asn	Leu	Ile	Glu	
				370			375					380					
30	GCG	TTC	CGG	CGC	GGG	TTG	GAC	ATC	CAT	ACG	AAA	ACA	GCC	ATG	GAC	ATT	1200
	Ala	Phe	Arg	Arg	Gly	Leu	Asp	Ile	His	Thr	Lys	Thr	Ala	Met	Asp	Ile	
						390					395					400	
	TTC	CAT	GTG	AGC	GAA	GAA	GAC	GTG	ACA	GCC	AAC	ATG	CGC	CGC	CAA	GCG	1248
	Phe	His	Val	Ser	Glu	Glu	Asp	Val	Thr	Ala	Asn	Met	Arg	Arg	Gln	Ala	
35					405					410					415		
	AAG	GCC	GTC	AAT	TTT	GGC	ATC	GTG	TAC	GGC	ATT	AGT	GAT	TAC	GGT	CTG	1296
	Lys	Ala	Val	Asn	Phe	Gly	Ile	Val	Tyr	Gly	Ile	Ser	Asp	Tyr	Gly	Leu	
				420					425					430			
40	GCG	CAA	AAC	TTG	AAC	ATT	ACG	CGC	AAA	GAA	GCG	GCT	GAA	TTT	ATT	GAG	1344
	Ala	Gln	Asn	Leu	Asn	Ile	Thr	Arg	Lys	Glu	Ala	Ala	Glu	Phe	Ile	Glu	
				435				440					445				
	CGA	TAT	TTT	GCC	AGT	TTT	CCA	GGT	GTA	AAG	CAA	TAT	ATG	GAC	AAC	ATT	1392
	Arg	Tyr	Phe	Ala	Ser	Phe	Pro	Gly	Val	Lys	Gln	Tyr	Met	Asp	Asn	Ile	
45				450			455						460				
	GTG	CAA	GAA	GCG	AAA	CAA	AAA	GGG	TAT	GTG	ACG	ACG	CTG	CTG	CAT	CGG	1440
	Val	Gln	Glu	Ala	Lys	Gln	Lys	Gly	Tyr	Val	Thr	Thr	Leu	Leu	His	Arg	
						470					475					480	
50	CGC	CGC	TAT	TTG	CCC	GAT	ATT	ACA	AGC	CGC	AAC	TTC	AAC	GTC	CGC	AGC	1488
	Arg	Arg	Tyr	Leu	Pro	Asp	Ile	Thr	Ser	Arg	Asn	Phe	Asn	Val	Arg	Ser	
					485					490					495		

55

5 TTC GCC GAG CGG ACG GCG ATG AAC ACA CCG ATC CAA GGG AGT GCC GCT 1536
 Phe Ala Glu Arg Thr Ala Met Asn Thr Pro Ile Gln Gly Ser Ala Ala
 500 505 510
 GAT ATT ATT AAA AAA GCG ATG ATC GAT CTA AGC GTG AGG CTG CGC GAA 1584
 Asp Ile Ile Lys Lys Ala Met Ile Asp Leu Ser Val Arg Leu Arg Glu
 515 520 525
 10 GAA CGG CTG CAG GCG CGC CTG TTG CTG CAA GTG CAT GAC GAA CTC ATT 1632
 Glu Arg Leu Gln Ala Arg Leu Leu Gln Val His Asp Glu Leu Ile
 530 535 540
 TTG GAG GCG CCG AAA GAG GAA ATC GAG CGG CTG TGC CGC CTC GTT CCA 1680
 Leu Glu Ala Pro Lys Glu Glu Ile Glu Arg Leu Cys Arg Leu Val Pro
 545 550 555 560
 GAG GTG ATG GAG CAA GCC GTC GCA CTC CGC GTG CCG CTG AAA GTC GAT 1728
 Glu Val Met Glu Gln Ala Val Ala Leu Arg Val Pro Leu Lys Val Asp
 565 570 575
 20 TAC CAT TAC GGT CCG ACG TGG TAC GAC GCC AAA TAA 1764
 Tyr His Tyr Gly Pro Thr Trp Tyr Asp Ala Lys
 580 585

(2) INFORMATION FOR SEQ ID NO:23:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 587 amino acids
 (B) TYPE: amino acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:23:

35 Asp Glu Gly Glu Lys Pro Leu Ala Gly Met Asp Phe Ala Ile Ala Asp
 1 5 10 15
 Ser Val Thr Asp Glu Met Leu Ala Asp Lys Ala Ala Leu Val Val Glu
 20 25 30
 Val Val Gly Asp Asn Tyr His His Ala Pro Ile Val Gly Ile Ala Leu
 35 40 45
 Ala Asn Glu Arg Gly Arg Phe Phe Leu Arg Pro Glu Thr Ala Leu Ala
 50 55 60
 40 Asp Pro Lys Phe Leu Ala Trp Leu Gly Asp Glu Thr Lys Lys Lys Thr
 65 70 75 80
 Met Phe Asp Ser Lys Arg Ala Ala Val Ala Leu Lys Trp Lys Gly Ile
 85 90 95
 Glu Leu Arg Gly Val Val Phe Asp Leu Leu Leu Ala Ala Tyr Leu Leu
 100 105 110
 45 Asp Pro Ala Gln Ala Ala Gly Asp Val Ala Ala Val Ala Lys Met His
 115 120 125
 Gln Tyr Glu Ala Val Arg Ser Asp Glu Ala Val Tyr Gly Lys Gly Ala
 130 135 140
 Lys Arg Thr Val Pro Asp Glu Pro Thr Leu Ala Glu His Leu Ala Arg
 145 150 155 160
 50 Lys Ala Ala Ala Ile Trp Ala Leu Glu Glu Pro Leu Met Asp Glu Leu
 165 170 175
 Arg Arg Asn Glu Gln Asp Arg Leu Leu Thr Glu Leu Glu Gln Pro Leu
 180 185 190

	Ala	Gly	Ile	Leu	Ala	Asn	Met	Glu	Phe	Thr	Gly	Val	Lys	Val	Asp	Thr
			195					200					205			
5	Lys	Arg	Leu	Glu	Gln	Met	Gly	Ala	Glu	Leu	Thr	Glu	Gln	Leu	Gln	Ala
		210					215					220				
	Val	Glu	Arg	Arg	Ile	Tyr	Glu	Leu	Ala	Gly	Gln	Glu	Phe	Asn	Ile	Asn
	225					230					235				240	
	Ser	Pro	Lys	Gln	Leu	Gly	Thr	Val	Leu	Phe	Asp	Lys	Leu	Gln	Leu	Pro
				245						250					255	
10	Val	Leu	Lys	Lys	Thr	Lys	Thr	Gly	Tyr	Ser	Thr	Ser	Ala	Asp	Val	Leu
			260					265						270		
	Glu	Lys	Leu	Ala	Pro	His	His	Glu	Ile	Val	Glu	His	Ile	Leu	His	Tyr
		275						280					285			
	Arg	Gln	Leu	Gly	Lys	Leu	Gln	Ser	Thr	Tyr	Ile	Glu	Gly	Leu	Leu	Lys
	290						295					300				
15	Val	Val	His	Pro	Val	Thr	Gly	Lys	Val	His	Thr	Met	Phe	Asn	Gln	Ala
	305					310					315				320	
	Leu	Thr	Gln	Thr	Gly	Arg	Leu	Ser	Ser	Val	Glu	Pro	Asn	Leu	Gln	Asn
				325						330					335	
	Ile	Pro	Ile	Arg	Leu	Glu	Glu	Gly	Arg	Lys	Ile	Arg	Gln	Ala	Phe	Val
				340				345						350		
20	Pro	Ser	Glu	Pro	Asp	Trp	Leu	Ile	Phe	Ala	Ala	Asp	Tyr	Ser	Gln	Ile
		355					360						365			
	Glu	Leu	Arg	Val	Leu	Ala	His	Ile	Ala	Glu	Asp	Asp	Asn	Leu	Ile	Glu
	370						375					380				
	Ala	Phe	Arg	Arg	Gly	Leu	Asp	Ile	His	Thr	Lys	Thr	Ala	Met	Asp	Ile
25	385					390					395				400	
	Phe	His	Val	Ser	Glu	Asp	Val	Thr	Ala	Asn	Met	Arg	Arg	Gln	Ala	
				405						410				415		
	Lys	Ala	Val	Asn	Phe	Gly	Ile	Val	Tyr	Gly	Ile	Ser	Asp	Tyr	Gly	Leu
			420						425					430		
30	Ala	Gln	Asn	Leu	Asn	Ile	Thr	Arg	Lys	Glu	Ala	Ala	Glu	Phe	Ile	Glu
		435						440					445			
	Arg	Tyr	Phe	Ala	Ser	Phe	Pro	Gly	Val	Lys	Gln	Tyr	Met	Asp	Asn	Ile
	450					455						460				
	Val	Gln	Glu	Ala	Lys	Gln	Lys	Gly	Tyr	Val	Thr	Thr	Leu	Leu	His	Arg
	465					470					475				480	
35	Arg	Arg	Tyr	Leu	Pro	Asp	Ile	Thr	Ser	Arg	Asn	Phe	Asn	Val	Arg	Ser
				485						490					495	
	Phe	Ala	Glu	Arg	Thr	Ala	Met	Asn	Thr	Pro	Ile	Gln	Gly	Ser	Ala	Ala
			500					505						510		
	Asp	Ile	Ile	Lys	Lys	Ala	Met	Ile	Asp	Leu	Ser	Val	Arg	Leu	Arg	Glu
		515						520					525			
40	Glu	Arg	Leu	Gln	Ala	Arg	Leu	Leu	Gln	Val	His	Asp	Glu	Leu	Ile	
	530						535					540				
	Leu	Glu	Ala	Pro	Lys	Glu	Glu	Ile	Glu	Arg	Leu	Cys	Arg	Leu	Val	Pro
	545					550					555				560	
	Glu	Val	Met	Glu	Gln	Ala	Val	Ala	Leu	Arg	Val	Pro	Leu	Lys	Val	Asp
				565						570					575	
45	Tyr	His	Tyr	Gly	Pro	Thr	Trp	Tyr	Asp	Ala	Lys					
			580						585							

(2) INFORMATION FOR SEQ ID NO:24:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 1767 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 1...1764
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:24:

10	ACG GAT GAA GGC GAA AAG CCG CTC GCC GGG ATG GAT TTT GCG ATC GCC	48
	Thr Asp Glu Gly Glu Lys Pro Leu Ala Gly Met Asp Phe Ala Ile Ala	
	1 5 10 15	
15	GAC AGC GTC ACG GAC GAA ATG CTC GCC GAC AAA GCG GCC CTC GTC GTG	96
	Asp Ser Val Thr Asp Glu Met Leu Ala Asp Lys Ala Ala Leu Val Val	
	20 25 30	
20	GAG GTG GTG GGC GAC AAC TAT CAC CAT GCC CCG ATT GTC GGG ATC GCC	144
	Glu Val Val Gly Asp Asn Tyr His His Ala Pro Ile Val Gly Ile Ala	
	35 40 45	
25	TTG GCC AAC GAA CGC GGG CCG TTT TTC CTG CGC CCG GAG ACG GCG CTC	192
	Leu Ala Asn Glu Arg Gly Arg Phe Phe Leu Arg Pro Glu Thr Ala Leu	
	50 55 60	
30	GCC GAT CCG AAA TTT CTC GCT TGG CTT GGC GAT GAG ACG AAG AAA AAA	240
	Ala Asp Pro Lys Phe Leu Ala Trp Leu Gly Asp Glu Thr Lys Lys Lys	
	65 70 75 80	
35	ACG ATG TTT GAT TCA AAG CCG GCG GCC GTC GCG CTA AAA TGG AAA GGA	288
	Thr Met Phe Asp Ser Lys Arg Ala Ala Val Ala Leu Lys Trp Lys Gly	
	85 90 95	
40	ATC GAA CTG CGC GGC GTC GTG TTC GAT CTG TTG CTG GCC GCT TAC TTG	336
	Ile Glu Leu Arg Gly Val Val Phe Asp Leu Leu Leu Ala Ala Tyr Leu	
	100 105 110	
45	CTC GAT CCG GCG CAG GCG GCG GGC GAC GTT GCC GCG GTG GCG AAA ATG	384
	Leu Asp Pro Ala Gln Ala Ala Gly Asp Val Ala Ala Val Ala Lys Met	
	115 120 125	
50	CAT CAG TAC GAG GCG GTG CGA TCG GAT GAG GCG GTC TAT GGA AAA GGA	432
	His Gln Tyr Glu Ala Val Arg Ser Asp Glu Ala Val Tyr Gly Lys Gly	
	130 135 140	
55	GCG AAG CGG ACG GTT CCT GAT GAA CCG ACG CTT GCC GAG CAT CTC GCC	480
	Ala Lys Arg Thr Val Pro Asp Glu Pro Thr Leu Ala Glu His Leu Ala	
	145 150 155 160	
60	CGC AAG GCG GCG GCC ATT TGG GCG CTT GAA GAG CCG TTG ATG GAC GAA	528
	Arg Lys Ala Ala Ala Ile Trp Ala Leu Glu Glu Pro Leu Met Asp Glu	
	165 170 175	
65	CTG CGC CGC AAC GAA CAA GAT CCG CTG CTG ACC GAG CTC GAA CAG CCG	576
	Leu Arg Arg Asn Glu Gln Asp Arg Leu Leu Thr Glu Leu Glu Gln Pro	
	180 185 190	
70	CTG GCT GGC ATT TTG GCC AAT ATG GAA TTT ACT GGA GTG AAA GTG GAC	624
	Leu Ala Gly Ile Leu Ala Asn Met Glu Phe Thr Gly Val Lys Val Asp	
	195 200 205	

5	ACG AAG CGG CTT GAA CAG ATG GGG GCG GAG CTC ACC GAG CAG CTG CAG Thr Lys Arg Leu Glu Gln Met Gly Ala Glu Leu Thr Glu Gln Leu Gln 210 215 220	672
	GCG GTC GAG CGG CGC ATT TAC GAA CTC GCC GGC CAA GAG TTC AAC ATT Ala Val Glu Arg Arg Ile Tyr Glu Leu Ala Gly Gln Glu Phe Asn Ile 225 230 235 240	720
10	AAC TCG CCG AAA CAG CTC GGG ACG GTT TTA TTT GAC AAG CTG CAG CTC Asn Ser Pro Lys Gln Leu Gly Thr Val Leu Phe Asp Lys Leu Gln Leu 245 250 255	768
15	CCG GTG TTG AAA AAG ACA AAA ACC GGC TAT TCG ACT TCA GCC GAT GTG Pro Val Leu Lys Lys Thr Lys Thr Gly Tyr Ser Thr Ser Ala Asp Val 260 265 270	816
	CTT GAG AAG CTT GCA CCG CAC CAT GAA ATC GTC GAA CAT ATT TTG CAT Leu Glu Lys Leu Ala Pro His His Glu Ile Val Glu His Ile Leu His 275 280 285	864
20	TAC CGC CAA CTC GGC AAG CTG CAG TCA ACG TAT ATT GAA GGC CTG CTG Tyr Arg Gln Leu Gly Lys Leu Gln Ser Thr Tyr Ile Glu Gly Leu Leu 290 295 300	912
25	AAA GTG GTG CAC CCC GTG ACG GGC AAA GTG CAC ACG ATG TTC AAT CAG Lys Val Val His Pro Val Thr Gly Lys Val His Thr Met Phe Asn Gln 305 310 315 320	960
	GCG TTG ACG CAA ACC GGG CGC CTC AGC TCC GTC GAA CCG AAT TTG CAA Ala Leu Thr Gln Thr Gly Arg Leu Ser Ser Val Glu Pro Asn Leu Gln 325 330 335	1008
30	AAC ATT CCG ATT CGG CTT GAG GAA GGG CGG AAA ATC CGC CAG GCG TTC Asn Ile Pro Ile Arg Leu Glu Glu Gly Arg Lys Ile Arg Gln Ala Phe 340 345 350	1056
35	GTG CCG TCG GAG CCG GAC TGG CTC ATC TTT GCG GCC GAC TAT TCG CAA Val Pro Ser Glu Pro Asp Trp Leu Ile Phe Ala Ala Asp Tyr Ser Gln 355 360 365	1104
	ATC GAG CTG CGC GTC CTC GCC CAT ATC GCG GAA GAT GAC AAT TTG ATT Ile Glu Leu Arg Val Leu Ala His Ile Ala Glu Asp Asp Asn Leu Ile 370 375 380	1152
40	GAA GCG TTC CGG CGC GGG TTG GAC ATC CAT ACG AAA ACA GCC ATG GAC Glu Ala Phe Arg Arg Gly Leu Asp Ile His Thr Lys Thr Ala Met Asp 385 390 395 400	1200
45	ATT TTC CAT GTG AGC GAA GAA GAC GTG ACA GCC AAC ATG CGC CGC CAA Ile Phe His Val Ser Glu Glu Asp Val Thr Ala Asn Met Arg Arg Gln 405 410 415	1248
	GCG AAG GCC GTC AAT TTT GGC ATC GTG TAC GGC ATT AGT GAT TAC GGT Ala Lys Ala Val Asn Phe Gly Ile Val Tyr Gly Ile Ser Asp Tyr Gly 420 425 430	1296
50	CTG GCG CAA AAC TTG AAC ATT ACG CGC AAA GAA GCG GCT GAA TTT ATT Leu Ala Gln Asn Leu Asn Ile Thr Arg Lys Glu Ala Ala Glu Phe Ile 435 440 445	1344

55

5 GAG CGA TAT TTT GCC AGT TTT CCA GGT GTA AAG CAA TAT ATG GAC AAC 1392
 Glu Arg Tyr Phe Ala Ser Phe Pro Gly Val Lys Gln Tyr Met Asp Asn
 450 455 460

ATT GTG CAA GAA GCG AAA CAA AAA GGG TAT GTG ACG ACG CTG CTG CAT 1440
 Ile Val Gln Glu Ala Lys Gln Lys Gly Tyr Val Thr Thr Leu Leu His
 465 470 475 480

10 CGG CGC CGC TAT TTG CCC GAT ATT ACA AGC CGC AAC TTC AAC GTC CGC 1488
 Arg Arg Arg Tyr Leu Pro Asp Ile Thr Ser Arg Asn Phe Asn Val Arg
 485 490 495

15 AGC TTC GCC GAG CGG ACG GCG ATG AAC ACA CCG ATC CAA GGG AGT GCC 1536
 Ser Phe Ala Glu Arg Thr Ala Met Asn Thr Pro Ile Gln Gly Ser Ala
 500 505 510

GCT GAT ATT ATT AAA AAA GCG ATG ATC GAT CTA AGC GTG AGG CTG CGC 1584
 Ala Asp Ile Ile Lys Lys Ala Met Ile Asp Leu Ser Val Arg Leu Arg
 515 520 525

20 GAA GAA CGG CTG CAG GCG CGC CTG TTG CTG CAA GTG CAT GAC GAA CTC 1632
 Glu Glu Arg Leu Gln Ala Arg Leu Leu Leu Gln Val His Asp Glu Leu
 530 535 540

25 ATT TTG GAG GCG CCG AAA GAG GAA ATC GAG CGG CTG TGC CGC CTC GTT 1680
 Ile Leu Glu Ala Pro Lys Glu Glu Ile Glu Arg Leu Cys Arg Leu Val
 545 550 555 560

CCA GAG GTG ATG GAG CAA GCC GTC GCA CTC CGC GTG CCG CTG AAA GTC 1728
 Pro Glu Val Met Glu Gln Ala Val Ala Leu Arg Val Pro Leu Lys Val
 565 570 575

30 GAT TAC CAT TAC GGT CCG ACG TGG TAC GAC GCC AAA TAA 1767
 Asp Tyr His Tyr Gly Pro Thr Trp Tyr Asp Ala Lys
 580 585

(2) INFORMATION FOR SEQ ID NO:25:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 588 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:25:

Thr Asp Glu Gly Glu Lys Pro Leu Ala Gly Met Asp Phe Ala Ile Ala
 1 5 10 15
 Asp Ser Val Thr Asp Glu Met Leu Ala Asp Lys Ala Ala Leu Val Val
 20 25 30
 Glu Val Val Gly Asp Asn Tyr His Ala Pro Ile Val Gly Ile Ala
 35 40 45
 Leu Ala Asn Glu Arg Gly Arg Phe Phe Leu Arg Pro Glu Thr Ala Leu
 50 55 60
 Ala Asp Pro Lys Phe Leu Ala Trp Leu Gly Asp Glu Thr Lys Lys Lys
 65 70 75 80
 Thr Met Phe Asp Ser Lys Arg Ala Ala Val Ala Leu Lys Trp Lys Gly
 85 90 95

Ile Glu Leu Arg Gly Val Val Phe Asp Leu Leu Leu Ala Ala Tyr Leu
 100 105 110
 5 Leu Asp Pro Ala Gln Ala Ala Gly Asp Val Ala Ala Val Ala Lys Met
 115 120 125
 His Gln Tyr Glu Ala Val Arg Ser Asp Glu Ala Val Tyr Gly Lys Gly
 130 135 140
 Ala Lys Arg Thr Val Pro Asp Glu Pro Thr Leu Ala Glu His Leu Ala
 145 150 155 160
 10 Arg Lys Ala Ala Ala Ile Trp Ala Leu Glu Glu Pro Leu Met Asp Glu
 165 170 175
 Leu Arg Arg Asn Glu Gln Asp Arg Leu Leu Thr Glu Leu Glu Gln Pro
 180 185 190
 Leu Ala Gly Ile Leu Ala Asn Met Glu Phe Thr Gly Val Lys Val Asp
 195 200 205
 15 Thr Lys Arg Leu Glu Gln Met Gly Ala Glu Leu Thr Glu Gln Leu Gln
 210 215 220
 Ala Val Glu Arg Arg Ile Tyr Glu Leu Ala Gly Gln Glu Phe Asn Ile
 225 230 235 240
 20 Asn Ser Pro Lys Gln Leu Gly Thr Val Leu Phe Asp Lys Leu Gln Leu
 245 250 255
 Pro Val Leu Lys Lys Thr Lys Thr Gly Tyr Ser Thr Ser Ala Asp Val
 260 265 270
 Leu Glu Lys Leu Ala Pro His His Glu Ile Val Glu His Ile Leu His
 275 280 285
 25 Tyr Arg Gln Leu Gly Lys Leu Gln Ser Thr Tyr Ile Glu Gly Leu Leu
 290 295 300
 Lys Val Val His Pro Val Thr Gly Lys Val His Thr Met Phe Asn Gln
 305 310 315 320
 Ala Leu Thr Gln Thr Gly Arg Leu Ser Ser Val Glu Pro Asn Leu Gln
 325 330 335
 30 Asn Ile Pro Ile Arg Leu Glu Glu Gly Arg Lys Ile Arg Gln Ala Phe
 340 345 350
 Val Pro Ser Glu Pro Asp Trp Leu Ile Phe Ala Ala Asp Tyr Ser Gln
 355 360 365
 Ile Glu Leu Arg Val Leu Ala His Ile Ala Glu Asp Asp Asn Leu Ile
 370 375 380
 35 Glu Ala Phe Arg Arg Gly Leu Asp Ile His Thr Lys Thr Ala Met Asp
 385 390 395 400
 Ile Phe His Val Ser Glu Glu Asp Val Thr Ala Asn Met Arg Arg Gln
 405 410 415
 Ala Lys Ala Val Asn Phe Gly Ile Val Tyr Gly Ile Ser Asp Tyr Gly
 420 425 430
 40 Leu Ala Gln Asn Leu Asn Ile Thr Arg Lys Glu Ala Ala Glu Phe Ile
 435 440 445
 Glu Arg Tyr Phe Ala Ser Phe Pro Gly Val Lys Gln Tyr Met Asp Asn
 450 455 460
 Ile Val Gln Glu Ala Lys Gln Lys Gly Tyr Val Thr Thr Leu Leu His
 465 470 475 480
 45 Arg Arg Arg Tyr Leu Pro Asp Ile Thr Ser Arg Asn Phe Asn Val Arg
 485 490 495
 Ser Phe Ala Glu Arg Thr Ala Met Asn Thr Pro Ile Gln Gly Ser Ala
 500 505 510
 Ala Asp Ile Ile Lys Lys Ala Met Ile Asp Leu Ser Val Arg Leu Arg
 515 520 525
 50 Glu Glu Arg Leu Gln Ala Arg Leu Leu Leu Gln Val His Asp Glu Leu
 530 535 540
 Ile Leu Glu Ala Pro Lys Glu Glu Ile Glu Arg Leu Cys Arg Leu Val
 545 550 555 560
 Pro Glu Val Met Glu Gln Ala Val Ala Leu Arg Val Pro Leu Lys Val

55

565 570 575
 Asp Tyr His Tyr Gly Pro Thr Trp Tyr Asp Ala Lys
 580 585

(2) INFORMATION FOR SEQ ID NO:26:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1773 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 1...1770
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:26:

20	GTC CAA ACG GAT GAA GGC GAA AAG CCG CTC GCC GGG ATG GAT TTT GCG	48
	Val Gln Thr Asp Glu Gly Glu Lys Pro Leu Ala Gly Met Asp Phe Ala	
	1 5 10 15	
25	ATC GCC GAC AGC GTC ACG GAC GAA ATG CTC GCC GAC AAA GCG GCC CTC	96
	Ile Ala Asp Ser Val Thr Asp Glu Met Leu Ala Asp Lys Ala Ala Leu	
	20 25 30	
30	GTC GTG GAG GTG GTG GGC GAC AAC TAT CAC CAT GCC CCG ATT GTC GGG	144
	Val Val Glu Val Val Gly Asp Asn Tyr His His Ala Pro Ile Val Gly	
	35 40 45	
35	ATC GCC TTG GCC AAC GAA CGC GGG CGG TTT TTC CTG CGC CCG GAG ACG	192
	Ile Ala Leu Ala Asn Glu Arg Gly Arg Phe Phe Leu Arg Pro Glu Thr	
	50 55 60	
40	GCG CTC GCC GAT CCG AAA TTT CTC GCT TGG CTT GGC GAT GAG ACG AAG	240
	Ala Leu Ala Asp Pro Lys Phe Leu Ala Trp Leu Gly Asp Glu Thr Lys	
	65 70 75 80	
45	AAA AAA ACG ATG TTT GAT TCA AAG CGG GCG GCC GTC GCG CTA AAA TGG	288
	Lys Lys Thr Met Phe Asp Ser Lys Arg Ala Ala Val Ala Leu Lys Trp	
	85 90 95	
50	AAA GGA ATC GAA CTG CGC GGC GTC GTG TTC GAT CTG TTG CTG GCC GCT	336
	Lys Gly Ile Glu Leu Arg Gly Val Val Phe Asp Leu Leu Leu Ala Ala	
	100 105 110	
55	TAC TTG CTC GAT CCG GCG CAG GCG GCG GGC GAC GTT GCC GCG GTG GCG	384
	Tyr Leu Leu Asp Pro Ala Gln Ala Ala Gly Asp Val Ala Ala Val Ala	
	115 120 125	
60	AAA ATG CAT CAG TAC GAG GCG GTG CGA TCG GAT GAG GCG GTC TAT GGA	432
	Lys Met His Gln Tyr Glu Ala Val Arg Ser Asp Glu Ala Val Tyr Gly	
	130 135 140	
65	AAA GGA GCG AAG CGG ACG GTT CCT GAT GAA CCG ACG CTT GCC GAG CAT	480
	Lys Gly Ala Lys Arg Thr Val Pro Asp Glu Pro Thr Leu Ala Glu His	

	145	150	155	160	
5	CTC GCC CGC AAG GCG GCG GCC ATT TGG GCG CTT GAA GAG CCG TTG ATG Leu Ala Arg Lys 165 Ala Ala Ala Ile Trp Ala Leu Glu Glu Pro Leu Met 175				528
10	GAC GAA CTG CGC CGC AAC GAA CAA GAT CGG CTG CTG ACC GAG CTC GAA Asp Glu Leu Arg Arg Asn Glu Gln Asp Arg Leu Leu Thr Glu Leu Glu 190				576
	CAG CCG CTG GCT GGC ATT TTG GCC AAT ATG GAA TTT ACT GGA GTG AAA Gln Pro Leu Ala Gly Ile Leu Ala Asn Met Glu Phe Thr Gly Val Lys 205				624
15	GTG GAC ACG AAG CGG CTT GAA CAG ATG GGG GCG GAG CTC ACC GAG CAG Val Asp Thr Lys Arg Leu Glu Gln Met Gly Ala Glu Leu Thr Glu Gln 220				672
20	CTG CAG GCG GTC GAG CGG CGC ATT TAC GAA CTC GCC GGC CAA GAG TTC Leu Gln Ala Val Glu Arg Arg Ile Tyr Glu Leu Ala Gly Gln Glu Phe 240				720
	AAC ATT AAC TCG CCG AAA CAG CTC GGG ACG GTT TTA TTT GAC AAG CTG Asn Ile Asn Ser Pro Lys Gln Leu Gly Thr Val Leu Phe Asp Lys Leu 255				768
25	CAG CTC CCG GTG TTG AAA AAG ACA AAA ACC GGC TAT TCG ACT TCA GCC Gln Leu Pro Val Leu Lys Lys Thr Lys Thr Gly Tyr Ser Thr Ser Ala 270				816
30	GAT GTG CTT GAG AAG CTT GCA CCG CAC CAT GAA ATC GTC GAA CAT ATT Asp Val Leu Glu Lys Leu Ala Pro His His Glu Ile Val Glu His Ile 285				864
	TTG CAT TAC CGC CAA CTC GGC AAG CTG CAG TCA ACG TAT ATT GAA GGG Leu His Tyr Arg Gln Leu Gly Lys Leu Gln Ser Thr Tyr Ile Glu Gly 300				912
35	CTG CTG AAA GTG GTG CAC CCC GTG ACG GGC AAA GTG CAC ACG ATG TTC Leu Leu Lys Val Val His Pro Val Thr Gly Lys Val His Thr Met Phe 320				960
40	AAT CAG GCG TTG ACG CAA ACC GGG CGC CTC AGC TCC GTC GAA CCG AAT Asn Gln Ala Leu Thr Gln Thr Gly Arg Leu Ser Ser Val Glu Pro Asn 335				1008
	TTG CAA AAC ATT CCG ATT CGG CTT GAG GAA GGG CGG AAA ATC CGC CAG Leu Gln Asn Ile Pro Ile Arg Leu Glu Glu Gly Arg Lys Ile Arg Gln 350				1056
45	GCG TTC GTG CCG TCG GAG CCG GAC TGG CTC ATC TTT GCG GCC GAC TAT Ala Phe Val Pro Ser Glu Pro Asp Trp Leu Ile Phe Ala Ala Asp Tyr 365				1104
50	TCG CAA ATC GAG CTG CGC GTC CTC GCC CAT ATC GCG GAA GAT GAC AAT Ser Gln Ile Glu Leu Arg Val Leu Ala His Ile Ala Glu Asp Asp Asn 380				1152
	TTG ATT GAA GCG TTC CGG CGC GGG TTG GAC ATC CAT ACG AAA ACA GCC				1200

5 Leu Ile Glu Ala Phe Arg Arg Gly Leu Asp Ile His Thr Lys Thr Ala
 385 390 395 400
 ATG GAC ATT TTC CAT GTG AGC GAA GAA GAC GTG ACA GCC AAC ATG CGC 1248
 Met Asp Ile Phe His Val Ser Glu Glu Asp Val Thr Ala Asn Met Arg
 405 410 415
 10 CGC CAA GCG AAG GCC GTC AAT TTT GGC ATC GTG TAC GGC ATT AGT GAT 1296
 Arg Gln Ala Lys Ala Val Asn Phe Gly Ile Val Tyr Gly Ile Ser Asp
 420 425 430
 TAC GGT CTG GCG CAA AAC TTG AAC ATT ACG CGC AAA GAA GCG GCT GAA 1344
 Tyr Gly Leu Ala Gln Asn Leu Asn Ile Thr Arg Lys Glu Ala Ala Glu
 435 440 445
 15 TTT ATT GAG CGA TAT TTT GCC AGT TTT CCA GGT GTA AAG CAA TAT ATG 1392
 Phe Ile Glu Arg Tyr Phe Ala Ser Phe Pro Gly Val Lys Gln Tyr Met
 450 455 460
 20 GAC AAC ATT GTG CAA GAA GCG AAA CAA AAA GGG TAT GTG ACG ACG CTG 1440
 Asp Asn Ile Val Gln Glu Ala Lys Gln Lys Gly Tyr Val Thr Thr Leu
 465 470 475 480
 CTG CAT CGG CGC CGC TAT TTG CCC GAT ATT ACA AGC CGC AAC TTC AAC 1488
 Leu His Arg Arg Arg Tyr Leu Pro Asp Ile Thr Ser Arg Asn Phe Asn
 485 490 495
 25 GTC CGC AGC TTC GCC GAG CGG ACG GCG ATG AAC ACA CCG ATC CAA GGG 1536
 Val Arg Ser Phe Ala Glu Arg Thr Ala Met Asn Thr Pro Ile Gln Gly
 500 505 510
 30 AGT GCC GCT GAT ATT ATT AAA AAA GCG ATG ATC GAT CTA AGC GTG AGG 1584
 Ser Ala Ala Asp Ile Ile Lys Lys Ala Met Ile Asp Leu Ser Val Arg
 515 520 525
 CTG CGC GAA GAA CGG CTG CAG GCG CGC CTG TTG CTG CAA GTG CAT GAC 1632
 Leu Arg Glu Glu Arg Leu Gln Ala Arg Leu Leu Gln Val His Asp
 530 535 540
 35 GAA CTC ATT TTG GAG GCG CCG AAA GAG GAA ATC GAG CGG CTG TGC CGC 1680
 Glu Leu Ile Leu Glu Ala Pro Lys Glu Glu Ile Glu Arg Leu Cys Arg
 545 550 555 560
 40 CTC GTT CCA GAG GTG ATG GAG CAA GCC GTC GCA CTC CGC GTG CCG CTG 1728
 Leu Val Pro Glu Val Met Glu Gln Ala Val Ala Leu Arg Val Pro Leu
 565 570 575
 AAA GTC GAT TAC CAT TAC GGT CCG ACG TGG TAC GAC GCC AAA TAA 1773
 Lys Val Asp Tyr His Tyr Gly Pro Thr Trp Tyr Asp Ala Lys
 580 585 590

(2) INFORMATION FOR SEQ ID NO:27:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 590 amino acids
 - (B) TYPE: amino acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:27:

5	Val	Gln	Thr	Asp	Glu	Gly	Glu	Lys	Pro	Leu	Ala	Gly	Met	Asp	Phe	Ala
	1				5					10					15	
	Ile	Ala	Asp	Ser	Val	Thr	Asp	Glu	Met	Leu	Ala	Asp	Lys	Ala	Ala	Leu
				20					25					30		
	Val	Val	Glu	Val	Val	Gly	Asp	Asn	Tyr	His	His	Ala	Pro	Ile	Val	Gly
			35					40						45		
10	Ile	Ala	Leu	Ala	Asn	Glu	Arg	Gly	Arg	Phe	Phe	Leu	Arg	Pro	Glu	Thr
		50				55						60				
	Ala	Leu	Ala	Asp	Pro	Lys	Phe	Leu	Ala	Trp	Leu	Gly	Asp	Glu	Thr	Lys
	65					70					75					80
	Lys	Lys	Thr	Met	Phe	Asp	Ser	Lys	Arg	Ala	Ala	Val	Ala	Leu	Lys	Trp
					85					90					95	
15	Lys	Gly	Ile	Glu	Leu	Arg	Gly	Val	Val	Phe	Asp	Leu	Leu	Leu	Ala	Ala
				100					105					110		
	Tyr	Leu	Leu	Asp	Pro	Ala	Gln	Ala	Ala	Gly	Asp	Val	Ala	Ala	Val	Ala
			115					120					125			
	Lys	Met	His	Gln	Tyr	Glu	Ala	Val	Arg	Ser	Asp	Glu	Ala	Val	Tyr	Gly
	130						135					140				
20	Lys	Gly	Ala	Lys	Arg	Thr	Val	Pro	Asp	Glu	Pro	Thr	Leu	Ala	Glu	His
	145					150					155					160
	Leu	Ala	Arg	Lys	Ala	Ala	Ala	Ile	Trp	Ala	Leu	Glu	Glu	Pro	Leu	Met
					165					170					175	
25	Asp	Glu	Leu	Arg	Arg	Asn	Glu	Gln	Asp	Arg	Leu	Leu	Thr	Glu	Leu	Glu
			180						185					190		
	Gln	Pro	Leu	Ala	Gly	Ile	Leu	Ala	Asn	Met	Glu	Phe	Thr	Gly	Val	Lys
			195					200					205			
	Val	Asp	Thr	Lys	Arg	Leu	Glu	Gln	Met	Gly	Ala	Glu	Leu	Thr	Glu	Gln
		210					215					220				
30	Leu	Gln	Ala	Val	Glu	Arg	Arg	Ile	Tyr	Glu	Leu	Ala	Gly	Gln	Glu	Phe
	225					230					235					240
	Asn	Ile	Asn	Ser	Pro	Lys	Gln	Leu	Gly	Thr	Val	Leu	Phe	Asp	Lys	Leu
					245					250					255	
	Gln	Leu	Pro	Val	Leu	Lys	Lys	Thr	Lys	Thr	Gly	Tyr	Ser	Thr	Ser	Ala
			260						265					270		
35	Asp	Val	Leu	Glu	Lys	Leu	Ala	Pro	His	His	Glu	Ile	Val	Glu	His	Ile
			275					280					285			
	Leu	His	Tyr	Arg	Gln	Leu	Gly	Lys	Leu	Gln	Ser	Thr	Tyr	Ile	Glu	Gly
		290					295					300				
	Leu	Leu	Lys	Val	Val	His	Pro	Val	Thr	Gly	Lys	Val	His	Thr	Met	Phe
	305					310					315					320
40	Asn	Gln	Ala	Leu	Thr	Gln	Thr	Gly	Arg	Leu	Ser	Ser	Val	Glu	Pro	Asn
					325					330					335	
	Leu	Gln	Asn	Ile	Pro	Ile	Arg	Leu	Glu	Gly	Arg	Lys	Ile	Arg	Gln	
			340						345					350		
	Ala	Phe	Val	Pro	Ser	Glu	Pro	Asp	Trp	Leu	Ile	Phe	Ala	Ala	Asp	Tyr
			355					360					365			
45	Ser	Gln	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Ile	Ala	Glu	Asp	Asp	Asn
		370					375					380				
	Leu	Ile	Glu	Ala	Phe	Arg	Arg	Gly	Leu	Asp	Ile	His	Thr	Lys	Thr	Ala
	385					390					395					400
	Met	Asp	Ile	Phe	His	Val	Ser	Glu	Glu	Asp	Val	Thr	Ala	Asn	Met	Arg
					405					410					415	
50	Arg	Gln	Ala	Lys	Ala	Val	Asn	Phe	Gly	Ile	Val	Tyr	Gly	Ile	Ser	Asp
				420					425					430		
	Tyr	Gly	Leu	Ala	Gln	Asn	Leu	Asn	Ile	Thr	Arg	Lys	Glu	Ala	Ala	Glu
			435					440					445			

55

Phe Ile Glu Arg Tyr Phe Ala Ser Phe Pro Gly Val Lys Gln Tyr Met
 450 455 460
 5 Asp Asn Ile Val Gln Glu Ala Lys Gln Lys Gly Tyr Val Thr Thr Leu
 465 470 475 480
 Leu His Arg Arg Arg Tyr Leu Pro Asp Ile Thr Ser Arg Asn Phe Asn
 485 490 495
 Val Arg Ser Phe Ala Glu Arg Thr Ala Met Asn Thr Pro Ile Gln Gly
 500 505 510
 10 Ser Ala Ala Asp Ile Ile Lys Lys Ala Met Ile Asp Leu Ser Val Arg
 515 520 525
 Leu Arg Glu Glu Arg Leu Gln Ala Arg Leu Leu Leu Gln Val His Asp
 530 535 540
 Glu Leu Ile Leu Glu Ala Pro Lys Glu Glu Ile Glu Arg Leu Cys Arg
 545 550 555 560
 15 Leu Val Pro Glu Val Met Glu Gln Ala Val Ala Leu Arg Val Pro Leu
 565 570 575
 Lys Val Asp Tyr His Tyr Gly Pro Thr Trp Tyr Asp Ala Lys
 580 585 590

(2) INFORMATION FOR SEQ ID NO:28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 99 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:28:

AACGCAGTCT ACGGGTTTAC GATGATGTTA AACAAAATTT TGGCGGAAGA GCAGCCGACC 60
 CACATTCTCG TGGCGTTTGA CGCCGGGAAA ACGACGTC 99

(2) INFORMATION FOR SEQ ID NO:29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 97 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:

GCAGCGGAAA CTGTTCCGAC AGTTCGGCG GCGTCTGCTG CCGCCCGCCT TTAAAGTCTT 60
 GGAACGTTTC ATGGCGGAAC GTCGTTTTCC CGGCGTC 97

(2) INFORMATION FOR SEQ ID NO:30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 97 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:

GCAGCGGAAA CTGTTCCGAC AGTTCGGCG GCGTCTGCTG CCGGCCGCCT TTCGCGTCTT 60
 GGAACGTTTC ATGGCGGAAC GTCGTTTTCC CGGCGTC 97

(2) INFORMATION FOR SEQ ID NO:31:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2631 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 1...2631
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:

TTG AAA AAC AAG CTC GTC TTA ATT GAC GGC AAC AGC GTG GCG TAC CGC	48
Leu Lys Asn Lys Leu Val Leu Ile Asp Gly Asn Ser Val Ala Tyr Arg	
1 5 10 15	
GCC TTT TTC GCG TTG CCG CTT TTG CAT AAC GAT AAA GGG ATT CAT ACG	96
Ala Phe Phe Ala Leu Pro Leu Leu His Asn Asp Lys Gly Ile His Thr	
20 25 30	
AAC GCA GTC TAC GGG TTT ACG ATG ATG TTA AAC AAA ATT TTG GCG GAA	144
Asn Ala Val Tyr Gly Phe Thr Met Leu Asn Lys Ile Leu Ala Glu	
35 40 45	
GAG CAG CCG ACC CAC ATT CTC GTG GCG TTT GAC GCC GGG AAA ACG ACG	192
Glu Gln Pro Thr His Ile Leu Val Ala Phe Asp Ala Gly Lys Thr Thr	
50 55 60	
TTC CGC CAT GAA ACG TTC CAA GAC TTT AAA GGC GGG CCG CAG CAG ACG	240
Phe Arg His Glu Thr Phe Gln Asp Phe Lys Gly Gly Arg Gln Gln Thr	
65 70 75 80	
CCG CCG GAA CTG TCG GAA CAG TTT CCG CTG CTG CGC GAA TTG CTC AAG	288
Pro Pro Glu Leu Ser Glu Gln Phe Pro Leu Leu Arg Glu Leu Leu Lys	
85 90 95	
GCG TAC CGC ATC CCC GCC TAT GAG CTC GAC CAT TAC GAA GCG GAC GAT	336
Ala Tyr Arg Ile Pro Ala Tyr Glu Leu Asp His Tyr Glu Ala Asp Asp	
100 105 110	
ATT ATC GGA ACG ATG GCG GCG CGG GCT GAG CGA GAA GGG TTT GCA GTG	384
Ile Ile Gly Thr Met Ala Ala Arg Ala Glu Arg Glu Gly Phe Ala Val	
115 120 125	
AAA GTC ATT TCC GGC GAC CGC GAT TTA ACC CAG CTT GCT TCC CCG CAA	432
Lys Val Ile Ser Gly Asp Arg Asp Leu Thr Gln Leu Ala Ser Pro Gln	
130 135 140	
GTG ACG GTG GAG ATT ACG AAA AAA GGG ATT ACC GAC ATC GAG TCG TAC	480
Val Thr Val Glu Ile Thr Lys Lys Gly Ile Thr Asp Ile Glu Ser Tyr	
145 150 155 160	
ACG CCG GAG ACG GTC GTG GAA AAA TAC GGC CTC ACC CCG GAG CAA ATT	528
Thr Pro Glu Thr Val Val Glu Lys Tyr Gly Leu Thr Pro Glu Gln Ile	
165 170 175	

5	GTC Val	GAC Asp	TTG Leu	AAA Lys 180	GGA Gly	TTG Leu	ATG Met	GGC Gly	GAC Asp 185	AAA Lys	TCC Ser	GAC Asp	AAC Asn 190	ATC Ile	CCT Pro	GGC Gly	576
	GTG Val	CCC Pro	GGC Gly 195	ATC Ile	GGG Gly	GAA Glu	AAA Lys	ACA Thr 200	GCC Ala	GTC Val	AAG Lys	CTG Leu	CTC Leu 205	AAG Lys	CAA Gln	TTC Phe	624
10	GGC Gly	ACG Thr 210	GTC Val	GAA Glu	AAC Asn	GTA Val 215	CTG Leu	GCA Ala	TCG Ser	ATC Ile	GAT Asp	GAG Glu 220	ATC Ile	AAA Lys	GGG Gly	GAG Glu	672
15	AAG Lys 225	CTG Leu	AAA Lys	GAA Glu	AAT Asn 230	TTG Leu	CGC Arg	CAA Gln	TAC Tyr	CGG Arg 235	GAT Asp	TTG Leu	GCG Ala	CTT Leu	TTA Leu	AGC Ser 240	720
	AAA Lys	CAG Gln	CTG Leu	GCC Ala 245	GCT Ala	ATT Ile	TGC Cys	CGC Arg	GAC Asp 250	GCC Ala	CCG Pro	GTT Val	GAG Glu	CTG Leu	ACG Thr 255	CTC Leu	768
20	GAT Asp	GAC Asp	ATT Ile 260	GTC Val	TAC Tyr	AAA Lys	GGA Gly	GAA Glu	GAC Asp 265	CGG Arg	GAA Glu	AAA Lys	GTG Val 270	GTC Val	GCC Ala	TTG Leu	816
25	TTT Phe	CAG Gln 275	GAG Glu	CTC Leu	GGA Gly	TTC Phe	CAG Gln 280	TCG Ser	TTT Phe	CTC Leu	GAC Asp	AAG Lys	ATG Met 285	GCC Ala	GTC Val	CAA Gln	864
	ACG Thr 290	GAT Asp	GAA Glu	GGC Gly	GAA Glu	AAG Lys	CCG Pro 295	CTC Leu	GCC Ala	GGG Gly	ATG Met	GAT Asp 300	TTT Phe	GCG Ala	ATC Ile	GCC Ala	912
30	GAC Asp 305	AGC Ser	GTC Val	ACG Thr	GAC Asp	GAA Glu 310	ATG Met	CTC Leu	GCC Ala	GAC Asp 315	AAA Lys	GCG Ala	GCC Ala	CTC Leu	GTC Val	GTG Val 320	960
35	GAG Glu	GTG Val	GTG Val	GGC Gly 325	GAC Asp	AAC Asn	TAT Tyr	CAC His	CAT His	GCC Ala 330	CCG Pro	ATT Ile	GTC Val	GGG Gly 335	ATC Ile	GCC Ala	1008
	TTG Leu	GCC Ala	AAC Asn 340	GAA Glu	CGC Arg	GGG Gly	CGG Arg	TTT Phe 345	TTC Phe	CTG Leu	CGC Arg	CCG Pro	GAG Glu	ACG Thr 350	GCG Ala	CTC Leu	1056
40	GCC Ala	GAT Asp 355	CCG Pro	AAA Lys	TTT Phe	CTC Leu	GCT Ala	TGG Trp 360	CTT Leu	GGC Gly	GAT Asp	GAG Glu	ACG Thr 365	AAG Lys	AAA Lys	AAA Lys	1104
45	ACG Thr 370	ATG Met	TTT Phe	GAT Asp	TCA Ser	AAG Lys	CGG Arg 375	GCG Ala	GCC Ala	GTC Val	GCG Ala	CTA Leu	AAA Lys	TGG Trp	AAA Lys	GGA Gly	1152
	ATC Ile 385	GAA Glu	CTG Leu	CGC Arg	GGC Gly	GTC Val 390	GTG Val	TTC Phe	GAT Asp	CTG Leu 395	TTG Leu	CTG Leu	GCC Ala	GCT Ala	TAC Tyr	TTG Leu 400	1200
50	CTC Leu	GAT Asp	CCG Pro	GCG Ala	CAG Gln 405	GCG Ala	GCG Ala	GGC Gly	GAC Asp	GTT Val 410	GCC Ala	GCG Ala	GTG Val	GCG Ala	AAA Lys	ATG Met 415	1248

55

5	CAT CAG TAC GAG GCG GTG CGA TCG GAT GAG GCG GTC TAT GGA AAA GGA His Gln Tyr Glu Ala Val Arg Ser Asp Glu Ala Val Tyr Gly Lys Gly 420 425 430	1296
	GCG AAG CCG ACG GTT CCT GAT GAA CCG ACG CTT GCC GAG CAT CTC GCC Ala Lys Arg Thr Val Pro Asp Glu Pro Thr Leu Ala Glu His Leu Ala 435 440 445	1344
10	CGC AAG CCG GCG GCC ATT TGG GCG CTT GAA GAG CCG TTG ATG GAC GAA Arg Lys Ala Ala Ala Ile Trp Ala Leu Glu Glu Pro Leu Met Asp Glu 450 455 460	1392
15	CTG CGC CGC AAC GAA CAA GAT CGG CTG CTG ACC GAG CTC GAA CAG CCG Leu Arg Arg Asn Glu Gln Asp Arg Leu Leu Thr Glu Leu Glu Gln Pro 465 470 475 480	1440
	CTG GCT GGC ATT TTG GCC AAT ATG GAA TTT ACT GGA GTG AAA GTG GAC Leu Ala Gly Ile Leu Ala Asn Met Glu Phe Thr Gly Val Lys Val Asp 485 490 495	1488
20	ACG AAG CCG CTT GAA CAG ATG GGG GCG GAG CTC ACC GAG CAG CTG CAG Thr Lys Arg Leu Glu Gln Met Gly Ala Glu Leu Thr Glu Gln Leu Gln 500 505 510	1536
25	GCG GTC GAG CCG CGC ATT TAC GAA CTC GCC GGC CAA GAG TTC AAC ATT Ala Val Glu Arg Arg Ile Tyr Glu Leu Ala Gly Gln Glu Phe Asn Ile 515 520 525	1584
	AAC TCG CCG AAA CAG CTC GGG ACG GTT TTA TTT GAC AAG CTG CAG CTC Asn Ser Pro Lys Gln Leu Gly Thr Val Leu Phe Asp Lys Leu Gln Leu 530 535 540	1632
30	CCG GTG TTG AAA AAG ACA AAA ACC GGC TAT TCG ACT TCA GCC GAT GTG Pro Val Leu Lys Lys Thr Lys Thr Gly Tyr Ser Thr Ser Ala Asp Val 545 550 555 560	1680
35	CTT GAG AAG CTT GCA CCG CAC CAT GAA ATC GTC GAA CAT ATT TTG CAT Leu Glu Lys Leu Ala Pro His His Glu Ile Val Glu His Ile Leu His 565 570 575	1728
	TAC CGC CAA CTC GGC AAG CTG CAG TCA ACG TAT ATT GAA GGG CTG CTG Tyr Arg Gln Leu Gly Lys Leu Gln Ser Thr Tyr Ile Glu Gly Leu Leu 580 585 590	1776
40	AAA GTG GTG CAC CCC GTG ACG GGC AAA GTG CAC ACG ATG TTC AAT CAG Lys Val Val His Pro Val Thr Gly Lys Val His Thr Met Phe Asn Gln 595 600 605	1824
45	GCG TTG ACG CAA ACC GGG CGC CTC AGC TCC GTC GAA CCG AAT TTG CAA Ala Leu Thr Gln Thr Gly Arg Leu Ser Ser Val Glu Pro Asn Leu Gln 610 615 620	1872
	AAC ATT CCG ATT CGG CTT GAG GAA GGG CGG AAA ATC CGC CAG GCG TTC Asn Ile Pro Ile Arg Leu Glu Glu Gly Arg Lys Ile Arg Gln Ala Phe 625 630 635 640	1920
50	GTG CCG TCG GAG CCG GAC TGG CTC ATC TTT GCG GCC GAC TAT TCG CAA Val Pro Ser Glu Pro Asp Trp Leu Ile Phe Ala Ala Asp Tyr Ser Gln 645 650 655	1968

55

5	ATC GAG CTG CGC GTC CTC GCC CAT ATC GCG GAA GAT GAC AAT TTG ATT Ile Glu Leu Arg Val Leu Ala His Ile Ala Glu Asp Asp Asn Leu Ile 660 665 670	2016
	GAA GCG TTC CGG CGC GGG TTG GAC ATC CAT ACG AAA ACA GCC ATG GAC Glu Ala Phe Arg Arg Gly Leu Asp Ile His Thr Lys Thr Ala Met Asp 675 680 685	2064
10	ATT TTC CAT GTG AGC GAA GAA GAC GTG ACA GCC AAC ATG CGC CGC CAA Ile Phe His Val Ser Glu Glu Asp Val Thr Ala Asn Met Arg Arg Gln 690 695 700	2112
15	GCG AAG GCC GTC AAT TTT GGC ATC GTG TAC GGC ATT AGT GAT TAC GGT Ala Lys Ala Val Asn Phe Gly Ile Val Tyr Gly Ile Ser Asp Tyr Gly 705 710 715 720	2160
	CTG GCG CAA AAC TTG AAC ATT ACG CGC AAA GAA GCG GCT GAA TTT ATT Leu Ala Gln Asn Leu Asn Ile Thr Arg Lys Glu Ala Ala Glu Phe Ile 725 730 735	2208
20	GAG CGA TAT TTT GCC AGT TTT CCA GGT GTA AAG CAA TAT ATG GAC AAC Glu Arg Tyr Phe Ala Ser Phe Pro Gly Val Lys Gln Tyr Met Asp Asn 740 745 750	2256
25	ATT GTG CAA GAA GCG AAA CAA AAA GGG TAT GTG ACG ACG CTG CTG CAT Ile Val Gln Glu Ala Lys Gln Lys Gly Tyr Val Thr Thr Leu Leu His 755 760 765	2304
	CGG CGC CGC TAT TTG CCC GAT ATT ACA AGC CGC AAC TTC AAC GTC CGC Arg Arg Arg Tyr Leu Pro Asp Ile Thr Ser Arg Asn Phe Asn Val Arg 770 775 780	2352
30	AGC TTC GCC GAG CGG ACG GCG ATG AAC ACA CCG ATC CAA GGG AGT GCC Ser Phe Ala Glu Arg Thr Ala Met Asn Thr Pro Ile Gln Gly Ser Ala 785 790 795 800	2400
35	GCT GAT ATT ATT AAA AAA GCG ATG ATC GAT CTA AGC GTG AGG CTG CGC Ala Asp Ile Ile Lys Lys Ala Met Ile Asp Leu Ser Val Arg Leu Arg 805 810 815	2448
	GAA GAA CGG CTG CAG GCG CGC CTG TTG CTG CAA GTG CAT GAC GAA CTC Glu Glu Arg Leu Gln Ala Arg Leu Leu Gln Val His Asp Glu Leu 820 825 830	2496
40	ATT TTG GAG GCG CCG AAA GAG GAA ATC GAG CGG CTG TGC CGC CTC GTT Ile Leu Glu Ala Pro Lys Glu Glu Ile Glu Arg Leu Cys Arg Leu Val 835 840 845	2544
45	CCA GAG GTG ATG GAG CAA GCC GTC GCA CTC CGC GTG CCG CTG AAA GTC Pro Glu Val Met Glu Gln Ala Val Ala Leu Arg Val Pro Leu Lys Val 850 855 860	2592
50	GAT TAC CAT TAC GGT CCG ACG TGG TAC GAC GCC AAA TAA Asp Tyr His Tyr Gly Pro Thr Trp Tyr Asp Ala Lys 865 870 875	2631

(2) INFORMATION FOR SEQ ID NO:32:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 876 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:

10 Leu Lys Asn Lys Leu Val Leu Ile Asp Gly Asn Ser Val Ala Tyr Arg
 1 5 10 15
 Ala Phe Phe Ala Leu Pro Leu Leu His Asn Asp Lys Gly Ile His Thr
 20 25 30
 Asn Ala Val Tyr Gly Phe Thr Met Met Leu Asn Lys Ile Leu Ala Glu
 35 40 45
 15 Glu Gln Pro Thr His Ile Leu Val Ala Phe Asp Ala Gly Lys Thr Thr
 50 55 60
 Phe Arg His Glu Thr Phe Gln Asp Phe Lys Gly Gly Arg Gln Gln Thr
 65 70 75 80
 Pro Pro Glu Leu Ser Glu Gln Phe Pro Leu Leu Arg Glu Leu Leu Lys
 85 90 95
 20 Ala Tyr Arg Ile Pro Ala Tyr Glu Leu Asp His Tyr Glu Ala Asp Asp
 100 105 110
 Ile Ile Gly Thr Met Ala Ala Arg Ala Glu Arg Glu Gly Phe Ala Val
 115 120 125
 Lys Val Ile Ser Gly Asp Arg Asp Leu Thr Gln Leu Ala Ser Pro Gln
 130 135 140
 25 Val Thr Val Glu Ile Thr Lys Lys Gly Ile Thr Asp Ile Glu Ser Tyr
 145 150 155 160
 Thr Pro Glu Thr Val Val Glu Lys Tyr Gly Leu Thr Pro Glu Gln Ile
 165 170 175
 Val Asp Leu Lys Gly Leu Met Gly Asp Lys Ser Asp Asn Ile Pro Gly
 180 185 190
 30 Val Pro Gly Ile Gly Glu Lys Thr Ala Val Lys Leu Leu Lys Gln Phe
 195 200 205
 Gly Thr Val Glu Asn Val Leu Ala Ser Ile Asp Glu Ile Lys Gly Glu
 210 215 220
 35 Lys Leu Lys Glu Asn Leu Arg Gln Tyr Arg Asp Leu Ala Leu Leu Ser
 225 230 235 240
 Lys Gln Leu Ala Ala Ile Cys Arg Asp Ala Pro Val Glu Leu Thr Leu
 245 250 255
 Asp Asp Ile Val Tyr Lys Gly Glu Asp Arg Glu Lys Val Val Ala Leu
 260 265 270
 40 Phe Gln Glu Leu Gly Phe Gln Ser Phe Leu Asp Lys Met Ala Val Gln
 275 280 285
 Thr Asp Glu Gly Glu Lys Pro Leu Ala Gly Met Asp Phe Ala Ile Ala
 290 295 300
 Asp Ser Val Thr Asp Glu Met Leu Ala Asp Lys Ala Ala Leu Val Val
 305 310 315 320
 45 Glu Val Val Gly Asp Asn Tyr His His Ala Pro Ile Val Gly Ile Ala
 325 330 335
 Leu Ala Asn Glu Arg Gly Arg Phe Phe Leu Arg Pro Glu Thr Ala Leu
 340 345 350
 Ala Asp Pro Lys Phe Leu Ala Trp Leu Gly Asp Glu Thr Lys Lys Lys
 355 360 365
 50 Thr Met Phe Asp Ser Lys Arg Ala Ala Val Ala Leu Lys Trp Lys Gly
 370 375 380
 Ile Glu Leu Arg Gly Val Val Phe Asp Leu Leu Ala Ala Tyr Leu
 385 390 395 400
 Leu Asp Pro Ala Gln Ala Ala Gly Asp Val Ala Ala Val Ala Lys Met

				405					410				415
	His	Gln	Tyr	Glu	Ala	Val	Arg	Ser	Asp	Glu	Ala	Val	Tyr
5				420					425				430
	Ala	Lys	Arg	Thr	Val	Pro	Asp	Glu	Pro	Thr	Leu	Ala	Glu
				435					440				445
	Arg	Lys	Ala	Ala	Ala	Ile	Trp	Ala	Leu	Glu	Glu	Pro	Leu
				450					455				460
10	Leu	Arg	Arg	Asn	Glu	Gln	Asp	Arg	Leu	Leu	Thr	Glu	Leu
				465					470				475
	Leu	Ala	Gly	Ile	Leu	Ala	Asn	Met	Glu	Phe	Thr	Gly	Val
				485					490				495
	Thr	Lys	Arg	Leu	Glu	Gln	Met	Gly	Ala	Glu	Leu	Thr	Glu
				500					505				510
15	Ala	Val	Glu	Arg	Arg	Ile	Tyr	Glu	Leu	Ala	Gly	Gln	Glu
				515					520				525
	Asn	Ser	Pro	Lys	Gln	Leu	Gly	Thr	Val	Leu	Phe	Asp	Lys
				530					535				540
	Pro	Val	Leu	Lys	Lys	Thr	Lys	Thr	Gly	Tyr	Ser	Thr	Ser
				545					550				555
20	Leu	Glu	Lys	Leu	Ala	Pro	His	His	Glu	Ile	Val	Glu	His
				565					570				575
	Tyr	Arg	Gln	Leu	Gly	Lys	Leu	Gln	Ser	Thr	Tyr	Ile	Glu
				580					585				590
	Lys	Val	Val	His	Pro	Val	Thr	Gly	Lys	Val	His	Thr	Met
				595					600				605
25	Ala	Leu	Thr	Gln	Thr	Gly	Arg	Leu	Ser	Ser	Val	Glu	Pro
				610					615				620
	Asn	Ile	Pro	Ile	Arg	Leu	Glu	Glu	Gly	Arg	Lys	Ile	Arg
				625					630				635
	Val	Pro	Ser	Glu	Pro	Asp	Trp	Leu	Ile	Phe	Ala	Ala	Asp
				645					650				655
30	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Ile	Ala	Glu	Asp	Asp
				660					665				670
	Glu	Ala	Phe	Arg	Arg	Gly	Leu	Asp	Ile	His	Thr	Lys	Thr
				675					680				685
	Ile	Phe	His	Val	Ser	Glu	Glu	Asp	Val	Thr	Ala	Asn	Met
				690					695				700
35	Ala	Lys	Ala	Val	Asn	Phe	Gly	Ile	Val	Tyr	Gly	Ile	Ser
				705					710				715
	Leu	Ala	Gln	Asn	Leu	Asn	Ile	Thr	Arg	Lys	Glu	Ala	Ala
				725					730				735
	Glu	Arg	Tyr	Phe	Ala	Ser	Phe	Pro	Gly	Val	Lys	Gln	Tyr
				740					745				750
40	Ile	Val	Gln	Glu	Ala	Lys	Gln	Lys	Gly	Tyr	Val	Thr	Thr
				755					760				765
	Arg	Arg	Arg	Tyr	Leu	Pro	Asp	Ile	Thr	Ser	Arg	Asn	Phe
				770					775				780
	Ser	Phe	Ala	Glu	Arg	Thr	Ala	Met	Asn	Thr	Pro	Ile	Gln
				785					790				795
45	Ala	Asp	Ile	Ile	Lys	Lys	Ala	Met	Ile	Asp	Leu	Ser	Val
				805					810				815
	Glu	Glu	Arg	Leu	Gln	Ala	Arg	Leu	Leu	Gln	Val	His	Asp
				820					825				830
	Ile	Leu	Glu	Ala	Pro	Lys	Glu	Glu	Ile	Glu	Arg	Leu	Cys
				835					840				845
50	Pro	Glu	Val	Met	Glu	Gln	Ala	Val	Ala	Leu	Arg	Val	Pro
				850					855				860
	Asp	Tyr	His	Tyr	Gly	Pro	Thr	Trp	Tyr	Asp	Ala	Lys	
				865					870				875

(2) INFORMATION FOR SEQ ID NO:33:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2631 base pairs
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: single
 (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: Coding Sequence
 (B) LOCATION: 1...2631
 (D) OTHER INFORMATION:

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:

5	TTG AAA AAC AAG CTC GTC TTA ATT GAC GGC AAC AGC GTG GCG TAC CGC	48
	Leu Lys Asn Lys Leu Val Leu Ile Asp Gly Asn Ser Val Ala Tyr Arg	
	1 5 10 15	
20	GCC TTT TTC GCG TTG CCG CTT TTG CAT AAC GAT AAA GGG ATT CAT ACG	96
	Ala Phe Phe Ala Leu Pro Leu Leu His Asn Asp Lys Gly Ile His Thr	
	20 25 30	
25	AAC GCA GTC TAC GGG TTT ACG ATG ATG TTA AAC AAA ATT TTG GCG GAA	144
	Asn Ala Val Tyr Gly Phe Thr Met Met Leu Asn Lys Ile Leu Ala Glu	
	35 40 45	
30	GAG CAG CCG ACC CAC ATT CTC GTG GCG TTT GAC GCC GGG AAA ACG ACG	192
	Glu Gln Pro Thr His Ile Leu Val Ala Phe Asp Ala Gly Lys Thr Thr	
	50 55 60	
35	TTC CGC CAT GAA ACG TTC CAA GAC GCG AAA GGC GGC CCG CAG CAG ACG	240
	Phe Arg His Glu Thr Phe Gln Asp Ala Lys Gly Gly Arg Gln Gln Thr	
	65 70 75 80	
40	CCG CCG GAA CTG TCG GAA CAG TTT CCG CTG CTG CCG GAA TTG CTC AAG	288
	Pro Pro Glu Leu Ser Glu Gln Phe Pro Leu Leu Arg Glu Leu Leu Lys	
	85 90 95	
45	GCG TAC CGC ATC CCC GCC TAT GAG CTC GAC CAT TAC GAA GCG GAC GAT	336
	Ala Tyr Arg Ile Pro Ala Tyr Glu Leu Asp His Tyr Glu Ala Asp Asp	
	100 105 110	
50	ATT ATC GGA ACG ATG GCG GCG CGG GCT GAG CGA GAA GGG TTT GCA GTG	384
	Ile Ile Gly Thr Met Ala Ala Arg Ala Glu Arg Glu Gly Phe Ala Val	
	115 120 125	
55	AAA GTC ATT TCC GGC GAC CGC GAT TTA ACC CAG CTT GCT TCC CCG CAA	432
	Lys Val Ile Ser Gly Asp Arg Asp Leu Thr Gln Leu Ala Ser Pro Gln	
	130 135 140	
60	GTG ACG GTG GAG ATT ACG AAA AAA GGG ATT ACC GAC ATC GAG TCG TAC	480
	Val Thr Val Glu Ile Thr Lys Lys Gly Ile Thr Asp Ile Glu Ser Tyr	
	145 150 155 160	
65	ACG CCG GAG ACG GTC GTG GAA AAA TAC GGC CTC ACC CCG GAG CAA ATT	528
	Thr Pro Glu Thr Val Val Glu Lys Tyr Gly Leu Thr Pro Glu Gln Ile	
	165 170 175	

5	GTC Val	GAC Asp	TTG Leu	AAA Lys 180	GGA Gly	TTG Leu	ATG Met	GGC Gly	GAC Asp 185	AAA Lys	TCC Ser	GAC Asp	AAC Asn 190	ATC Ile	CCT Pro	GGC Gly	576
	GTG Val	CCC Pro	GGC Gly 195	ATC Ile	GGG Gly	GAA Glu	AAA Lys	ACA Thr 200	GCC Ala	GTC Val	AAG Lys	CTG Leu	CTC Leu 205	AAG Lys	CAA Gln	TTC Phe	624
10	GGC Gly	ACG Thr 210	GTC Val	GAA Glu	AAC Asn	GTA Val	CTG Leu 215	GCA Ala	TCG Ser	ATC Ile	GAT Asp	GAG Glu 220	ATC Ile	AAA Lys	GGG Gly	GAG Glu	672
15	AAG Lys 225	CTG Leu	AAA Lys	GAA Glu	AAT Asn 230	TTG Leu	CGC Arg	CAA Gln	TAC Tyr	CGG Arg 235	GAT Asp	TTG Leu	GCG Ala	CTT Leu	TTA Leu	AGC Ser 240	720
	AAA Lys	CAG Gln	CTG Leu	GCC Ala 245	GCT Ala	ATT Ile	TGC Cys	CGC Arg	GAC Asp 250	GCC Ala	CCG Pro	GTT Val	GAG Glu	CTG Leu	ACG Thr 255	CTC Leu	768
20	GAT Asp	GAC Asp	ATT Ile 260	GTC Val	TAC Tyr	AAA Lys	GGA Gly	GAA Glu 265	GAC Asp 265	CGG Arg	GAA Glu	AAA Lys	GTG Val 270	GTC Val	GCC Ala	TTG Leu	816
25	TTT Phe	CAG Gln 275	GAG Glu	CTC Leu	GGA Gly	TTC Phe	CAG Gln 280	TCG Ser	TTT Phe	CTC Leu	GAC Asp	AAG Lys 285	ATG Met 285	GCC Ala	GTC Val	CAA Gln	864
	ACG Thr 290	GAT Asp	GAA Glu	GGC Gly	GAA Glu	AAG Lys	CCG Pro 295	CTC Leu	GCC Ala	GGG Gly	ATG Met 300	GAT Asp	TTT Phe	GCG Ala	ATC Ile	GCC Ala	912
30	GAC Asp 305	AGC Ser	GTC Val	ACG Thr	GAC Asp	GAA Glu 310	ATG Met	CTC Leu	GCC Ala	GAC Asp 315	AAA Lys	GCG Ala	GCC Ala	CTC Leu	GTC Val	GTG Val 320	960
35	GAG Glu	GTG Val	GTG Val	GGC Gly 325	GAC Asp	AAC Asn	TAT Tyr	CAC His	CAT His	GCC Ala 330	CCG Pro	ATT Ile	GTC Val	GGG Gly 335	ATC Ile	GCC Ala	1008
	TTG Leu	GCC Ala	AAC Asn 340	GAA Glu	CGC Arg	GGG Gly	CGG Arg	TTT Phe 345	TTC Phe	CTG Leu	CGC Arg	CCG Pro	GAG Glu 350	ACG Thr	GCG Ala	CTC Leu	1056
40	GCC Ala	GAT Asp 355	CCG Pro	AAA Lys	TTT Phe	CTC Leu	GCT Ala	TGG Trp 360	CTT Leu	GGC Gly	GAT Asp	GAG Glu 365	ACG Thr	AAG Lys	AAA Lys	AAA Lys	1104
45	ACG Thr 370	ATG Met	TTT Phe	GAT Asp	TCA Ser	AAG Lys	CGG Arg 375	GCG Ala	GCC Ala	GTC Val	GCG Ala	CTA Leu 380	AAA Lys	TGG Trp	AAA Lys	GGA Gly	1152
	ATC Ile 385	GAA Glu	CTG Leu	CGC Arg	GGC Gly 390	GTC Val	GTG Val	TTC Phe	GAT Asp	CTG Leu 395	TTG Leu	CTG Leu	GCC Ala	GCT Ala	TAC Tyr	TTG Leu 400	1200
50	CTC Leu	GAT Asp	CCG Pro	GCG Ala	CAG Gln 405	GCG Ala	GCG Ala	GGC Gly	GAC Asp 410	GTT Val 410	GCC Ala	GCG Ala	GTG Val	GCG Ala	AAA Lys 415	ATG Met	1248

55

5	CAT His	CAG Gln	TAC Tyr	GAG Glu	GCG Ala	GTG Val	CGA Arg	TCG Ser	GAT Asp	GAG Glu	GCG Ala	GTC Val	TAT Tyr	GGA Gly	AAA Lys	GGA Gly	1296
			420					425						430			
	GCG Ala	AAG Lys	CGG Arg	ACG Thr	GTT Val	CCT Pro	GAT Asp	GAA Glu	CCG Pro	ACG Thr	CTT Leu	GCC Ala	GAG Glu	CAT His	CTC Leu	GCC Ala	1344
			435					440					445				
10	CGC Arg	AAG Lys	GCG Ala	GCG Ala	GCC Ala	ATT Ile	TGG Trp	GCG Ala	CTT Leu	GAA Glu	GAG Glu	CCG Pro	TTG Leu	ATG Met	GAC Asp	GAA Glu	1392
		450					455					460					
	CTG Leu	CGC Arg	CGC Arg	AAC Asn	GAA Glu	CAA Gln	GAT Asp	CGG Arg	CTG Leu	CTG Leu	ACC Thr	GAG Glu	CTC Leu	GAA Glu	CAG Gln	CCG Pro	1440
15		465				470					475					480	
	CTG Leu	GCT Ala	GGC Gly	ATT Ile	TTG Leu	GCC Ala	AAT Asn	ATG Met	GAA Glu	TTT Phe	ACT Thr	GGA Gly	GTG Val	AAA Lys	GTG Val	GAC Asp	1488
					485					490					495		
20	ACG Thr	AAG Lys	CGG Arg	CTT Leu	GAA Glu	CAG Gln	ATG Met	GGG Gly	GCG Ala	GAG Glu	CTC Leu	ACC Thr	GAG Glu	CAG Gln	CTG Leu	CAG Gln	1536
				500					505					510			
	GCG Ala	GTC Val	GAG Glu	CGG Arg	CGC Arg	ATT Ile	TAC Tyr	GAA Glu	CTC Leu	GCC Ala	GGC Gly	CAA Gln	GAG Glu	TTC Phe	AAC Asn	ATT Ile	1584
25			515					520					525				
	AAC Asn	TCG Ser	CCG Pro	AAA Lys	CAG Gln	CTC Leu	GGG Gly	ACG Thr	GTT Val	TTA Leu	TTT Phe	GAC Asp	AAG Lys	CTG Leu	CAG Gln	CTC Leu	1632
		530					535					540					
30	CCG Pro	GTG Val	TTG Leu	AAA Lys	AAG Lys	ACA Thr	AAA Lys	ACC Thr	GGC Gly	TAT Tyr	TCG Ser	ACT Thr	TCA Ser	GCC Ala	GAT Asp	GTG Val	1680
		545				550					555					560	
	CTT Leu	GAG Glu	AAG Lys	CTT Leu	GCA Ala	CCG Pro	CAC His	CAT His	GAA Glu	ATC Ile	GTC Val	GAA Glu	CAT His	ATT Ile	TTG Leu	CAT His	1728
35					565					570					575		
	TAC Tyr	CGC Arg	CAA Gln	CTC Leu	GGC Gly	AAG Lys	CTG Leu	CAG Gln	TCA Ser	ACG Thr	TAT Tyr	ATT Ile	GAA Glu	GGG Gly	CTG Leu	CTG Leu	1776
				580					585					590			
40	AAA Lys	GTG Val	GTG Val	CAC His	CCC Pro	GTG Val	ACG Thr	GGC Gly	AAA Lys	GTG Val	CAC His	ACG Thr	ATG Met	TTC Phe	AAT Asn	CAG Gln	1824
			595					600					605				
	GCG Ala	TTG Leu	ACG Thr	CAA Gln	ACC Thr	GGG Gly	CGC Arg	CTC Leu	AGC Ser	TCC Ser	GTC Val	GAA Glu	CCG Pro	AAT Asn	TTG Leu	CAA Gln	1872
45		610					615					620					
	AAC Asn	ATT Ile	CCG Pro	ATT Ile	CGG Arg	CTT Leu	GAG Glu	GAA Glu	GGG Gly	CGG Arg	AAA Lys	ATC Ile	CGC Arg	CAG Gln	GCG Ala	TTC Phe	1920
		625				630				635						640	
50	GTG Val	CCG Pro	TCG Ser	GAG Glu	CCG Pro	GAC Asp	TGG Trp	CTC Leu	ATC Ile	TTT Phe	GCG Ala	GCC Ala	GAC Asp	TAT Tyr	TCG Ser	CAA Gln	1968
					645					650					655		

55

5	ATC GAG CTG CGC GTC CTC GCC CAT ATC GCG GAA GAT GAC AAT TTG ATT Ile Glu Leu Arg Val Leu Ala His Ile Ala Glu Asp Asp Asn Leu Ile 660 665 670	2016
	GAA GCG TTC CGG CGC GGG TTG GAC ATC CAT ACG AAA ACA GCC ATG GAC Glu Ala Phe Arg Arg Gly Leu Asp Ile His Thr Lys Thr Ala Met Asp 675 680 685	2064
10	ATT TTC CAT GTG AGC GAA GAA GAC GTG ACA GCC AAC ATG CGC CGC CAA Ile Phe His Val Ser Glu Glu Asp Val Thr Ala Asn Met Arg Arg Gln 690 695 700	2112
15	GCG AAG GCC GTC AAT TTT GGC ATC GTG TAC GGC ATT AGT GAT TAC GGT Ala Lys Ala Val Asn Phe Gly Ile Val Tyr Gly Ile Ser Asp Tyr Gly 705 710 715 720	2160
	CTG GCG CAA AAC TTG AAC ATT ACG CGC AAA GAA GCG GCT GAA TTT ATT Leu Ala Gln Asn Leu Asn Ile Thr Arg Lys Glu Ala Ala Glu Phe Ile 725 730 735	2208
20	GAG CGA TAT TTT GCC AGT TTT CCA GGT GTA AAG CAA TAT ATG GAC AAC Glu Arg Tyr Phe Ala Ser Phe Pro Gly Val Lys Gln Tyr Met Asp Asn 740 745 750	2256
25	ATT GTG CAA GAA GCG AAA CAA AAA GGG TAT GTG ACG ACG CTG CTG CAT Ile Val Gln Glu Ala Lys Gln Lys Gly Tyr Val Thr Thr Leu Leu His 755 760 765	2304
	CGG CGC CGC TAT TTG CCC GAT ATT ACA AGC CGC AAC TTC AAC GTC CGC Arg Arg Arg Tyr Leu Pro Asp Ile Thr Ser Arg Asn Phe Asn Val Arg 770 775 780	2352
30	AGC TTC GCC GAG CGG ACG GCG ATG AAC ACA CCG ATC CAA GGG AGT GCC Ser Phe Ala Glu Arg Thr Ala Met Asn Thr Pro Ile Gln Gly Ser Ala 785 790 795 800	2400
35	GCT GAT ATT ATT AAA AAA GCG ATG ATC GAT CTA AGC GTG AGG CTG CGC Ala Asp Ile Ile Lys Lys Ala Met Ile Asp Leu Ser Val Arg Leu Arg 805 810 815	2448
	GAA GAA CGG CTG CAG GCG CGC CTG TTG CTG CAA GTG CAT GAC GAA CTC Glu Glu Arg Leu Gln Ala Arg Leu Leu Leu Gln Val His Asp Glu Leu 820 825 830	2496
40	ATT TTG GAG GCG CCG AAA GAG GAA ATC GAG CGG CTG TGC CGC CTC GTT Ile Leu Glu Ala Pro Lys Glu Glu Ile Glu Arg Leu Cys Arg Leu Val 835 840 845	2544
45	CCA GAG GTG ATG GAG CAA GCC GTC GCA CTC CGC GTG CCG CTG AAA GTC Pro Glu Val Met Glu Gln Ala Val Ala Leu Arg Val Pro Leu Lys Val 850 855 860	2592
	GAT TAC CAT TAC GGT CCG ACG TGG TAC GAC GCC AAA TAA Asp Tyr His Tyr Gly Pro Thr Trp Tyr Asp Ala Lys 865 870 875	2631

(2) INFORMATION FOR SEQ ID NO:34:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 876 amino acids

(B) TYPE: amino acid

(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:

10 Leu Lys Asn Lys Leu Val Leu Ile Asp Gly Asn Ser Val Ala Tyr Arg
 1 5 10 15
 Ala Phe Phe Ala Leu Pro Leu Leu His Asn Asp Lys Gly Ile His Thr
 20 25 30
 Asn Ala Val Tyr Gly Phe Thr Met Met Leu Asn Lys Ile Leu Ala Glu
 35 40 45
 15 Glu Gln Pro Thr His Ile Leu Val Ala Phe Asp Ala Gly Lys Thr Thr
 50 55 60
 Phe Arg His Glu Thr Phe Gln Asp Ala Lys Gly Gly Arg Gln Gln Thr
 65 70 75 80
 Pro Pro Glu Leu Ser Glu Gln Phe Pro Leu Leu Arg Glu Leu Leu Lys
 85 90 95
 20 Ala Tyr Arg Ile Pro Ala Tyr Glu Leu Asp His Tyr Glu Ala Asp Asp
 100 105 110
 Ile Ile Gly Thr Met Ala Ala Arg Ala Glu Arg Glu Gly Phe Ala Val
 115 120 125
 Lys Val Ile Ser Gly Asp Arg Asp Leu Thr Gln Leu Ala Ser Pro Gln
 130 135 140
 25 Val Thr Val Glu Ile Thr Lys Lys Gly Ile Thr Asp Ile Glu Ser Tyr
 145 150 155 160
 Thr Pro Glu Thr Val Val Glu Lys Tyr Gly Leu Thr Pro Glu Gln Ile
 165 170 175
 Val Asp Leu Lys Gly Leu Met Gly Asp Lys Ser Asp Asn Ile Pro Gly
 180 185 190
 30 Val Pro Gly Ile Gly Glu Lys Thr Ala Val Lys Leu Leu Lys Gln Phe
 195 200 205
 Gly Thr Val Glu Asn Val Leu Ala Ser Ile Asp Glu Ile Lys Gly Glu
 210 215 220
 35 Lys Leu Lys Glu Asn Leu Arg Gln Tyr Arg Asp Leu Ala Leu Leu Ser
 225 230 235 240
 Lys Gln Leu Ala Ala Ile Cys Arg Asp Ala Pro Val Glu Leu Thr Leu
 245 250 255
 Asp Asp Ile Val Tyr Lys Gly Glu Asp Arg Glu Lys Val Val Ala Leu
 260 265 270
 40 Phe Gln Glu Leu Gly Phe Gln Ser Phe Leu Asp Lys Met Ala Val Gln
 275 280 285
 Thr Asp Glu Gly Glu Lys Pro Leu Ala Gly Met Asp Phe Ala Ile Ala
 290 295 300
 Asp Ser Val Thr Asp Glu Met Leu Ala Asp Lys Ala Ala Leu Val Val
 305 310 315 320
 45 Glu Val Val Gly Asp Asn Tyr His His Ala Pro Ile Val Gly Ile Ala
 325 330 335
 Leu Ala Asn Glu Arg Gly Arg Phe Phe Leu Arg Pro Glu Thr Ala Leu
 340 345 350
 Ala Asp Pro Lys Phe Leu Ala Trp Leu Gly Asp Glu Thr Lys Lys Lys
 355 360 365
 50 Thr Met Phe Asp Ser Lys Arg Ala Ala Val Ala Leu Lys Trp Lys Gly
 370 375 380
 Ile Glu Leu Arg Gly Val Val Phe Asp Leu Leu Ala Ala Tyr Leu
 385 390 395 400
 Leu Asp Pro Ala Gln Ala Ala Gly Asp Val Ala Ala Val Ala Lys Met

				405					410				415	
5	His	Gln	Tyr	Glu	Ala	Val	Arg	Ser	Asp	Glu	Ala	Val	Tyr	Gly
				420					425				430	
	Ala	Lys	Arg	Thr	Val	Pro	Asp	Glu	Pro	Thr	Leu	Ala	Glu	His
			435					440				445		
	Arg	Lys	Ala	Ala	Ala	Ile	Trp	Ala	Leu	Glu	Glu	Pro	Leu	Met
		450					455					460		
10	Leu	Arg	Arg	Asn	Glu	Gln	Asp	Arg	Leu	Leu	Thr	Glu	Leu	Gln
	465					470					475			480
	Leu	Ala	Gly	Ile	Leu	Ala	Asn	Met	Glu	Phe	Thr	Gly	Val	Lys
				485					490					495
	Thr	Lys	Arg	Leu	Glu	Gln	Met	Gly	Ala	Glu	Leu	Thr	Glu	Gln
			500						505				510	
15	Ala	Val	Glu	Arg	Arg	Ile	Tyr	Glu	Leu	Ala	Gly	Gln	Glu	Phe
		515						520					525	
	Asn	Ser	Pro	Lys	Gln	Leu	Gly	Thr	Val	Leu	Phe	Asp	Lys	Leu
		530					535					540		
	Pro	Val	Leu	Lys	Lys	Thr	Lys	Thr	Gly	Tyr	Ser	Thr	Ser	Ala
	545					550					555			560
20	Leu	Glu	Lys	Leu	Ala	Pro	His	His	Glu	Ile	Val	Glu	His	Ile
				565						570				575
	Tyr	Arg	Gln	Leu	Gly	Lys	Leu	Gln	Ser	Thr	Tyr	Ile	Glu	Gly
			580						585				590	
	Lys	Val	Val	His	Pro	Val	Thr	Gly	Lys	Val	His	Thr	Met	Phe
		595						600					605	
25	Ala	Leu	Thr	Gln	Thr	Gly	Arg	Leu	Ser	Ser	Val	Glu	Pro	Asn
		610				615						620		
	Asn	Ile	Pro	Ile	Arg	Leu	Glu	Glu	Gly	Arg	Lys	Ile	Arg	Gln
	625					630					635			640
	Val	Pro	Ser	Glu	Pro	Asp	Trp	Leu	Ile	Phe	Ala	Ala	Asp	Tyr
				645						650				655
30	Ile	Glu	Leu	Arg	Val	Leu	Ala	His	Ile	Ala	Glu	Asp	Asp	Asn
			660						665					670
	Glu	Ala	Phe	Arg	Arg	Gly	Leu	Asp	Ile	His	Thr	Lys	Thr	Ala
		675						680					685	
	Ile	Phe	His	Val	Ser	Glu	Glu	Asp	Val	Thr	Ala	Asn	Met	Arg
		690				695						700		
35	Ala	Lys	Ala	Val	Asn	Phe	Gly	Ile	Val	Tyr	Gly	Ile	Ser	Asp
	705					710					715			720
	Leu	Ala	Gln	Asn	Leu	Asn	Ile	Thr	Arg	Lys	Glu	Ala	Ala	Glu
				725						730				735
	Glu	Arg	Tyr	Phe	Ala	Ser	Phe	Pro	Gly	Val	Lys	Gln	Tyr	Met
			740						745					750
40	Ile	Val	Gln	Glu	Ala	Lys	Gln	Lys	Gly	Tyr	Val	Thr	Thr	Leu
		755					760						765	
	Arg	Arg	Arg	Tyr	Leu	Pro	Asp	Ile	Thr	Ser	Arg	Asn	Phe	Asn
		770					775					780		
	Ser	Phe	Ala	Glu	Arg	Thr	Ala	Met	Asn	Thr	Pro	Ile	Gln	Gly
	785					790					795			800
45	Ala	Asp	Ile	Ile	Lys	Lys	Ala	Met	Ile	Asp	Leu	Ser	Val	Arg
				805						810				815
	Glu	Glu	Arg	Leu	Gln	Ala	Arg	Leu	Leu	Leu	Gln	Val	His	Asp
			820					825					830	
	Ile	Leu	Glu	Ala	Pro	Lys	Glu	Glu	Ile	Glu	Arg	Leu	Cys	Arg
		835					840					845		
50	Pro	Glu	Val	Met	Glu	Gln	Ala	Val	Ala	Leu	Arg	Val	Pro	Leu
		850				855						860		
	Asp	Tyr	His	Tyr	Gly	Pro	Thr	Trp	Tyr	Asp	Ala	Lys		
	865					870					875			

55

Claims

1. A purified recombinant DNA molecule comprising a nucleotide sequence encoding a protein derived from Bacillus stearothermophilus having a thermostable DNA polymerase activity, or encoding an active DNA-polymerizing truncated form of said protein or encoding a protein having substantial sequence homology to the active protein.
2. The purified recombinant DNA molecule of Claim 1 wherein said nucleotide sequence comprises different domains encoding a DNA polymerase region, a 3'-5' exonuclease region, and a 5'-3' exonuclease region of said Bacillus stearothermophilus-derived protein.
3. The purified recombinant DNA molecule of Claim 2 wherein the Bacillus stearothermophilus-derived protein has a 3'-5' exonuclease activity.
4. The purified recombinant DNA molecule of Claim 2 wherein the Bacillus stearothermophilus-derived protein has a 5'-3' exonuclease activity.
5. The purified recombinant DNA molecule of Claim 2 wherein said nucleotide sequence comprising a domain encoding the 5'-3' exonuclease activity of said Bacillus stearothermophilus-derived protein has been modified so as to reduce or remove said 5'-3' exonuclease activity.
6. The purified recombinant DNA molecule of Claim 1 wherein said nucleotide sequence comprises at least 50 contiguous nucleotides of the nucleotide sequence SEQ ID NO:21.
7. The purified recombinant DNA molecule of Claim 1 wherein said nucleotide sequence comprises at least 150 contiguous nucleotides of the nucleotide sequence SEQ ID NO:21.
8. The purified recombinant DNA molecule of Claim 1 wherein said nucleotide sequence comprises at least 200 contiguous nucleotides of the nucleotide sequence SEQ ID NO:21.
9. The purified recombinant DNA molecule of Claim 1 wherein said DNA molecule has a nucleotide sequence selected from the subgroup consisting of SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:31 and SEQ ID NO:33.
10. The purified recombinant DNA molecule of Claim 2 wherein said DNA molecule has a nucleotide sequence selected from the subgroup consisting of SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:31 and SEQ ID NO:33.
11. The purified recombinant DNA molecule of Claim 5 wherein said DNA molecule has a nucleotide sequence selected from the subgroup consisting of:
 - a. SEQ ID NO:22, and
 - b. ATG, followed by SEQ ID NO:22.
12. The purified recombinant DNA molecule of Claim 5 wherein said DNA molecule has a nucleotide sequence selected from the subgroup consisting of:
 - a. SEQ ID NO:26, and
 - b. ATG, followed by SEQ ID NO:26.
13. The purified recombinant DNA molecule of Claim 5 wherein said DNA molecule has a nucleotide sequence selected from the subgroup consisting of:
 - a. SEQ ID NO:24, and
 - b. ATG, followed by SEQ ID NO:24.
14. The purified recombinant DNA molecule of Claim 5 wherein said DNA molecule has a nucleotide sequence selected from the subgroup consisting of:
 - a. SEQ ID NO:31, and

b. ATG, followed by SEQ ID NO:31.

15. The purified recombinant DNA molecule of Claim 5 wherein said DNA molecule has a nucleotide sequence selected from the subgroup consisting of:

- a. SEQ ID NO:33, and
b. ATG, followed by SEQ ID NO:33.

16. A purified recombinant DNA molecule capable of expression in a heterologous host cell comprising:

- (a) a DNA fragment having a origin of replication for multiplying said molecule within said host cell,
(b) a DNA fragment comprising a promoter region effective for the expression of a protein encoded by said recombinant DNA molecule in said host cell,
(c) a DNA fragment encoding a protein derived from Bacillus stearothermophilus having a thermostable DNA polymerase activity, or encoding an active DNA-polymerizing truncated form of the above protein or encoding a protein having substantial sequence homology to the active protein, and
(d) a DNA fragment comprising a selectable marker gene,

the DNA fragments being so linked that the protein having thermostable DNA polymerase activity is expressed in said host cell.

17. The recombinant DNA molecule of Claim 16 in which the DNA fragment encoding a protein having a thermostable DNA polymerase activity further encodes a 5'-3' exonuclease activity of said protein.

18. The purified recombinant DNA molecule of Claim 16 wherein a DNA fragment encoding said protein also encodes a 5'-3' exonuclease domain within the amino acid sequence of said protein, the DNA fragment having been modified so that a 5'-3' exonuclease activity is diminished or absent in a protein expressed therefrom as compared to a second protein expressed by the same DNA fragment without said modification.

19. The purified recombinant DNA molecule of Claim 16 wherein said DNA fragment encoding a protein having thermostable DNA polymerase activity results from the deletion of one or more nucleotide residue from another DNA fragment encoding a full length Bacillus stearothermophilus DNA polymerase having 5'-3' exonuclease activity, wherein the 5'-3' exonuclease activity of said protein is diminished or absent as compared to said full length Bacillus stearothermophilus DNA polymerase.

20. The purified recombinant DNA molecule of Claim 19 wherein said DNA fragment encoding a protein having thermostable DNA polymerase activity results from the deletion of from about 858 to about 867 nucleotides from the 5' terminus of said other coding DNA fragment and the addition of a translation initiation codon to the 5' end of a resulting DNA fragment.

21. The purified recombinant DNA molecule of Claim 20 wherein said DNA fragment encoding a protein having thermostable DNA polymerase activity results from the deletion of 858 nucleotides from the 5' terminus of said other coding DNA fragment and the addition of a translation initiation codon to the 5' end of a resulting DNA fragment.

22. The purified recombinant DNA molecule of Claim 20 wherein said DNA fragment encoding a protein having thermostable DNA polymerase activity results from the deletion of 867 nucleotides from the 5' terminus of said other coding DNA fragment.

23. The purified recombinant DNA molecule of Claim 20 wherein said DNA fragment encoding a protein having thermostable DNA polymerase activity results from the deletion of 864 nucleotides from the 5' terminus of said other coding DNA fragment and the addition of a translation initiation codon to the 5' end of a resulting DNA fragment.

24. The purified recombinant DNA molecule of Claim 18 comprising the alteration of one or more codon within the coding region of said unmodified DNA fragment.

25. The purified recombinant DNA molecule of Claim 24 where said alteration results, upon expression of said DNA molecule, in the substitution of a phenylalanine residue for a tyrosine residue at a position corresponding to amino acid 73, as measured from the amino terminus of SEQ ID NO: 20.

26. The purified recombinant DNA molecule of Claim 24 where said alteration results, upon expression of said DNA molecule, in the substitution of an alanine residue for a tyrosine residue at a position corresponding to amino acid 73, as measured from the amino terminus of SEQ ID NO: 20.
27. A host cell containing the recombinant DNA molecule of any of claims 16 to 26.
28. A purified protein derived from Bacillus stearothermophilus expressed and produced in a heterologous host cell which migrates with an apparent molecular weight of about 98,000 Daltons as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis and has an amino acid sequence selected from the group consisting of:
- a) SEQ ID NO:20,
 - b) SEQ ID NO:31,
 - c) SEQ ID NO:33,
 - d) a methionine followed by SEQ ID NO:20,
 - e) a methionine followed by SEQ ID NO:31,
 - f) a methionine followed by SEQ ID NO:33,
 - g) an amino acid sequence having substantial sequence homology to SEQ ID NO:20,
 - h) an amino acid sequence having substantial sequence homology to SEQ ID NO:31, and
 - i) an amino acid sequence having substantial sequence homology to SEQ ID NO:33.
29. The purified protein of Claim 28 comprising a protein having DNA polymerase activity.
30. The purified protein of Claim 29 further comprising a protein having little or no 5'-3' exonuclease activity.
31. A method of using the purified protein of Claim 30 in a primer extension reaction to catalyze the formation of a bond between the 3' hydroxyl group at the growing end of a nucleic acid primer and a nucleotide triphosphate, comprising:
- a. contacting the protein with a template nucleic acid, a nucleic acid primer, nucleotide monomers, and cofactors necessary for DNA polymerase activity to form a reaction mixture, and
 - b. incubating said reaction mixture at a temperature sufficient to cause the sequential template-directed addition of nucleotides to the 3' end of the nucleic acid primer.
32. A purified protein derived from Bacillus stearothermophilus expressed and produced in a heterologous host cell which migrates with an apparent molecular weight of about 60,000 Daltons as determined by sodium dodecyl sulfate polyacrylamide gel electrophoresis and has an amino acid sequence selected from the group consisting of SEQ ID NO:23, SEQ ID NO: 25, SEQ ID NO: 27, a methionine residue followed by one of the above amino acid sequences, and amino acid sequences having substantial sequence homology to the above amino acid sequences.
33. The purified protein of Claim 32 comprising a protein having DNA polymerase activity.
34. The purified protein of Claim 33 further comprising a protein having little or no 5'-3' exonuclease activity.
35. A purified thermostable DNA polymerase enzyme produced by an E. coli host cell wherein said enzyme is a proteolytic cleavage product produced upon expression of a gene encoding a Bst DNA polymerase enzyme.
36. A purified thermostable DNA polymerase enzyme produced by digestion of the protein of claim 32 with a protease.
37. The purified thermostable DNA polymerase enzyme of Claim 36, wherein said protease is subtilisin.
38. The enzyme of Claim 35 wherein said enzyme lacks a 5'-3' exonuclease activity.
39. The enzyme of Claim 36 wherein said enzyme lacks a 5'-3' exonuclease activity.
40. A purified thermostable DNA polymerase enzyme having little or no 5'-3' exonuclease activity.
41. A method of producing a purified thermostable DNA polymerase derived from Bacillus stearothermophilus comprising:

- a. inserting a DNA vector containing a gene encoding said polymerase into a host cell capable of expressing the polymerase,
- b. culturing said vector-containing host cell under conditions in which said thermostable DNA polymerase is expressed, and
- c. extracting said thermostable DNA polymerase from the host cell culture.

42. A method of purifying a Bacillus stearothermophilus-derived thermostable DNA polymerase expressed in a plurality of heterologous host cells, comprising the steps:

- a. extracting said thermostable DNA polymerase from said host cells and forming a cell extract,
- b. contacting said extract with an anion exchange medium in a solution comprising a salt concentration of about 25 millimolar,
- c. eluting said thermostable DNA polymerase from said anion exchange medium with a solution having an ionic strength corresponding to a salt concentration of at least about 0.1 to 0.2 M NaCl,
- d. binding said thermostable DNA polymerase to a cation exchange resin,
- e. eluting said thermostable DNA polymerase with a solution having an ionic strength corresponding to a salt concentration of at least about 0.25-0.30 M NaCl,
- f. binding said thermostable DNA polymerase to an anion exchange resin,
- g. eluting said thermostable DNA polymerase with a solution having an ionic strength corresponding to a salt concentration of at least about 0.2 and 0.4 M NaCl.

43. A purified protein having at least 50 contiguous amino acids contained in the amino acid sequence SEQ ID NO:20.

44. The purified protein of Claim 43 wherein said protein has a DNA polymerase activity.

45. A purified protein having at least 75 contiguous amino acids contained in the amino acid sequence SEQ ID NO:20.

46. The purified protein of Claim 45 wherein said protein has a DNA polymerase activity.

47. A modified thermostable DNA polymerase derived from Bacillus stearothermophilus which lacks or has a decreased 5'-3' exonuclease activity, and which has an amino acid sequence selected from group consisting of SEQ ID NO:22, SEQ ID NO: 24, SEQ ID NO: 26, SEQ ID NO:31 and SEQ ID NO:33, a methionine residue followed by one of the above amino acid sequences, and amino acid sequences having substantial sequence homology to the above amino acid sequences.

48. A purified recombinant DNA molecule comprising a nucleotide sequence encoding at least a portion of a thermostable DNA polymerase derived from Bacillus stearothermophilus, or a fragment or derivative of said portion wherein the fragment or portion encodes a polypeptide having an activity which:

- a. can elicit an immune response to said thermostable DNA polymerase,
- b. can catalyze the template-directed incorporation of nucleotide triphosphates to the 3' end of a nucleic acid primer hybridized to a portion of said template, or
- c. has a combination of said activities.

Primers and probes

Oligo 15	5'- T T A A T C G A C G G C A G C A G C G T G G C G T A C C G C G C C T T T T T C G C C T T G -3'
Oligo 21	5'- T T G A T G G G T G A T A A G T C G G A T A A C A T T C C T G G G T -3'
Oligo 16	5'- G A G C A G C G C A T T T A T G A G C T C G C C G G C C A A G A A T T C A A -3'
Oligo 17	5'- A A T T C A C C G A A A C A G C T C G G C G T C A A T T T A T T T G A A A A -3'
Oligo 20	3'- T T T T G G C C G A T G A G G T G T A G T C G C C T A C A C G A C C T T -5'
Oligo 24	3'- G C C G C G G C G A T A A A C G G C C T A T A A T G C T C G G C G T T G A A G T T -5'
Oligo 25	3'- G G C T A A G T T C C C C T C G C G G C G A C T G T A A T A A T T T T C C G C T A C -5'

Figure 1




Figure 2





Figure 3



coordinates assume amplicon = 1143 bp

Figure 4

Summary of SstI Southern blot hybridizations with various probes

	5'-3' exo		3'-5' exo	polymerase			
	↑ 15	↑ 21		↑ 16	↑ 20	↑ 24	↑ 25
Sst I fragment sizes							
> 9 kb						X	
≤ 9	X						
2.1				X	X	X	X
low	X	X					

Figure 5




Figure 6






Figure 7


Strategy for construction of pUC Bst1




(1) Cut genomic clone pGem Bst 2.1 Sst with Hind III + Sal I and gel isolate the 3' gene fragment plus extra downstream sequence = fragment A




(2) Cut pUC18 with Hind III + Sal I and gel isolate vector fragment



(3) Ligate fragment A with pUC18 vector fragment = pUC Bst 3' end



(4) Cut and gel isolate the Aat II + Hind III 5' gene fragment from pGem Bst 5' end = fragment B



(5) Cut pUC Bst 3' end from step 3 with Aat II + Hind III and gel isolate the large vector / Bst fragment

(6) Ligate the above pUC Bst 3' end vector / Bst fragment with fragment B and select full length clone pUC Bst #1




Figure 8

Strategy for the construction of pUC Bs2


GP94003
Sheet 9 of 14
PATENT

Figure 9


Fragments 1 and 2 used to construct pUC Bst3

Figure 10


Construction of modified versions of pUC Bst2

Figure 11

N terminal alignments of Klenow type enzymes

	First aa coordinate	
Bca DNA polymerase	...	ESPSSSEEEKPLAKMAFTLADRVTTEMLADKAALVVE--
Uncloned Bst subtilisin fragment (Bio-Rad)		AEGEEKPLEEMEFAI VDVITTEEMLADKLAALVVE--
Bst 1 enzyme	--	MAVQTDEGEKPLAGMDFAI ADS VTDEMLADKAALVVE--
Bst 2 enzyme	290	DEGEKPLAGMDFAI ADS VTDEMLADKAALVVE--
Bst 1 subtilisin fragment	289	TDEGEKPLAGMDFAI ADS VTDEMLADKAALVVE--
Bst 3 naturally occurring cleavage product and Bst 4 enzyme	287	VQTDEGEKPLAGMDFAI ADS VTDEMLADKAALVVE--

Figure 12





Figure 13

SDS PAGE (10%) of Lysates and Purified Bst Polymerase



- 1 Molecular Weight markers (98kD,66kD,45kD,31kD)
- 2 Negative Control Lysate
- 3 Bst-1 Clone Lysate
- 4 Purified Bst-1
- 5 Purified Bst-1 Klenow Fragment
- 6 Purified Bst-3
- 7 Purified Bst-3 Klenow Fragment



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 95 10 4961

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
D,X	<p>DATABASE WPI Section Ch, Week 9351 Derwent Publications Ltd., London, GB; Class B04, AN 93-408323 & JP-A-05 304 964 (TAKARA SHUZO CO LTD) , 19 November 1993 * abstract *</p> <p>---</p>	<p>1-4,16, 17,27, 31,41,48</p>	<p>C12N15/54 C12N15/10 C12N9/12 C12N1/21 //(C12N1/21, C12R1:19)</p>
X	<p>DATABASE WPI Section Ch, Week 8829 Derwent Publications Ltd., London, GB; Class B04, AN 88-203377 & SU-A-1 311 251 (LENGD NUCLER PHYS) , 30 January 1988 * abstract *</p> <p>---</p>	<p>16,17, 31,48</p>	
X	<p>EP-A-0 497 272 (BECTON DICKINSON CO) 5 August 1992 * page 7, line 41 - line 45 *</p> <p>---</p>	<p>1,5,31, 35-40</p>	
X	<p>DNA SEQUENCE (1991), 1(3), 173-80 CODEN: DNSEES;ISSN: 1042-5179, 1991 MCCLARY, J. ET AL 'Sequencing with the large fragment of DNA polymerase I from Bacillus stearothermophilus' * page 179, left column, paragraph 2 * * page 175, left column, line 1 - page 177, left column, paragraph 3 * ---</p> <p style="text-align: center;">-/--</p>	<p>31, 35-40,48</p>	<p>TECHNICAL FIELDS SEARCHED (Int.Cl.6) C12N</p>
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 23 June 1995	Examiner Hornig, H
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p>		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons ----- & : member of the same patent family, corresponding document</p>	

EPO FORM 150 (3.82 (P/C01))



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 95 10 4961

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	BIOLOGICAL ABSTRACTS, vol. BA84, Philadelphia, PA, US; abstract no. 97671, YE S ET AL 'HEAT-STABLE DNA POLYMERASE I LARGE FRAGMENT RESOLVES HAIRPIN STRUCTURE IN DNA SEQUENCING.' * abstract * & SCI SIN SER B (CHEM BIOL AGRIC MED EARTH SCI) 30 (5). 1987. 503-506. CODEN: SSBSEF ISSN: 0253-5823, ---	31, 35-40, 48	
X	BIOTECHNIQUES (1991), 11(4), 464, 466 CODEN: BTNQDQ; ISSN: 0736-6205, 1991 LU, YOUYI ET AL 'Large fragment of DNA polymerase I from Bacillus stearothermophilus (Bst polymerase) is stable at ambient temperature' the whole document ---	31, 35-40, 48	
D,A	J. BIOL. CHEM., vol. 264, no. 11, 15 April 1989 AM. SOC. BIOCHEM. MOL. BIOL., INC., BALTIMORE, US; , pages 6427-6437, F.C. LAWYER ET AL. 'Isolation characterization, and expression in Escherichia coli of the DNA polymerase gene from Thermus aquaticus' the whole document ---	1-48	TECHNICAL FIELDS SEARCHED (Int.Cl.6)
A	CELL, vol. 59, no. 1, 6 October 1989 CELL PRESS, CAMBRIDGE, MA, US; , pages 219-228, A. BERNARD ET AL. 'A conserved 3'-5' exonuclease active in Procaryotic and eucaryotic DNA polymerases' the whole document ---	1-48	
		-/--	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 23 June 1995	Examiner Hornig, H
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons --- & : member of the same patent family, corresponding document	

EPO FORM 150 (01.82) (P4/C01)



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number
EP 95 10 4961

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
D,A	EP-A-0 517 418 (TAKARA SHUZO CO) 9 December 1992 the whole document	1-48	
P,X	WO-A-95 03430 (GEN-PROBE INCORPORATED) 2 February 1995 * page 9, line 3 - line 5 * * page 21, line 8 - page 23, line 5 * * page 29, line 23 - page 32, line 36 * * claims 1-20 *	31, 35-40,48	
P,X	WO-A-94 16107 (UNIV JEFFERSON) 21 July 1994 the whole document	31, 35-40,48	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
Place of search	Date of completion of the search	Examiner	
THE HAGUE	23 June 1995	Hornig, H	
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1500 (04/92) (P4/C01)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)